# Consolidated New Input Materials (2026-01-21)

# Source: 20260115_VC_PE_Portfolio.xlsx

### Sheet: Sheet1

| Country | Fund | Company Name | Classification | Detailed Summary of Operations | Pet Food? | Nutraceuticals? | In the list ? | veterinary clinic ? |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| USA | Digitalis Ventures | Astra Therapeutics | Veterinary | A biotechnology firm developing the next generation of small molecule anti-parasitic drugs. By harnessing comparative structural data and advanced computational chemistry, Astra targets parasites that have developed resistance to current treatments, addressing a critical unmet need in veterinary medicine. | No | No |  |  |  |
| USA | Digitalis Ventures | Dandylion | Other (Consumer) | A consumer brand focused on "skin-first" dog grooming products. Dandylion formulates gentle, pH-balanced hygiene solutions designed to make dog care easier and safer, responding to the trend of pet owners scrutinizing ingredient labels for topical products much like they do for their own cosmetics. | No | No |  |  |  |
| USA | Digitalis Ventures | Gallant Therapeutics | Veterinary | A clinical-stage biotech pioneering off-the-shelf (allogeneic) stem cell therapies. Gallant targets the root causes of chronic diseases such as feline chronic gingivostomatitis (FCGS) and canine osteoarthritis. Their approach utilizes uterine-derived mesenchymal stromal cells (MSCs) to regulate the immune system and promote tissue repair, moving beyond symptom management to curative intent. | No | No (Therapeutic) |  |  |  |
| USA | Digitalis Ventures | Honor Pet | Other (Services) | A service provider reimagining the end-of-life experience for pets. Honor Pet offers modern, transparent, and compassionate aftercare and cremation services, addressing the emotional needs of pet owners during the grieving process with a focus on dignity and trust. | No | No |  |  |  |
| USA | Digitalis Ventures | Napo | Other (Insurance) | A UK-based "insurtech" startup that integrates preventative wellness into pet insurance policies. Napo offers comprehensive coverage that includes access to veterinary video consultations and behaviorist advice, incentivizing proactive health management to reduce long-term claims costs. | No | No |  |  |  |
| USA | Digitalis Ventures | Oncura | Veterinary | A medical technology company democratizing access to advanced imaging. Oncura provides a platform that connects general practice veterinarians with board-certified radiologists via real-time tele-ultrasound. This allows GPs to perform complex scans with remote guidance, keeping revenue and patient care within the primary clinic. | No | No |  |  |  |
| USA | Digitalis Ventures | Made by Nacho | Other (Consumer) | A premium cat food brand co-founded by celebrity chef Bobby Flay. The company is dedicated exclusively to feline nutrition, offering high-protein wet and dry foods, treats, and toppers. The brand leverages culinary expertise to solve the "palatability gap" often found in high-quality cat foods. | Yes (Primary) | No | No |  |  |
| USA | Digitalis Ventures | MoeGo | Other (Software) | A vertical SaaS platform for the pet grooming industry. MoeGo provides an all-in-one business management solution for mobile groomers and salons, handling scheduling, routing, payments, and client communications, thereby digitizing a traditionally pen-and-paper industry. | No | No |  |  |  |
| USA | Digitalis Ventures | Mollybox | Other (Retail) | A subscription-based e-commerce platform serving the Chinese pet market. Mollybox delivers curated boxes of pet food, treats, and toys, capitalizing on the rapid growth of pet ownership and the desire for convenience among China's urban middle class. | Yes (Retailer) | No | No |  |  |
| USA | Digitalis Ventures | Native Pet | Other (Consumer) | A functional supplement company bridging the gap between "treats" and "medicine." Native Pet utilizes whole-food ingredients (e.g., pumpkin, bone broth, wild-caught salmon) to create effective nutraceuticals for digestive health, allergy relief, and calming. Their "clean label" approach appeals to health-conscious owners. | Yes (Toppers) | Yes (Core Business) | Yes |  |  |
| USA | Digitalis Ventures | Pacagen | Veterinary | A biotechnology company developing treatments to neutralize pet allergens. Their research focuses on modifying or neutralizing the proteins (like Fel d 1) in cat and dog dander that cause allergic reactions in humans, potentially allowing allergic individuals to own pets without symptoms. | No | No |  |  |  |
| USA | Digitalis Ventures | Pawp | Other (Services) | A digital health clinic and membership platform offering 24/7 access to veterinary professionals via text and video. Pawp differentiates itself with an "emergency fund" model, providing financial coverage for life-threatening emergencies without the premiums or exclusions of traditional insurance. | No | No |  | Clinic  |  |
| USA | Digitalis Ventures | PetMedix | Veterinary | Acquired by Zoetis. A biotech company that developed a transgenic mouse platform to produce fully species-specific monoclonal antibodies for dogs and cats. This technology enables the creation of highly targeted, low-immunogenicity therapeutics for chronic diseases like atopic dermatitis and cancer. | No | No |  |  |  |
| USA | Digitalis Ventures | Rejuvenate Bio | Veterinary | A spinout from the Wyss Institute at Harvard developing gene therapies to reverse age-related diseases. Their lead programs target conditions like mitral valve disease in dogs, with the long-term goal of translating these longevity technologies to human medicine. | No | No |  |  |  |
| USA | Digitalis Ventures | RiverDog | Other (Services) | An operator of premium dog daycare, boarding, and training facilities. RiverDog emphasizes enrichment-based care and crate-free environments, catering to owners who view their dogs as family members requiring socialization and mental stimulation. | No | No |  |  |  |
| USA | Digitalis Ventures | ScoutBio | Veterinary | Acquired by Ceva Santé Animale. A biotechnology company focused on "one-time" AAV-vectored gene therapies. ScoutBio developed therapeutics that enable a patient's own cells to produce therapeutic proteins, targeting chronic conditions like anemia and osteoarthritis pain. | No | No |  |  |  |
| USA | Digitalis Ventures | Scratchpay | Other (Fintech) | A financial technology company offering "Care Now, Pay Later" solutions for veterinary costs. Scratchpay integrates with practice management systems to provide instant loan approvals for pet owners, reducing economic euthanasia and enabling access to necessary medical care. | No | No |  |  |  |
| USA | Digitalis Ventures | Smalls | Other (Consumer) | A direct-to-consumer (DTC) cat food brand specializing in fresh, human-grade meat recipes. Smalls disrupts the "kibble" market by offering high-protein, high-moisture diets that mimic a cat's ancestral nutritional requirements, delivered via a subscription model. | Yes (Primary) | No | No |  |  |
| USA | Digitalis Ventures | Tuft + Paw | Other (Consumer) | A modern cat furniture brand focusing on aesthetics and design. Tuft + Paw creates litter boxes, scratching posts, and beds that function as high-end home decor, addressing the "ugly pet furniture" problem for design-conscious cat owners. | No | No |  |  |  |
| USA | Digitalis Ventures | Vedi | Veterinary | A health data platform that creates a universal medical record for animals. Vedi automates the capture of health data (vaccinations, pathology) and links it to a microchip, ensuring accurate, portable health records for veterinarians and owners. | No | No |  |  |  |
| USA | Ani.VC | The Cat Health Company | Veterinary | A longevity startup dedicated exclusively to extending the healthy lifespan of cats. The company focuses on identifying and developing new therapeutics for age-related feline diseases, utilizing both computational biology and wet-lab approaches to achieve "nine lives extension." | No | No (Therapeutic) |  |  |  |
| USA | Ani.VC | MI:RNA | Veterinary | A diagnostics company pioneering the use of microRNA biomarkers for early disease detection. MI:RNA’s technology allows veterinarians to detect conditions like heart disease, kidney failure, and cancer at a molecular level before clinical symptoms manifest, enabling earlier and more effective intervention. | No | No |  |  |  |
| USA | Ani.VC | DOG PPL | Other (Services) | A "canine social club" that merges a rigorously maintained dog park with a members-only social lounge for humans. The concept addresses the safety concerns of public dog parks by requiring behavioral assessments and vaccination proof, creating a safe "third place" for millennials and their dogs. | No | No |  |  |  |
| USA | Ani.VC | Vetmab Biosciences | Veterinary | A biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for companion animals. Vetmab aims to treat chronic veterinary diseases with biologic drugs that offer high specificity and fewer side effects than traditional small-molecule drugs. | No | No |  |  |  |
| USA | Ani.VC | RetrievAir | Other (Tech) | While public details are limited, the company operates in the retrieval technology space. In the context of Ani.VC's portfolio, this likely pertains to advanced pet tracking, safety retrieval systems, or medical sample logistics for veterinary diagnostics. | No | No |  |  |  |
| USA | Ani.VC | Lil Luv Dog | Other (Consumer) | A consumer-facing brand within the pet care sector. Given the fund's focus, this entity likely operates in the consumables or accessories market, potentially focusing on wellness or lifestyle products for small dogs. | Unclear | Unclear |  |  |  |
| USA | Stray Dog Capital | Bond Pet Foods | Other (Biotech) | A biotechnology leader using precision fermentation to produce animal-identical meat proteins without slaughter. Bond "brews" chicken protein using yeast and DNA, creating a high-purity, sustainable protein source specifically for pet food manufacturers. | Yes (Ingredients) | No | No |  |  |
| USA | Stray Dog Capital | Wild Earth | Other (Consumer) | A pioneering pet food company that utilizes yeast protein (koji) as a primary ingredient. Wild Earth produces high-protein, plant-based dog food that is complete and balanced, challenging the necessity of meat in canine diets. They also market functional supplements. | Yes (Primary) | Yes | No |  |  |
| USA | Stray Dog Capital | Because Animals | Other (Biotech) | Now evolving into new entities. This company focused on developing cultured meat specifically for pets. They famously worked on growing mouse meat for cat food, arguing that a species-appropriate ancestral diet could be produced without killing animals. | Yes | No | No |  |  |
| USA | Stray Dog Capital | BlueNalu | Other (Food) | A cellular aquaculture company producing seafood directly from fish cells. While currently focused on high-value human markets (e.g., Bluefin Tuna toro), the technology holds long-term potential for producing mercury-free, sustainable fish protein for premium pet foods. | No | No |  |  |  |
| USA | Stray Dog Capital | Upside Foods (Memphis Meats) | Other (Food) | A frontrunner in the cultivated meat revolution, producing chicken from animal cells. Tyson Ventures is also an investor. Upside’s regulatory wins pave the way for cultured meat across the entire food system, including pet nutrition. | No | No |  |  |  |
| USA | Stray Dog Capital | SuperMeat | Other (Food) | An Israeli food-tech company growing cultured chicken meat. They operate a "The Chicken" production facility/restaurant to demonstrate the viability of growing meat without birds. | No | No |  |  |  |
| USA | Stray Dog Capital | Mosa Meat | Other (Food) | A Dutch food technology company that created the world's first lab-grown hamburger. Their advancements in serum-free media are critical for reducing the cost of cultured meat to levels viable for pet food applications. | No | No |  |  |  |
| USA | Stray Dog Capital | Meatless Farm | Other (Food) | Exited. A producer of plant-based meat alternatives (mince, burgers). While human-focused, their ingredients (pea/soy protein blends) are representative of the inputs used in plant-based pet diets. | No | No |  |  |  |
| USA | Stray Dog Capital | Miyoko's Creamery | Other (Food) | A dairy-free creamery producing artisan vegan cheeses and butters using traditional fermentation techniques. Their focus on simple, whole-food ingredients mirrors the "clean label" trend in pet treats. | No | No |  |  |  |
| USA | Borealis Ventures | Embark Veterinary | Veterinary | The "23andMe" of the canine world. Embark offers the most advanced DNA testing service for dogs, providing breed identification and screening for over 200 genetic health risks. Their massive database drives research into canine hereditary diseases. | No | No |  |  |  |
| USA | Borealis Ventures | Fidocure (The One Health Company) | Veterinary | A precision medicine company for dogs with cancer. Fidocure uses genomic sequencing of canine tumors to identify specific mutations, then recommends targeted human cancer drugs (like PARP inhibitors) that can treat those mutations, bridging the gap between human and veterinary oncology. | No | No |  |  |  |
| USA | Borealis Ventures | Vetcove | Veterinary | A B2B purchasing platform for veterinary hospitals. Vetcove aggregates catalogs from all major distributors (Covetrus, MWI, etc.), allowing clinics to compare prices, track inventory, and manage purchasing from a single dashboard, significantly increasing practice efficiency. | No | No |  |  |  |
| USA | Borealis Ventures | Astra Therapeutics | Veterinary | Co-invested with Digitalis. Developing novel small molecule therapeutics for parasitic infections in animals. | No | No |  |  |  |
| USA | Borealis Ventures | Triveni Bio | Other (Biotech) | A biotechnology company utilizing genetics to develop therapeutics for immunological and inflammatory disorders. While primarily human-focused, the foundational science of I&I (Inflammation & Immunology) often crosses over into veterinary applications (e.g., atopic dermatitis). | No | No |  |  |  |
| USA | S2G Investments  | Enthos | Other (AgTech) | A circular economy company using Black Soldier Fly (BSF) larvae to upcycle organic waste into high-quality protein meal and oil. These insect-based ingredients are premium inputs for pet food and aquaculture feed, offering a sustainable alternative to fishmeal. | Yes (Ingredients) | No | No |  |  |
| USA | S2G Investments  | Sentera | Other (AgTech) | A digital agriculture company providing drone-based analytics and sensors to measure crop health and yield. Sentera's technology optimizes the production of row crops (corn, soy) that form the baseload of the animal feed supply chain. | No | No |  |  |  |
| USA | S2G Investments  | EarthOptics | Other (AgTech) | A soil data measurement company using ground-penetrating radar and machine learning to map soil health and carbon. Their technology enables farmers to verify carbon sequestration, incentivizing regenerative practices for crops used in food and feed. | No | No |  |  |  |
| USA | S2G Investments  | Pasture Bio | Veterinary/Ag | A biotechnology company developing vaccines to reduce enteric methane emissions in cattle. By mitigating the climate impact of livestock, they aim to make traditional animal protein production more sustainable. | No | No |  |  |  |
| USA | S2G Investments  | Wildtype | Other (Food) | A cultivated seafood company focusing on salmon. Wildtype grows sushi-grade salmon from cells. While currently targeting high-end human culinary markets, the technology is a precursor to sustainable fish ingredients for premium pet diets. | No | No |  |  |  |
| USA | S2G Investments  | Trace Genomics | Other (AgTech) | A soil science company using genomics to identify pathogens and beneficial microbes in the soil. This "soil DNA" testing helps farmers prevent crop disease and optimize yields without excessive chemical inputs. | No | No |  |  |  |
| USA | S2G Investments  | Kingdom Supercultures | Other (Food Tech) | A biodesign company designing microbial communities (cultures) to transform food ingredients. Their technology can create novel flavors, textures, and preservatives for the food and pet food industries naturally. | Yes (Ingredients) | No | No |  |  |
| USA | Tyson Ventures | Protix | Other (AgTech) | A leading Dutch insect ingredients company. Tyson acquired a minority stake to form a joint venture for building a massive insect ingredient facility in the US. Protix produces insect protein specifically for pet food and aquaculture, capitalizing on the hypoallergenic and sustainable properties of bugs. | Yes (Ingredients) | No | Yes  |  |  |
| USA | Tyson Ventures | Upside Foods | Other (Food) | A pioneer in the cultivated meat industry. Tyson was an early investor, supporting their mission to grow chicken from cells. This investment hedges Tyson's core poultry business against future disruption by slaughter-free meat. | No | No |  |  |  |
| USA | Tyson Ventures | Soft Robotics | Other (Tech) | A robotics company developing soft grippers and 3D vision systems for food processing. Their technology automates the handling of delicate food items (like raw meat or produce) in sanitary environments, relevant for pet food manufacturing. | No | No |  |  |  |
| USA | Tyson Ventures | Future Meat (Believer Meats) | Other (Food) | An Israeli cultivated meat company focused on reducing the cost of production to reach price parity with conventional meat. They utilize a unique media rejuvenation process to increase efficiency. | No | No |  |  |  |
| USA | Tyson Ventures | MycoTechnology | Other (Food Tech) | A food technology company using mycelium fermentation to process plant proteins (like pea and rice). Their fermentation process improves taste by removing bitter off-notes and enhances nutritional bioavailability, applicable to both human and pet food formulations. | Yes (Ingredients) | No | No |  |  |
| USA | Tyson Ventures | Clear Labs | Other (Tech) | A food safety platform using Next-Generation Sequencing (NGS) to detect pathogens like Salmonella and Listeria. This technology is critical for ensuring the safety of the meat supply chain, including raw materials for pet food. | No | No |  |  |  |
| France | Seventure Partners  | ViroVet | Veterinary | A Belgian biopharmaceutical company developing novel antiviral therapies for livestock. They utilize unique technology based on VHH (single-domain antibodies) to control viral diseases, aiming to reduce the reliance on antibiotics in animal agriculture. | No | No |  |  |  |
| France | Seventure Partners  | Proteon Pharmaceuticals | Veterinary | A company using bacteriophages (viruses that kill specific bacteria) as an alternative to antibiotics in aquaculture and poultry farming. Their products improve animal health and production efficiency without contributing to antimicrobial resistance. | No | No (Therapeutic) |  |  |  |
| France | Seventure Partners  | String Bio | Other (Biotech) | A biotech firm that converts methane gas into single-cell protein ingredients via fermentation. This "PRO-DG" protein is a sustainable, traceable ingredient used in animal feed and aquaculture, with applications for pet food. | Yes (Ingredients) | No | No |  |  |
| France | Seventure Partners  | Tibot | Veterinary/Ag | A robotics company developing autonomous robots (Spoutnic) for poultry farming. These robots move randomly to encourage bird movement, reducing floor eggs and improving animal welfare and productivity. | No | No |  |  |  |
| France | Seventure Partners  | Inspecto | Other (AgTech) | A technology company that developed a portable device for the early detection of chemical residues (pesticides) and contaminants in food and crops. This ensures the safety of raw materials entering the food and feed chain. | No | No |  |  |  |
| France | Seventure Partners  | Microbiotica | Other (Biotech) | A leader in microbiome-based therapeutics discovery. They use a proprietary platform to identify gut bacteria linked to specific phenotypes. While human-focused, the science of microbiome modulation translates directly to animal health. | No | No |  |  |  |
| France | Seventure Partners  | Enterome | Other (Biotech) | A clinical-stage biopharmaceutical company developing immunotherapies for cancer and immune diseases based on the gut microbiome. They focus on "OncoMimics" and "EndoMimics" derived from gut bacteria. | No | No |  |  |  |
| France | Seventure Partners  | LiMM Therapeutics | Other (Biotech) | A biopharmaceutical company bridging the gap between neuroscience and immunology. They focus on the neuronal regulation of innate immunity cells to treat inflammatory and metabolic diseases. | No | No |  |  |  |
| France | Seventure Partners  | Peptobiotics | Other (AgTech) | A synthetic biology company producing recombinant antimicrobial peptides. These peptides serve as a direct replacement for antibiotics in livestock feed, promoting growth and health without resistance risks. | No | No |  |  |  |
| France | Seventure Partners  | Kapsera | Other (AgTech) | A company specializing in the formulation and delivery of bio-inputs. They use microfluidics to encapsulate active ingredients (like biopesticides or probiotics) in biodegradable alginate capsules, enhancing their stability and efficacy in the field. | No | No |  |  |  |
| USA | Gryphon Investors | Vetnique Labs | Other (Consumer) | A leading pet health and wellness platform founded by a veterinarian. Vetnique is famous for Glandex, a patented supplement for anal gland health. Under Gryphon, they have expanded into a multi-brand platform, recently acquiring Lintbells (see below). | No | Yes (Core Business) | No |  |  |
| USA | Gryphon Investors | Heartland Veterinary Partners | Veterinary | A Veterinary Support Organization (VSO) supporting a network of over 300 veterinary practices across the Midwest and Southern US. Heartland provides non-clinical administrative support (HR, finance, marketing) to allow vets to focus on medicine. | No | No |  | Clinic |  |
| USA | Gryphon Investors | Lintbells (YuMOVE) | Other (Consumer) | Acquired by Vetnique. A UK-based leader in natural joint supplements for dogs and cats. Their flagship brand, YuMOVE, is the #1 veterinary joint supplement in the UK. This acquisition creates a trans-Atlantic nutraceutical giant. | No | Yes (Core Business) | Yes |  |  |
| USA | Gryphon Investors | Fleet Labs | Other (Consumer) | Exited. A manufacturer of personal care and over-the-counter (OTC) products. While primarily human-focused (Summer's Eve, Fleet Enema), the investment demonstrates Gryphon's expertise in consumer health manufacturing and branding. | No | No |  |  |  |
| USA | Morgan Stanley Capital Partners  | FoodScience Corporation | Other (Consumer) | A formulator and manufacturer of nutritional supplements for humans and pets. FoodScience owns the trusted brands VetriScience (veterinary exclusive) and Pet Naturals (retail). They also operate a massive private label manufacturing division, producing supplements for many other brands. | No | Yes (Core Business) | Yes |  |  |
| USA | Morgan Stanley Capital Partners  | Manna Pro (Compana) | Other (Consumer) | Exited. A diversified pet care and nutrition company. Under MSCP, it grew from a farm-focused brand into a consumer pet powerhouse, acquiring brands like Fruitables (treats) and Espree (grooming) before being sold to The Carlyle Group. | Yes (Treats) | Yes | No |  |  |
| USA | Morgan Stanley Capital Partners  | Pathway Vet Alliance (Thrive) | Veterinary | Exited. A leading veterinary hospital network. MSCP partnered with founders to scale this into one of the largest networks in the US (now known as Thrive Pet Healthcare), focusing on professionalizing operations and expanding specialty care. | No | No |  | Clinic |  |
| USA | Morgan Stanley Capital Partners  | Sebela Pharmaceuticals | Other (Pharma) | A specialty pharmaceutical company focused on gastroenterology, dermatology, and women's health. While human-focused, it underscores MSCP's competency in building specialty pharma platforms. | No | No |  |  |  |
| Sweden | EQT Group | IVC Evidensia | Veterinary | Europe's largest veterinary care provider, operating a network of over 2,500 clinics and hospitals across 20 countries. EQT drives value through procurement scale, digital transformation, and the implementation of high clinical standards. | No | Yes (Sells/Prescribes) | No | Clinic |  |
| Sweden | EQT Group | Zooplus | Other (Retail) | The leading online retailer of pet food and supplies in Europe, operating in 30 countries. EQT took Zooplus private to accelerate its transition into a holistic pet care platform, integrating commerce with services. | Yes (Retailer) | Yes (Retailer) | No |  |  |
| Sweden | EQT Group | Dechra Pharmaceuticals | Veterinary | A global specialist in veterinary pharmaceuticals acquired by EQT in 2024. Dechra focuses on high-quality endocrinology (e.g., Vetoryl for Cushing's), dermatology, and analgesia products for companion animals. | No | Yes (Specific lines) | NOO ?? |  |  |
| Sweden | EQT Group | VetPartners | Veterinary | The leading network of veterinary clinics in Australia and New Zealand. Acquired by EQT to replicate the successful IVC Evidensia model in the Asia-Pacific region. | No | No |  | Clinic |  |
| Sweden | EQT Group | ManyPets | Other (Insurance) | A digital-first pet insurance provider offering policies in the UK, Sweden, and the US. ManyPets is known for its user-friendly tech stack and innovative coverage options, such as covering pre-existing conditions in certain markets. | No | No |  |  |  |
| Sweden | EQT Group | Musti Group | Other (Retail) | The leading Nordic pet care specialist. Musti operates an omnichannel model combining physical retail stores with grooming services and veterinary care, dominating the pet market in Finland, Sweden, and Norway. | Yes (Retailer) | Yes (Retailer) |  | Clinic |  |
| Sweden | EQT Group | Bespak | Other (Pharma) | A contract development and manufacturing organization (CDMO) specializing in drug delivery devices, particularly inhalers. While broadly pharma, delivery devices are increasingly relevant for veterinary asthma and respiratory treatments. | No | No |  |  |  |
| Netherlands | Aqua-Spark | Protix | Other (AgTech) | The world's leading insect protein company (Black Soldier Fly). Protix converts organic waste into protein meal and lipids. They are a major supplier to the pet food industry (partnering with Tyson) for hypoallergenic, sustainable protein ingredients. | Yes (Ingredients) | No | Yes |  |  |
| Netherlands | Aqua-Spark | Calysta | Other (Biotech) | A biotechnology company producing "FeedKind" protein using gas fermentation (methanotrophs) to convert methane into single-cell protein. This creates a sustainable, non-animal protein source for aquaculture and pet food. | Yes (Ingredients) | No | No |  |  |
| Netherlands | Aqua-Spark | eFishery | Other (AgTech) | An Indonesian IoT technology company providing smart feeding systems for fish and shrimp farming. Their technology optimizes feed usage, reducing waste and improving the economics of aquaculture. | No | No |  |  |  |
| Netherlands | Aqua-Spark | Ace Aquatec | Other (AgTech) | A welfare technology company for aquaculture. They develop acoustic predator deterrents and electric stunning systems to ensure humane harvesting of fish, aligning with high-welfare standards. | No | No |  |  |  |
| Netherlands | Aqua-Spark | Sea6 Energy | Other (AgTech) | A company mechanizing ocean farming of tropical seaweed. Seaweed is processed into biostimulants for agriculture, functional ingredients for animal feed (including pet food), and renewable fuels. | Yes (Ingredients) | Yes (Ingredients) | No |  |  |
| Netherlands | Aqua-Spark | BioFishency | Other (AgTech) | Provides advanced water treatment systems for land-based aquaculture (RAS). Their electrochemical technology removes ammonia from water, enabling higher stocking densities and cleaner fish production. | No | No |  |  |  |
| Netherlands | Aqua-Spark | Chicoa Fish Farm | Other (Food) | A vertically integrated tilapia farm in Mozambique. It aims to build a scalable model for sustainable protein production in Sub-Saharan Africa. | No | No |  |  |  |
| USA | WP Global Partners | PetVet365 | Veterinary | A network of veterinary hospitals focused on a "Fear-Free" experience. Unlike traditional rollups that buy existing clinics, PetVet365 executes a de novo strategy, building new, modern hospitals from the ground up with a standardized, pet-friendly design (e.g., no exam tables, glass doors). | No | No |  | Clinic  |  |
| USA | WP Global Partners | Monogram Foods | Other (Food) | A major manufacturer of value-added meat products (jerky, bacon, corn dogs). While primarily a human food company, Monogram has significant co-manufacturing capabilities that extend to premium meat-based pet treats. | Yes (Treats) | No | No |  |  |
| USA | WP Global Partners | Medi-Tech | Other (Health) | A medical device manufacturer. This investment underscores WP Global's broader interest in healthcare manufacturing and supply chain. | No | No |  |  |  |
| UK | Inflexion | Medivet | Veterinary | Partially Exited. A major UK veterinary group operating a "hub-and-spoke" model with 24-hour hospitals supporting smaller satellite clinics. Inflexion helped them double their footprint before selling a majority stake to CVC Capital Partners. | No | No |  | Clinic  |  |
| UK | Inflexion | Lintbells (YuMOVE) | Other (Consumer) | Realized. A leader in natural joint supplements for dogs. Inflexion supported their expansion into the US market and D2C channels before selling the business to Gryphon Investors' Vetnique Labs in 2024. | No | Yes (Core Business) | Yes |  |  |
| UK | Inflexion | Kynetec | Other (Data) | Exited. A global leader in market research and data for the animal health and agriculture sectors. Kynetec provides critical data to pharma companies about vet prescription behaviors and farmer purchasing habits. | No | No |  |  |  |
| UK | Inflexion | Tierarzt Plus Partner (TPP) | Veterinary | A rapidly growing network of veterinary practices in Germany. Inflexion partnered with the founders to consolidate the fragmented German market, focusing on digitization and training to attract talent. | No | No |  | Clinic |  |
| UK | Inflexion | Village Vets | Veterinary | A veterinary group based in Ireland. Inflexion provides capital to facilitate the expansion of existing sites and the opening of new locations, bringing corporatized veterinary care to the Irish market. | No | No |  | Clinic |  |
| USA | NovaQuest Capital Management | Gallant Therapeutics | Veterinary | Co-invested with Digitalis. NovaQuest participated in the Series B financing to support the commercialization of Gallant’s off-the-shelf stem cell therapies for feline gingivostomatitis and canine osteoarthritis. | No | No (Therapeutic) |  |  |  |
| USA | NovaQuest Capital Management | Mileutis | Veterinary | An Israeli biopharmaceutical company developing residue-free, peptide-based immunotherapies. Their lead product aims to treat bovine mastitis (udder infection) in dairy cows without antibiotics, addressing a major cause of milk loss and antibiotic overuse. | No | No |  |  |  |
| USA | NovaQuest Capital Management | Arvelle Therapeutics | Other (Pharma) | A biopharmaceutical company focused on developing treatments for CNS disorders, specifically epilepsy. (Human health). | No | No |  |  |  |
| USA | NovaQuest Capital Management | Mycovia Pharmaceuticals | Other (Pharma) | A pharmaceutical company dedicated to women's health, specifically developing oral treatments for recurrent vulvovaginal candidiasis (yeast infections). | No | No |  |  |  |
| USA | NovaQuest Capital Management | Zoetis (Product Finance) | Veterinary | NovaQuest has historically provided product financing to Zoetis (and its predecessor Pfizer Animal Health) to fund the development of specific blockbuster animal health assets (details often confidential but typically involve late-stage R&D funding in exchange for royalties). | No | No |  |  |  |
| UK | Ocean 14 Capital | Enthos | Other (AgTech) | (Also in S2G portfolio). Uses insects to upcycle waste into protein for aquafeed and pet food. | Yes (Ingredients) | No | No |  |  |
| UK | Ocean 14 Capital | The Kingfish Company | Other (Food) | A land-based Recirculating Aquaculture System (RAS) producer of Yellowtail Kingfish in the Netherlands and US. Demonstrates high-tech, sustainable fish farming. | No | No |  |  |  |
| UK | Ocean 14 Capital | SyAqua | Other (AgTech) | A leader in shrimp genetics and nutrition. SyAqua uses advanced breeding programs to improve the growth rates and disease resistance of shrimp stocks globally. | No | No |  |  |  |
| UK | Ocean 14 Capital | AION | Other (Sustainability) | A spin-out from Aker BioMarine that provides circular plastic solutions. They help maritime industries recycle plastic waste into new products, reducing ocean pollution. | No | No |  |  |  |
| UK | Ocean 14 Capital | Novelplast | Other (Sustainability) | A plastics recycling company. They process PET plastic waste into high-quality pellets that can be reused in manufacturing, contributing to a circular economy. | No | No |  |  |  |
| UK | Ocean 14 Capital | Ava Ocean | Other (Food) | A Norwegian company harvesting scallops using a unique, non-invasive seabed harvesting technology that protects the ocean floor ecosystem. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | P&P Optica | Other (Tech) | Provides hyperspectral imaging systems for meat processing to detect foreign materials and assess quality (fat/lean ratio). Ensures safety of meat entering food/pet food supply. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | Green Dot Bioplastics | Other (Biotech) | Produces bio-based, compostable plastics using recycled agricultural feedstock. Used in packaging and durable goods. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | NanoGuard Technologies | Other (AgTech) | Uses cold plasma technology to sterilize food and feed, reducing mycotoxins and spoilage without chemicals. Applicable to pet food safety. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | Resilient Biotics | Veterinary | Developing microbiome-based therapeutics (LBPs) for respiratory diseases in livestock, replacing antibiotics. | No | No (Therapeutic) |  |  |  |
| UK | Fulcrum Global Capital  | Vytelle | Veterinary/Ag | Precision livestock company offering hormone-free IVF and individual animal data capture for cattle breeding. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | WeedOUT | Other (AgTech) | Develops bioherbicides that exploit sterility to combat resistant weeds. | No | No |  |  |  |
| UK | Fulcrum Global Capital  | Talam Biotech | Other (AgTech) | Uses microbes to block heavy metal uptake in crops, improving food safety. | No | No |  |  |  |
| USA | Cavallo Ventures | Bond Pet Foods | Other (Biotech) | Uses precision fermentation to produce animal-identical meat proteins (e.g., chicken) for pet food without slaughter. | Yes (Ingredients) | No | No |  |  |
| USA | Cavallo Ventures | Omeat | Other (Food) | Cultivated meat company using regenerative factors from cow plasma to grow meat. Focused on cost-effective scalability. | No | No |  |  |  |
| USA | Cavallo Ventures | Vestaron | Other (AgTech) | Develops peptide-based bio-insecticides that are safe for humans/animals but effective against pests. | No | No |  |  |  |
| USA | Cavallo Ventures | Native Microbials | Veterinary/Ag | Develops endomicrobial supplements (microbiome) for livestock to improve feed efficiency and health. | No | Yes (Livestock) | No |  |  |
| USA | Cavallo Ventures | Soma Detect | Other (AgTech) | Sensors for dairy cows measuring milk quality and health indicators in real-time. | No | No |  |  |  |
| USA | Cavallo Ventures | Pasture Bio | Veterinary/Ag | Developing vaccines to reduce methane emissions in cattle. | No | No |  |  |  |
| Netherlands | Anterra Capital | BiomEdit | Veterinary | Spin-out from Elanco. Develops microbiome-based therapeutics and novel probiotics for animal health (livestock and pets). | No | Yes (Therapeutic/Probiotic) | No |  |  |
| Netherlands | Anterra Capital | Enko | Other (AgTech) | Discovers novel small molecule crop protection products using DNA-encoded libraries (drug discovery tech applied to ag). | No | No |  |  |  |
| Netherlands | Anterra Capital | Invetx | Veterinary | Exited. Biopharma developing monoclonal antibodies for chronic diseases in companion animals. | No | No |  |  |  |
| Netherlands | Anterra Capital | Animol | Veterinary | Incubated. Focused on discovering novel small molecule drugs for animal health using accelerated discovery platforms. | No | No |  |  |  |
| Netherlands | Anterra Capital | Caribou Biosciences | Other (Biotech) | CRISPR genome editing company (IPO). Technology applicable to agriculture and therapeutics. | No | No |  |  |  |
| Netherlands | Anterra Capital | ProducePay | Other (Fintech) | Financial and data platform for the fresh produce supply chain. | No | No |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | BlueNalu | Other (Food) | Cellular aquaculture producing seafood from cells. Nutreco collaborates on supply chain/feed for cells. | No | No |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | Mosa Meat | Other (Food) | Cultivated meat pioneer (beef). Nutreco provides expertise in feed components for cell media. | No | No |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | Proteon Pharmaceuticals | Veterinary | Bacteriophage technology to combat bacteria in aquaculture and livestock, reducing antibiotic use. | No | No (Therapeutic) |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | ViAqua | Veterinary | RNA-particle platform for aquaculture health, specifically targeting viral diseases like White Spot Syndrome in shrimp. | No | No |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | Eruvaka | Other (AgTech) | IoT and cloud-based aquaculture pond management solutions (smart feeding). | No | No |  |  |  |
| Netherlands | NuFrontiers (Nutreco)  | Enough (formerly 3F Bio) | Other (Food) | Produces mycoprotein (fungi-based) via fermentation for sustainable protein. | Yes (Ingredients) | No | No |  |  |
| Switzerland | Blue Horizon | Beyond Meat | Other (Food) | Exited. Plant-based meat giant. | No | No |  |  |  |
| Switzerland | Blue Horizon | Mosa Meat | Other (Food) | Cultivated beef. | No | No |  |  |  |
| Switzerland | Blue Horizon | Wild Earth | Other (Consumer) | Plant-based pet food company using koji (fungi) protein. Offers high-protein dog food and supplements. | Yes (Primary) | Yes | No |  |  |
| Switzerland | Blue Horizon | The EVERY Company | Other (Biotech) | Precision fermentation to create animal-free egg proteins (pepsin, egg white). | No | No |  |  |  |
| Switzerland | Blue Horizon | Geltor | Other (Biotech) | Designer proteins (collagen, elastin) via fermentation for beauty and nutrition markets. | No | Yes (Ingredients) |  |  |  |
| Switzerland | Blue Horizon | Alpha Foods | Other (Food) | Plant-based convenience foods (burritos, nuggets). | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | 4AG Robotics | Other (AgTech) | Autonomous mushroom harvesting robots to address labor shortages. | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | Growers Edge | Other (Fintech) | Financial technology/warranty products for farmers to de-risk adoption of new ag technologies. | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | The Kingfish Company | Other (Food) | Land-based RAS aquaculture producing Yellowtail Kingfish. | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | Ecorobotix | Other (AgTech) | Ultra-high precision smart spraying systems for crops to reduce chemical usage. | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | Withcott Seedlings | Other (Ag) | Australian producer of vegetable tree seedlings. | No | No |  |  |  |
| UK | Cibus Capital (Cibus Fund) | Inscentinel (BeeHero) | Other (AgTech) | Precision pollination services using IoT sensors in beehives. | No | No |  |  |  |
| USA | Vestar Capital Partners | PetHonesty | Other (Consumer) | Premium natural pet health supplements (soft chews) for joint, digestion, and allergy health. | No | Yes (Core Business) | Yes  |  |  |
| USA | Vestar Capital Partners | Big Heart Pet Brands | Other (Consumer) | Exited (to Smucker). Major pet food company (Milk-Bone, Meow Mix). | Yes (Primary) | No | No |  |  |
| USA | Vestar Capital Partners | Manna Pro | Other (Consumer) | Exited (to Carlyle). Health and wellness products for pets (supplements, care). | Yes (Treats) | Yes | No |  |  |
| USA | Vestar Capital Partners | Sun Products | Other (Consumer) | Exited. Laundry and household cleaning products. | No | No |  |  |  |
| UK | Shore Capital | Mission Pet Health | Veterinary | The newly formed entity resulting from the merger of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP), creating a massive network of 700+ hospitals. | No | No |  | Clinic |  |
| UK | Bridgepoint  | Identicare | Other (Services) | UK pet microchipping and pet owner services company. | No | No |  |  |  |
| USA | Roark Capital  | Pet Valu | Other (Retail) | Exited. Major Canadian pet specialty retailer. | Yes (Retailer) | Yes (Retailer) | No |  |  |
| USA | Roark Capital | Pet Supermarket | Other (Retail) | Pet specialty retailer in the SE United States. | Yes (Retailer) | Yes (Retailer) | No |  |  |
| USA | TSG Consumer  | Thrive Pet Healthcare | Veterinary | Formerly Pathway Vet Alliance. A comprehensive veterinary network including primary care, specialty, and urgent care clinics. | No | No |  | Clinic  |  |
| USA | TSG Consumer  | Dogswell | Other (Consumer) | Manufacturer of dog treats with functional benefits. | Yes (Treats) | Yes (Functional) | No |  |  |
| USA | KKR | PetVet Care Centers | Veterinary | Acquirer/operator of general and specialty vet hospitals. | No | No |  | Clinic  |  |
| UK | BC Partners | Gambol Pet Group | Other (Consumer) | Major Chinese pet food manufacturer (Myfoodie brand). | Yes (Primary) | No | No |  |  |
| UK | BC Partners | PetSmart | Other (Retail) | Leading North American pet retailer (Products + Services). | Yes (Retailer) | Yes (Retailer) | No |  |  |
| USA | Advent International | Seek Pet Food | Other (Consumer) | Leading 3rd party manufacturer of pet food/kibble in China. | Yes (Mfg) | No | No |  |  |
| USA | Advent International | Felix Pharmaceuticals | Veterinary | Animal health generics manufacturer (Ireland). | No | No |  |  |  |
| USA | Hellman & Friedman | Zooplus | Other (Retail) | Leading European online pet platform (Partnered with EQT). | Yes (Retailer) | Yes (Retailer) | No |  |  |
| UK | Mayfair Equity | TrustedHousesitters | Other (Services) | Subscription-based pet-sitting and travel community. | No | No |  |  |  |
| Belgium / Germany | Verlinvest | Tom & Co | Other (Retail) | Leading pet retailer in Belgium and France. | Yes (Retailer) | Yes (Retailer) | No | Clinic |  |
| Belgium | Verlinvest | Nesto | Veterinary | Network of veterinary clinics in Belgium, Luxembourg, Germany. | No | No |  | Clinic |  |
| USA | Warburg Pincus | Bond Vet | Veterinary | Urgent care and walk-in veterinary clinic chain (tech-enabled). | No | No |  | Clinic |  |
| USA | Warburg Pincus | Mashura | Other (Tech) | Inventory intelligence/management for vets (CUBEX brand). | No | No |  |  |  |
| France | Eurazeo | Ultra Premium Direct | Other (Consumer) | Exited. French D2C premium pet food brand (sold to Inspired Pet Nutrition). | Yes (Primary) | No | Yes |  |  |
| USA | Paine Schwartz | Axiota Animal Health | Veterinary | Non-antibiotic nutritional health products for cattle (immune/stress support). | No | Yes (Livestock) |  |  |  |
| USA | Paine Schwartz | Hendrix Genetics | Other (Ag) | Multi-species animal genetics (turkeys, layers, swine, aquaculture). | No | No |  |  |  |
| USA | Main Post Partners | Nulo | Other (Consumer) | Premium high-protein, low-carb pet food brand (backed by athletes). | Yes (Primary) | No | No |  |  |
| UK | Cinven | Partner in Pet Food | Other (Consumer) | European private label pet food manufacturer (Sold majority to CVC). | Yes (Primary) | No | No |  |  |
| UK | Cinven | Arcaplanet | Other (Retail) | Leading pet store chain in Italy. | Yes (Retailer) | Yes (Retailer) | No |  |  |
| USA | Swander Pace | Merrick Pet Care | Other (Consumer) | Exited. Natural/organic pet food leader (Sold to Nestle Purina). | Yes (Primary) | No | No |  |  |
| UK | CapVest Partners | Inspired Pet Nutrition (IPN) | Other (Consumer) | The UK's largest independent pet food manufacturer. Owns mass-market brands Harringtons and Wagg. Recently acquired Butcher's Pet Care (wet food) and Ultra Premium Direct (France) to build a pan-European platform. | Yes (Primary) | Yes (Harringtons Supplements) |  |  |  |
| Sweden / Europe | Axcel | The Nutriment Company (formerly Voff) | Other (Consumer) | A leading European consolidator of premium "natural" pet food brands, specifically focusing on RAW (BARF) and air-dried diets. Portfolio includes Nutriment (UK), Leo & Wolf, Energique (Netherlands), and Dibo (Germany). | Yes (Primary) | Yes (AntiForte brand) |  |  |  |
|  | Axcel | Vetopia | Service Provider | A leading veterinary clinic group with over 220 clinics across Denmark, Norway, Sweden, Finland, Germany, Austria, and Switzerland. |  |  |  | Clinic |  |
| USA | Clearlake Capital | Wellness Pet Company | Other (Consumer) | A global pioneer in natural pet nutrition. Formed from the merger of WellPet and other assets. Brands include Wellness, Old Mother Hubbard, Whimzees, and Sojos. Focuses on outcome-based nutrition and dental health. | Yes (Primary) | Yes (Wellness Supplements) |  |  |  |
| USA | PAI Partners | Alphia, NovaTaste | Other (Manufacturing) | The largest custom manufacturer of super-premium pet food in the U.S. Provides turnkey co-manufacturing and R&D services for leading brands and retailers, producing over 1 billion pounds of dry food and treats annually. | Yes (Manufacturer) | No |  |  |  |
| France | Astanor Ventures | Ynsect | Other (AgTech / Ingredients) | A global leader in insect farming (mealworms) to produce high-performance protein and fertilizer. Produces Sprÿng, a premium protein ingredient specifically for the pet food market, offering sustainable and hypoallergenic benefits. | Yes (Ingredients) | No |  |  |  |
| Germany | Astanor Ventures | MicroHarvest | Other (AgTech / Ingredients) | A biotechnology company utilizing precision fermentation to produce sustainable proteins from bacteria. Their technology produces protein significantly faster than animal or plant sources, targeting the pet food and aquafeed markets. | Yes (Ingredients) | No |  |  |  |
| Belgium | The Craftory | Edgard & Cooper | Other (Consumer) | A sustainable pet food challenger brand known for using 100% fresh meat (no meat meal) and biodegradable packaging. They have expanded into dental sticks and functional treats. | Yes (Primary) | No |  |  |  |
| India | The Craftory | Drools | Other (Consumer) | India’s leading domestic pet food company. It holds a dominant market share in South Asia, producing dry food, wet food, and veterinary prescription diets (VetPro) for dogs and cats. | Yes (Primary) | Yes (VetPro Line) |  |  |  |
| UK | Five Seasons Ventures | Butternut Box | Other (Consumer) | A tech-enabled Direct-to-Consumer (DTC) fresh dog food company. They cook fresh meals at low temperatures and deliver them frozen to customers on a subscription basis. Recently acquired PsiBufet (Poland). | Yes (Primary) | No |  |  |  |
| Germany | Five Seasons Ventures | Mammaly | Other (Consumer) | A pet health brand specializing in functional snacks and supplements. They focus on preventative health issues like digestion, joint mobility, and calming, delivered in a treat format rather than a pill. | No | Yes (Core Business) |  |  |  |
| UK | Five Seasons Ventures | Untamed | Other (Consumer) | A premium DTC cat food brand rejecting "junk" ingredients. They offer high-protein, human-grade whole meat recipes in tins, focusing on feline health and longevity. | Yes (Primary) | No |  |  |  |
| USA | Linden Capital | Rarebreed Veterinary Partners | Veterinary | A technology-enabled veterinary services platform in the Northeast U.S. Operates a network of general practice hospitals and PetMedic urgent care clinics, focusing on staff retention and modernizing the care experience. | No | No |  | Clinic |  |
| USA | Linden Capital | Axiota Animal Health | Veterinary (Livestock) | A non-antibiotic animal health platform. Develops nutritional products (like Multimin 90 and Lactipro) to support immune function and transition periods in beef and dairy cattle. | No | Yes (Livestock) |  |  |  |
| Italy / Europe | NXMH | Whitebridge Pet Brands (EU) | Other (Consumer) | The European arm of Whitebridge (retained after NXMH sold the N. American business to General Mills). Includes Schesir, Stuzzy, and ADOC brands, focusing on natural, minimally processed wet food for cats and dogs. | Yes (Primary) | No |  |  |  |
| USA | JAB Holding Company | NVA (National Veterinary Associates) |  | One of the world's largest veterinary platforms operating 1,000+ general practice hospitals, equine centers, and pet resorts. | No | No |  | Clinic |  |
| USA | JAB Holding Company | Ethos Veterinary Health |  | A network of over 140 world-class specialty and emergency veterinary hospitals (distinct from NVA's general practice). | No | No |  | Clinic |  |
| USA | Nordic Capital | United Veterinary Care (UVC) |  | A rapidly growing chain of primary care, emergency, and specialty veterinary hospitals, primarily in the Eastern US. | No | No |  | Clinic |  |
| UK | BC Partners | VetPartners |  | A major European veterinary group (separate from the ANZ entity) operating hundreds of practices across the UK and Continental Europe. | No | No |  | Clinic |  |
| USA | General Atlantic | GoodVets |  | A veterinary care platform partnering with entrepreneurial veterinarians to build and operate modern, state-of-the-art care facilities. | No | No |  | Clinic |  |
| USA | Advent International | National PetCare Centers |  | An operator of veterinary hospitals (identified in investment history). | No | No |  | Clinic |  |


### Sheet: Sheet2

| Country | Fund | Company Name | Link | Pet Food? | Nutraceuticals? |
| --- | --- | --- | --- | --- | --- |
| USA | Digitalis Ventures | Native Pet | https://nativepet.com/?srsltid=AfmBOoq-Fuc0gYzpxNA_u71DQdxBDW0-ypGkcskN2ckZAkzuDT1ZnLZ2 | Yes (Toppers) | Yes (Core Business) |
| USA | Stray Dog Capital | Wild Earth | https://wildearth.com/collections/food?srsltid=AfmBOopi-U5MNQJPaaivMqPqvFmVeSixnucdY9kFXJL-0Nh9lv00ldEl | Yes (Primary) | Yes |
| USA | Gryphon Investors | Vetnique Labs | https://vetnique.com/?srsltid=AfmBOook0aPAA5nTt2mP1bc0ew1ww2Jf_QpnEAVH529aftmSy6kfFkUG | No | Yes (Core Business) |
| USA | Gryphon Investors | Lintbells (YuMOVE) | https://yumove.co.uk/ | No | Yes (Core Business) |
| USA | Morgan Stanley Capital Partners  | FoodScience Corporation | https://www.foodsciencecorp.com/ | No | Yes (Core Business) |
| USA | Morgan Stanley Capital Partners  | Manna Pro (Compana) | https://companapetbrands.com/press/compana-pet-brands-launch | Yes (Treats) | Yes |
| Sweden | EQT Group | IVC Evidensia | https://evidensia.vet/ | No | Yes (Sells/Prescribes) |
| Sweden | EQT Group | Zooplus | https://www.zooplus.fr/ | Yes (Retailer) | Yes (Retailer) |
| Sweden | EQT Group | Dechra Pharmaceuticals | https://www.dechra-us.com/management-areas/companion-animals/supplements-and-treats | No | Yes (Specific lines) |
| Sweden | EQT Group | Musti Group | https://www.mustigroup.com/about-us/ | Yes (Retailer) | Yes (Retailer) |
| Netherlands | Aqua-Spark | Sea6 Energy | https://www.sea6energy.com/ | Yes (Ingredients) | Yes (Ingredients) |
| UK | Inflexion | Lintbells (YuMOVE) |  | No | Yes (Core Business) |
| USA | Cavallo Ventures | Native Microbials | https://www.nativemicrobials.com/ | No | Yes (Livestock) |
| Netherlands | Anterra Capital | BiomEdit | https://biomedit.com/ | No | Yes (Therapeutic/Probiotic) |
| Switzerland | Blue Horizon | Wild Earth |  | Yes (Primary) | Yes |
| Switzerland | Blue Horizon | Geltor |  | No | Yes (Ingredients) |
| USA | Vestar Capital Partners | PetHonesty | https://www.pethonesty.com/?srsltid=AfmBOoqakZ_fW-B-OszaPhvDFG6anaQELCPtO7VWEP_Rf_UFmN8LGtlB | No | Yes (Core Business) |
| USA | Vestar Capital Partners | Manna Pro | https://mannapro.com/ | Yes (Treats) | Yes |
| USA | Roark Capital  | Pet Valu | https://www.petvalu.ca/ | Yes (Retailer) | Yes (Retailer) |
| USA | Roark Capital | Pet Supermarket | https://pet-supermarket.co.uk/?srsltid=AfmBOoqKT5Axwk-X2qBtJxwViyevaPePTUJYw9oPT_1vA12FI4Km_I6X | Yes (Retailer) | Yes (Retailer) |
| USA | TSG Consumer  | Dogswell | https://dogswell.com/treats/ | Yes (Treats) | Yes (Functional) |
| UK | BC Partners | PetSmart | https://www.petsmart.com/ | Yes (Retailer) | Yes (Retailer) |
| Belgium / Germany | Verlinvest | Tom & Co | https://www.tomandco.com/fr-fr/ | Yes (Retailer) | Yes (Retailer) |
| USA | Paine Schwartz | Axiota Animal Health | https://axiota.com/#products | Yes | Yes  |
| UK | Cinven | Arcaplanet | https://www.arcaplanet.it/?srsltid=AfmBOoo5zGf2u06j4Wh-UO3MkvIoJ9ydVwmGn0nE2ed0KCK4RORFUMxX | No | Yes (Livestock) |
| UK | CapVest Partners | Inspired Pet Nutrition (IPN) | https://ipn.co.uk/ | Yes (Retailer) | Yes (Retailer) |
| Sweden / Europe | Axcel | The Nutriment Company (formerly Voff) | https://nutriment.com/ | Yes (Primary) | Yes (Harringtons Supplements) |
| USA | Clearlake Capital | Wellness Pet Company | https://www.wellnesspet.com/ | Yes (Primary) | Yes (AntiForte brand) |
| India | The Craftory | Drools | https://drools.com/ | Yes (Primary) | Yes (Wellness Supplements) |
| Germany | Five Seasons Ventures | Mammaly | https://www.mammaly.de/?srsltid=AfmBOoqe-8Kl6Bd-m_aZ1CZhFrd4qOW_qzt1DAFg0zZfksvJn6nPso8u | Yes (Primary) | Yes (VetPro Line) |
| USA | Linden Capital | Axiota Animal Health |  | No | Yes (Core Business) |
|  |  |  |  | No | Yes (Livestock) |



---

# Source: Companies to contact.xlsx

### Sheet: Sheet1

| Christophe Bailet | Company | Country (HQ) | Key Products / Focus | Strategic Positioning | Size / Revenue | Financing | CEO | CFO | contact@ceva.com | mails |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Pharma & Vet Majors | Zoetis | 🇺🇸 USA | Vaccines, Simparica, Apoquel | Global #1: The "Pfizer of Pets." Innovation in Derma/Pain. | ~$9.3B | Public (NYSE) |  |  |  |  |
| Pharma & Vet Majors | Merck Animal Health | 🇺🇸 USA | Bravecto®, Vaccines | Pharma Heritage: Massive parasiticide & livestock portfolio. | ~$5.9B | Public (NYSE) |  |  |  |  |
| Pharma & Vet Majors | Boehringer Ingelheim | 🇩🇪 Germany | NexGard®, Frontline® | Parasiticide King: #1 in flea/tick globally. | ~$5.0B | Private (Family) |  |  |  |  |
| Pharma & Vet Majors | Elanco | 🇺🇸 USA | Seresto®, Galliprant® | Innovation Focus: Spun out of Eli Lilly; strong pipeline. | ~$4.4B | Public (NYSE) |  |  |  |  |
| Pharma & Vet Majors | Virbac | 🇫🇷 France | Anxitane®, Novifit® | Vet Pure-Play: Largest independent dedicated to animal health. | ~$1.5B | Public (Euronext) | Sébastien Huron | Habib Ramdani | Investor Relations / Finance | finances@virbac.com |
| Pharma & Vet Majors | Ceva Santé Animale | 🇫🇷 France | Adaptil® (Calming) | The Challenger: Leader in pheromones & preventive medicine. | ~$1.9B | Private (Mgmt) | Marc Prikazsky (Chairman & CEO) | Christophe Bailet | Corporate Contact | contact@ceva.com |
| Pharma & Vet Majors | Phibro | 🇺🇸 USA | Feed Additives | Consolidation: Acquired Zoetis's Medicated Feed Additive unit. | ~$1.4B | Public (Nasdaq) |  |  |  |  |
| Pharma & Vet Majors | Vetoquinol | 🇫🇷 France | Zylkène®, Flexadin® | "Essentials": High-margin preventive nutrition focus. | ~$580M | Public (Euronext) | Matthieu Frechin | Régis Vimal du Monteil | Investor Relations | investors@vetoquinol.com |
| Feed & Ingredient Giants | Cargill Animal Nutrition | 🇺🇸 USA | Diamond V, Provimi | Scale King: Vertical integration from crops to premixes. | Titan | Private (Family) |  |  |  |  |
| Feed & Ingredient Giants | Nutreco (Trouw) | 🇳🇱 Netherlands | Premixes | Sustainability: Huge footprint in aqua & livestock premixes. | Titan | Private (SHV) |  |  |  |  |
| Feed & Ingredient Giants | DSM-Firmenich | 🇨🇭 Swiss / 🇳🇱 NL | Vitamins, Bovaer® | Science-Driven: Vitamins, minerals, and sustainability. | Titan | Public (Euronext) |  |  |  |  |
| Feed & Ingredient Giants | ADM | 🇺🇸 USA | Protexin, DE111® | Fermentation: Massive fermentation capacity for probiotics. | Titan | Public (NYSE) |  |  |  |  |
| Feed & Ingredient Giants | Novonesis | 🇩🇰 Denmark | Probiotics, Enzymes | Biotech Platform: Merger of Novozymes + Chr. Hansen. | Titan | Public (CPH) |  |  |  |  |
| Feed & Ingredient Giants | Alltech | 🇺🇸 USA | Actigen® (Yeast) | Genomic Pioneer: Family-owned biotech giant. | ~$2B | Private (Family) |  |  |  |  |
| Feed & Ingredient Giants | ForFarmers | 🇳🇱 Netherlands | Compound Feed | Cost Leader: Low-cost producer model for livestock feed. | Titan | Public (Euronext) |  |  |  |  |
| Pet Food & Brand Giants | Nestlé Purina | 🇨🇭 Swiss / 🇺🇸 USA | Pro Plan, FortiFlora® | Global Titan: Massive R&D scale; "Pet Humanization" focus. | ~$22B | Public (Nestlé) | Nina Leigh Krueger (CEO North America)* | Stefan Schulte (Global CFO Nestlé Purina) | Bill Etling (Media/Corp Comm) | William.Etling@purina.nestle.com |
| Pet Food & Brand Giants | Mars Petcare | 🇺🇸 USA | Royal Canin, Pedigree | Services & Food: Owns huge vet chains (Banfield) + top brands. | ~$22B | Private (Family) |  |  |  |  |
| Pet Food & Brand Giants | Hill's (Colgate) | 🇺🇸 USA | Prescription Diet | Vet Endorsed: Clinical evidence as the primary moat. | ~$4.4B | Public (Colgate) |  |  |  |  |
| Pet Food & Brand Giants | General Mills | 🇺🇸 USA | Blue Buffalo | Natural Scale: Premium natural food leader. | ~$2.3B | Public (NYSE) |  |  |  |  |
| Pet Food & Brand Giants | Swedencare | 🇸🇪 Sweden | PlaqueOff®, NaturVet | Aggregator: Buys high-margin niche leaders (Dental/Supplements). | ~$240M | Public (Nasdaq) | Håkan Lagerberg | Jenny Graflind | Håkan Lagerberg (CEO) | hakan.lagerberg@swedencare.se jenny.graflind@swedencare.se  |
| Pet Food & Brand Giants | Freshpet | 🇺🇸 USA | Fresh Refrigerated Food | Category Creator: High-growth "Fresh" segment leader. | ~$500M | Public (Nasdaq) |  |  |  |  |
| Pet Food & Brand Giants | Wellness Pet | 🇺🇸 USA | Wellness Core | Premium Natural: Strong DTC and dental treat portfolio. | Large | Clearlake (PE) |  |  |  |  |
| Pet Food & Brand Giants | Nulo | 🇺🇸 USA | High-Protein Food | Challenger Brand: High-protein, grain-free positioning. | Large | Main Post (PE) |  |  |  |  |
| Commercial Supplements | Zesty Paws | 🇺🇸 USA | Probiotic Bites | Online #1: The category captain for supplements on Amazon. | Large | H&H Group | Michael Wan (CEO H&H Group North America)* | Simon Wort (CFO H&H Group) | Press & Partnerships | press@zestypaws.com |
| Commercial Supplements | Nutramax | 🇺🇸 USA | Dasuquin® | US Vet #1: The "Gold Standard" in US vet clinics. | Large | Private (Family) | Todd Henderson (President/CEO) | W. Craig Jones | Corporate Contact | contactus@nutramaxlabs.com |
| Commercial Supplements | YuMOVE (Lintbells) | 🇬🇧 UK | Joint Care | UK #1: Vertically integrated (owns NZ mussel farms). | Large | VetPartners | Fiona Hope | Paul Eastwood (Finance Director) | Corporate / Media | hello@yumove.com |
| Commercial Supplements | SmartPak | 🇺🇸 USA | Custom Supplements | Compliance: Unit-dose packaging for horses. | Large | Covetrus |  |  |  |  |
| Commercial Supplements | VetriScience | 🇺🇸 USA | GlycoFlex® | Legacy: 40+ years of vet formulas. Own manufacturing. | Large | Morgan Stanley |  |  |  |  |
| Specialized Ingredients | Gelita | 🇩🇪 Germany | Petagile® (Collagen) | Collagen Leader: Specific peptides for cartilage regeneration. | Titan | Private |  |  |  |  |
| Specialized Ingredients | Balchem | 🇺🇸 USA | ReaShure® (Choline) | Encapsulation: Precision coating for nutrient survival. | Titan | Public (Nasdaq) |  |  |  |  |
| Specialized Ingredients | Evonik | 🇩🇪 Germany | MetAMINO® | Amino Acid King: World's purest DL-Methionine. | Titan | Public (Germany) |  |  |  |  |
| Specialized Ingredients | Adisseo | 🇫🇷 FR / 🇨🇳 CN | Rovabio® (Enzymes) | Nutrient Unlocker: Enzymes for fiber digestion. | Titan | Sinochem (China) |  |  |  |  |
| Specialized Ingredients | Bioiberica | 🇪🇸 Spain | Condrovet® | Extraction Expert: #1 Heparin/Chondroitin producer. | Large | Private |  |  |  |  |
| Specialized Ingredients | Zinpro | 🇺🇸 USA | Availa® (Minerals) | Bioavailability: Minerals using amino-acid transport. | Large | Private |  |  |  |  |
| Specialized Ingredients | Lonza | 🇨🇭 Switzerland | UC-II® (Collagen) | Ingredient Brand: Licensor of the famous UC-II collagen. | Titan | Public (Swiss) |  |  |  |  |
| Specialized Ingredients | Aroma NZ | 🇳🇿 New Zealand | GlycOmega™ | Source Control: Green Lipped Mussel supplier. | Mid | Private |  |  |  |  |
| Startups & Biotech | BiomEdit | 🇺🇸 USA | Biome-Actives | Deep Tech: Synthetic biology for feed additives. Elanco Spin-Off | Startup | Gates, Anterra, Viking, Anterra Capital, Ginkgo Bioworks, Elanco, ferment, Nutreco | Aaron Schacht | Barbara Bodem (Director/Strategic Advisor) | General Contact | info@biomedit.com |
| Startups & Biotech | Proteon | 🇵🇱 Poland | BAFASAL® (Phages) | Bacteriophages: Killing bacteria without antibiotics. | Scale-up | Nutreco, AquaSpark |  |  |  |  |
| Startups & Biotech | Bond Pet Foods | 🇺🇸 USA | Brewed Protein | SynBio Chef: Yeast-fermented meat proteins. Partnership with Hill's Pet Nutrition | Startup | ADM, Cavallo, ADM Ventures, Cavallo Ventures, Genoa Ventures, iSelect Fund, Joan Jett, Lever VC, Lifely VC, Satori Capital, Sia Furler, Stage 1 Fund, Thia Ventures | Rich Kelleman | Mike Valeriati | Media Inquiries | hello@bondpets.com |
| Startups & Biotech | MicroHarvest | 🇩🇪 Germany | Single Cell Protein | Speed: Protein fermentation 5000x faster than soy. | Startup | FoodLabs |  |  |  |  |
| Startups & Biotech | AnimalBiome | 🇺🇸 USA | Gut Restore (FMT) | Poop Pills: Fecal transplants and DNA testing. | Growth | Cargill, Mars, DSM Firmenich, Cargill, Digitalis Venture | Carlton Osborne | Ann Marie Cotter | Press & Media | press@animalbiome.com |
| Startups & Biotech | Gnubiotics | 🇨🇭 Switzerland | Glycans | Milk Mimics: Replicating mother's milk sugars (HMOs). exclusive global partnership with ADM | Startup | ADM Ventures, Venture Kick, Fondation The Ark, Horizon 2020, UBS & Canton de Vaud, Innosuisse,  | Yemi Adesokan | Bernardo Horta e Costa | Yemi Adesokan | yemi@gnubiotics.com |
| Startups & Biotech | CanBiocin | 🇨🇦 Canada | K9-17 Strain | Strain Bank: Species-specific probiotics for dogs. | Startup | Natural Products Can |  |  |  |  |
| Startups & Biotech | Folium Science | 🇬🇧 UK | Guided Biotics™ | CRISPR: "Genetic Scalpel" to remove bad bacteria. | Early | Innovate UK |  |  |  |  |
| Startups & Biotech | Anizome | 🇺🇸 / 🇬🇧 | Discovery Platform | Data: Mapping the microbiome for Pharma discovery. | JV | Stonehaven/Baylor |  |  |  |  |
| Startups & Biotech | Biome9 | 🇬🇧 UK | AI Gut Test | AI Testing: European "Twin" to AnimalBiome. | Acquired | VAFO Group |  |  |  |  |
| Specialized Niche | Vetnique Labs | 🇺🇸 USA | Glandex® | Category Creator: Invented "Anal Gland" supplements. | Mid | Gryphon (PE) |  |  |  |  |
| Specialized Niche | Innovet | 🇮🇹 Italy | Redonyl® (PEA) | Pain: Palmitoylethanolamide (PEA) technology. | Acquired | Swedencare |  |  |  |  |
| Specialized Niche | Phytobiotics | 🇩🇪 Germany | Miarom® (Oils) | Sensory: Essential oils to mask animal scent from ticks. | Mid | Private, family owned | Dr. Hermann Roth | Kurt Wegleitner (Managing Director/Finance) | General Management | info@phytobiotics.com |
| Specialized Niche | Candioli | 🇮🇹 Italy | Acarene | Exotics: Safe mite control for birds/rabbits. | Mid | Private |  |  |  |  |
| Specialized Niche | ElleVet | 🇺🇸 USA | Calm & Comfort | Science: The only CBD with Cornell clinical data. | Growth | Private, Autofinancé | Haley Israelson |  | General Inquiries | info@ellevetsciences.com |
| Specialized Niche | Earth Animal | 🇺🇸 USA | Nature's Protection | Clean Label: Chemical-free flea/tick prevention. | Mid | Centripetal (PE) | Stewart Shanley | Jonathan Miller | Susan Goldstein (Media/PR) | media@earthanimal.com |
| Emerging Tech | Seaqure Labs | 🇸🇪 Sweden | Mycelium Fermentation | Circular: Sustainable aquaculture feed. | Startup | - |  |  |  |  |
| Emerging Tech | Rumin8 | 🇦🇺 Australia | Synthetic Chemistry | Methane: Scalable methane reduction. | Startup | Breakthrough Energy Ventures (BEV) : Le fonds fondé par Bill Gates, Harvest Road Group : La branche agroalimentaire de Tattarang, Aware Super, Main Sequence Ventures, Prelude Ventures | David Messina | Darren Hunt | Cameron Morse (Media Rep) | cameron.morse@fticonsulting.com |
| Emerging Tech | Symbrosia | 🇺🇸 USA | Seaweed Aquaculture | Methane: Natural methane reduction. | Startup | Idemitsu, Danone, Hatch, One Small Planet  Dec 2025: Symbrosia Raises Additional $5.8M in Series A-1 Funding to Accelerate Commercial Scale-Up of SeaGraze® |  |  |  |  |
| Emerging Tech | Hoofprint Biome | 🇺🇸 USA | Microbiome Engineering | Probiotics: For methane & yield. | Startup | SOSV, Amazon’s Climate Pledge Fund,  | Kathryn Polkoff |  | Founders/General | hello@hoofprintbiome.com |
| Emerging Tech | Veramaris | 🇳🇱 / 🇺🇸 | Algal Fermentation | Omega-3s: Sustainable sources (No fish). | JV | DSM/Evonik 50/50 owned | Mark van Nieuwland | Holger Kinzel | Corporate / Media | press@veramaris.com |
| Retail & Services | PetSmart | 🇺🇸 USA | Retail Chain | US Retail King: Largest pet specialty retailer in N. America. | Titan | Private (BC Partners) | Ken C. Hicks  | Alan Schnaid | Media & PR IR | MediaRelations@PetSmart.com InvestorRelations@PetSmart.com  |
| Retail & Services | IVC Evidensia | 🇬🇧 UK | Veterinary Clinics | Vet Aggregator: Europe’s largest veterinary care provider. | Titan | Private (EQT / Silver Lake) |  |  |  |  |
| Retail & Services | Zooplus | 🇩🇪 Germany | Online Retail | E-Commerce Giant: The "Amazon of Pets" for Europe. | Titan | Private (Hellman & Friedman) | Lionel Desclée | Steffen Schüller | IR Press Vendor/Marketplace | ir@zooplus.com press@zooplus.com info-marketplace@zooplus.com |
| Retail & Services | Pet Valu | 🇨🇦 Canada | Retail Chain | Neighborhood Retail: Canada’s dominant franchise retailer. | Titan | Public (TSX) |  |  |  |  |
| Retail & Services | Musti Group | 🇫🇮 Finland | Retail Chain | Nordic Leader: Dominant ecosystem in Nordics (Retail + Vet). | Large | Public / Sonae (80%) |  |  |  |  |
| Retail & Services | Arcaplanet | 🇮🇹 Italy | Retail Chain | Italian Leader: #1 Chain in Italy (merged with Maxi Zoo Italy). | Large | Private (Cinven) |  |  |  |  |
| Retail & Services | Pet Supermarket | 🇺🇸 USA | Retail Chain | Regional Power: Strong footprint in US Southeast. | Large | Private (Roark Capital) |  |  |  |  |
| Retail & Services | Tom & Co | 🇧🇪 Belgium | Retail Chain | Benelux Leader: Major Belgian/French specialty retailer. | Mid | Private (Investment Group) |  |  |  |  |
| Pet Food & Brands | Compana (Manna Pro) | 🇺🇸 USA | Care & Nutrition | The Aggregator: Massive portfolio (Fruitables, Bullymax, Higgins). | ~$600M+ | Private (Carlyle) |  |  |  |  |
| Pet Food & Brands | Wellness Pet Co. | 🇺🇸 USA | Wellness Core | Premium Pioneer: A legacy leader in natural pet food. | Large | Clearlake (PE) |  |  |  |  |
| Pet Food & Brands | Inspired Pet Nutrition | 🇬🇧 UK | Harringtons, Wagg | UK Manufacturing: Largest independent dry food producer in UK. | Large | CapVest (PE) |  |  |  |  |
| Pet Food & Brands | Drools | 🇮🇳 India | Dry Food / Treats | India's Unicorn: The dominant domestic pet food player in India. | ~$1B Val. | L Catterton / Nestlé |  |  |  |  |
| Pet Food & Brands | The Nutriment Co. | 🇸🇪 Sweden | Raw Food (Voff) | RAW Consolidation: Buying up raw food leaders (Leo & Wolf, etc). | Large | Axcel (PE) |  |  |  |  |
| Pet Food & Brands | Wild Earth | 🇺🇸 USA | Koji Dog Food | Alternative Protein: Fungi-based (Koji) vegan dog food. | Startup | VC (Cuban/VegInvest) |  |  |  |  |
| Supplements | FoodScience Corp | 🇺🇸 USA | VetriScience | Manufacturing: Parent of VetriScience; strong production arm. | Large | Morgan Stanley (PE) |  |  |  |  |
| Supplements | PetHonesty | 🇺🇸 USA | Functional Chews | E-Comm Scale: Rapid growth via Amazon/DTC to Retail. Direct competitors to Zesty paws  | Mid | Vestar Capital | Richard Greenberg | Nomit Shah | General Inquiries Press & Media PR Agency | hello@pethonesty.com press@pethonesty.com jhurson@lambert.com |
| Supplements | Native Pet | 🇺🇸 USA | Clean Supplements | Clean Label: "No filler" powders and chews (DTC focus). | Growth | VC (Cavallo/Mars) | Dan Schaefer | Kevin Bell | General Contact | info@nativepet.com |
| Supplements | Vetnique Labs | 🇺🇸 USA | Glandex | Problem Solver: Solved the "Anal Gland" niche; expanding. | Mid | Gryphon (PE) |  |  |  |  |
| Supplements | Mammaly | 🇩🇪 Germany | Functional Chews | DTC Leader: Rapidly growing German supplement snack brand.  Zesty Paws like but in a European zmpty market | Growth | Five Seasons VC | Stanislav Nazarenus & Alexander Thelen  (Co-CEOs) | Philipp Jacobs (VP Finance) | Corporate (Germany) | hello@mammaly.de |
| Supplements | Dogswell | 🇺🇸 USA | Functional Treats | Functional First: Jerky with benefits (Hip & Joint). | Mid | Private (Whitebridge) |  |  |  |  |
| Pharma & Biotech | Dechra | 🇬🇧 UK | Vet Pharma | Endocrinology: Global specialist in difficult diseases (Cushing's). | ~$900M+ | Private (EQT) |  |  |  |  |
| Pharma & Biotech | Axiota | 🇺🇸 USA | Cattle Health | Immune Support: Non-antibiotic health for beef/dairy (Multimin).  the only FDA-approved injectable supplement that delivers four trace minerals precisely  | Mid | Paine Schwartz | William (Bill) Weldon | Frank Pirozzi | Media & Events (Key Contact): Kimber Bay Investor Relations: Paine Schwartz Partners | kbay@axiota.com info@paineschwartz.com |
| Pharma & Biotech | Native Microbials | 🇺🇸 USA | Rumen Microbes | Dairy Yield: Mapping the rumen microbiome to improve yield. Partnership with Zesty Paws BiomEdit counterpart, more natural | Startup | VC Backed, Anterra Capital | Mike Seely | Carlo Scapinelli | General Info | info@nativemicrobials.com |
| Pharma & Biotech | Sea6 Energy | 🇮🇳 India | Red Seaweed | Ocean Tech: Tropical red seaweed for biostimulants/animal health. | Scale-up | BASF / Aqua-Spark |  |  |  |  |
| Pharma & Biotech | Geltor | 🇺🇸 USA | Bio-Collagen | Design Proteins: Fermentation-derived collagen (vegan). | Startup | VC (CPT Capital) |  |  |  |  |



---

# Source: GreenLabel_OpenAI.docx

Based on your whitepaper and current strategic intelligence for 2026,
the \"Green Label\" trend is not just continuing; it is mutating from a
soft marketing claim into a **hard procurement requirement**.

To answer your question directly: **Yes, green labels are being
institutionalized**, and they are creating a distinct, multi-billion
dollar market layer that operates on \"permission to play\" logic rather
than just consumer preference.

Here is the comprehensive analysis of the extent of this trend, its
institutionalization, and the emerging labels you need to know.

**1. How far will this trend go? (The Extent)**

The trend is moving from **Subjective Marketing** (e.g., \"Eco-friendly
packaging\") to **Objective Quantification** (e.g., \"Scope 3 Emission
Reduction\").

- **The Shift:** In livestock, \"Green\" is no longer about a sticker on
  a bag; it is about **Scope 3 Supply Chain Compliance**. Major
  integrators (like Danone or Tyson) now require feed suppliers to
  provide data on carbon footprint reduction to meet their corporate Net
  Zero goals.

- **Market Size:** Your whitepaper values the \"Green Claim Economy\"
  (Sustainability sector) at **\$3.35 billion** today, growing at **7.7%
  CAGR**.

- **The Limit:** The trend extends to the \"Great Divergence\" where:

  - **Livestock** green labels focus on *Efficiency* (Methane/Nitrogen
    reduction).

  - **Pets** green labels focus on *Purity* (Clean Label, No-Neurotoxin,
    Upcycled).

**2. Will Green Labels be Institutionalized?**

**Yes.** The institutionalization is happening right now through two
major regulatory mechanisms that are turning \"voluntary\" labels into
legal product categories.

**A. The US: The Innovative FEED Act (H.R. 2203)**

This is the most critical piece of institutionalization in the US.

- **Old Reality:** Currently, if a feed additive claims to \"reduce
  methane\" (an environmental benefit), the FDA classifies it as a
  **Drug**, requiring years of testing.

- **New Reality (Institutionalized):** The **Innovative FEED Act**
  creates a new pathway for \"Zootechnical Animal Food Substances.\" It
  allows products to make non-nutritive claims (like emission reduction
  or gut microbiome improvement) as **Food Additives**, not drugs.

- **Market Impact:** This opens the floodgates for products like
  **3-NOP** and **Asparagopsis** (seaweed) to be sold legally with a
  \"Green/Methane-Reducing\" label, instantly creating a new regulated
  market class.

**B. The EU: The \"Green Claims\" Directive & Farm to Fork**

- **Code of Good Labelling:** The EU has updated the Code of Good
  Labelling Practice to include environmental performance (PEFCR). You
  cannot just say \"Green\"; you must substantiate it with specific
  lifecycle data (LCA).

- **Institutional Driver:** The \"Farm to Fork\" strategy mandates a 50%
  reduction in nutrient loss, effectively forcing the adoption of
  \"Green\" nitrogen-efficiency tools like Phytase and Protease.

**3. Emerging New Green Labels: Everything You Need to Know**

New labels are emerging to capture specific value pools. They are
categorized by species and function:

**A. The \"Climate Compliance\" Labels (Livestock Focus)**

These are B2B labels used to secure contracts with major food producers.

- **\"Low Methane\" / \"Cooling\" Labels:**

  - **Ingredients:** **3-NOP** (Bovaer) and **Asparagopsis** (Red
    Seaweed).

  - **Promise:** Reduces enteric methane emissions by 30--80%.

  - **Market:** Farmers use this to sell \"Low Carbon Beef\" or
    \"Climate Smart Milk\" at a premium.

- **\"Nitrogen Efficient\" / \"Water Protection\" Labels:**

  - **Ingredients:** **Phytase** and **Protease** enzymes.

  - **Promise:** Reduces nitrogen and phosphorus excretion into
    soil/water (preventing algae blooms).

  - **Status:** Almost mandatory in the EU due to nitrate regulations.

**B. The \"Clean & Safe\" Labels (Pet Focus)**

These are B2C labels driven by owner anxiety and the \"humanization\"
trend.

- **\"No-Neurotoxin\" / \"Pesticide-Free\" Label:**

  - **Context:** Owners are increasingly afraid of isoxazoline (oral
    flea/tick pill) side effects like seizures.

  - **Emerging Label:** **\"Natural Ectoparasite Defense\"** using
    ingredients like cedar oil or peppermint. These take advantage of
    the EPA 25(b) exemption to bypass drug registration while claiming
    safety.

- **\"Upcycled\" / \"Circular\" Label:**

  - **Context:** Sustainability for pets.

  - **Ingredients:** **Insect Protein** (Black Soldier Fly Larvae) or
    **Algal DHA** (replacing fish oil).

  - **Promise:** \"Does not deplete the oceans.\" Algal DHA alone is a
    \$250M niche protecting supply chains from climate risks.

- **\"Postbiotic\" / \"Abiotic\" Label:**

  - **Context:** Moving beyond \"Live Probiotics\" which die in the bag.

  - **Emerging Label:** **\"Guaranteed Bio-Active\"**. Using inanimate
    microorganisms (Postbiotics) that survive processing and provide
    consistent immune signaling.

**Summary Table: The New Green Market Structure**

  ----------------------------------------------------------------------------------
  Label Category          Target Audience  Key Regulation/Driver  Winning
                                                                  Ingredients
  ----------------------- ---------------- ---------------------- ------------------
  **\"Low Carbon\"**      Dairy/Beef       Scope 3 / Innovative   3-NOP,
                          Integrators      FEED Act               Asparagopsis

  **\"Nitrogen Smart\"**  Swine/Poultry    EU Nitrates Directive  Phytase, Protease
                          Farms                                   

  **\"No-Neurotoxin\"**   Pet Owners       EPA 25(b) Exemption    Essential Oils,
                                                                  Geraniol

  **\"Ocean Safe\"**      Aqua/Pet Food    Supply Chain           Algal DHA, Insect
                                           Resilience             Protein
  ----------------------------------------------------------------------------------

Export to Sheets

**Strategic Prediction:** The market will split. In **Livestock**,
\"Green\" will become a **license to operate** (you won\'t be able to
sell milk without it). In **Pets**, \"Green\" will remain a **premium
differentiator** allowing brands to charge 20-30% more for
\"sustainable/clean\" claims.

Based on a fresh analysis of regulatory filings, industry reports, and
legislative texts from late 2025 and early 2026, here is your report on
the future of green labels in animal nutraceuticals.

**Strategic Intelligence Report: The Institutionalization of Green
Labels (2026)**

**Executive Summary:** The \"Green Label\" trend is rapidly hardening
from a marketing advantage into a regulatory \"license to operate.\" The
era of self-declared eco-friendliness is ending. By 2026, we are
witnessing the **bifurcation** of the market:

1.  **Livestock (B2B):** Green labels are becoming **standardized
    compliance metrics** (Scope 3, Nitrogen efficiency) required to sell
    to major integrators.

2.  **Pet Care (B2C):** Green labels are evolving into **\"Safety &
    Ethics\" certifications** (Upcycled, No-Toxin) driven by the
    humanization trend.

**1. Will Green Labels be Institutionalized? (The \"Hard\" Shift)**

**Yes.** The transition is being driven by specific legislation in the
EU and US that forces companies to substantiate claims with hard data
(Life Cycle Assessments).

**A. The European Union: The \"Green Claims\" Directive & PEFCR**

The EU is setting the global standard for data-driven labeling.

- **The Green Claims Directive (GCD):** As of early 2026, this directive
  (currently in trilogue negotiations) bans generic terms like \"carbon
  neutral\" or \"eco-friendly\" unless backed by a recognized Life Cycle
  Assessment (LCA). It effectively outlaws \"greenwashing\" by requiring
  third-party verification before a label can appear on a package.

- **PEFCR Integration:** The EU Member States have endorsed an updated
  **Code of Good Labelling Practice for Compound Feed**. This integrates
  the **Product Environmental Footprint Category Rules (PEFCR)**,
  meaning feed labels must now use a standardized methodology (GFLI
  database) to calculate environmental impact. You can no longer just
  *say* your feed is green; you must *calculate* it using the EU\'s
  specific formula.

**B. The United States: The Innovative FEED Act of 2025**

The US is opening a new regulatory lane that institutionalizes
\"environmental performance\" as a product class.

- **The Legislation:** The **Innovative FEED Act of 2025 (H.R. 2203)**
  creates a new category for \"Zootechnical Animal Food Substances.\"

- **The Shift:** Previously, a feed additive that claimed to \"reduce
  methane\" was regulated as a drug (a 5-8 year approval process). This
  Act reclassifies them closer to food additives. This institutionalizes
  the \"Green Label\" by giving products like **3-NOP** (methane
  blockers) a legal pathway to be sold specifically for their
  environmental benefits without being called drugs.

**2. Emerging New Green Labels: The New Market Hierarchy**

New labels are emerging to capture specific value pools, split clearly
between \"Climate Compliance\" (Livestock) and \"Eco-Purity\" (Pets).

**Category A: The \"Climate Compliance\" Labels (Livestock Focus)**

*Target: Integrators (Danone, Tyson, Fonterra) who need to hit Net Zero
targets.*

- **\"Scope 3 Verified\" / \"Low Carbon Feed\":**

  - **What it is:** A label certifying the feed has a lower carbon
    footprint per kg of gain.

  - **Key Driver:** Global dairy and beef processors are now mandating
    their suppliers reduce on-farm emissions. Feed with this label acts
    as a \"carbon credit\" in the supply chain.

  - **Key Ingredients:** Methane inhibitors (3-NOP, Red
    Seaweed/Asparagopsis), Rumen modifiers.

- **\"Nitrogen Smart\" / \"Water Safe\":**

  - **What it is:** Certifies that the feed reduces nitrogen excretion
    in manure (preventing algae blooms/water pollution).

  - **Key Driver:** Strict nitrate regulations in the Netherlands,
    Ireland, and increasingly the US Midwest.

  - **Key Ingredients:** High-efficiency Phytase, Protease enzymes, and
    crystalline amino acids.

**Category B: The \"Eco-Purity\" Labels (Pet Focus)**

*Target: Millennial/Gen Z owners who equate \"Green\" with \"Safe\" and
\"Moral\".*

- **\"Upcycled Certified\" (The Big Winner):**

  - **What it is:** A rapidly growing certification for products using
    \"waste\" streams (e.g., \"ugly\" vegetables, spent brewer\'s
    grains, salmon trimmings).

  - **Why it\'s winning:** It solves the \"food vs. feed\" moral
    conflict. Owners feel good that their pet isn\'t competing with
    humans for prime meat.

  - **Market Projection:** The upcycled animal feed market is projected
    to grow significantly (some estimates point toward \$42B+ by 2030
    for the broader sector).

- **\"Insect Protein\" / \"Planet Friendly Protein\":**

  - **What it is:** Dog food and treats made from Black Soldier Fly
    Larvae (BSFL) or Mealworms.

  - **The Pitch:** \"Hypoallergenic AND Sustainable.\" It uses a
    fraction of the water and land compared to beef or chicken.

- **\"No-Neurotoxin\" / \"Natural Defense\":**

  - **What it is:** While not strictly \"green,\" this label appeals to
    the same \"natural\" demographic. It markets essential oil-based
    flea/tick prevention (Cedarwood, Peppermint) as an eco-friendly
    alternative to chemical isoxazolines.

**3. Strategic Conclusion: How Far Will It Go?**

The trend will go as far as **Auditability**.

- **For Livestock:** If you cannot digitally prove your carbon reduction
  (via blockchain or verified LCA), you will eventually be de-listed by
  major food processors. The label is no longer a sticker; it is a data
  packet.

- **For Pets:** The \"Green\" label is merging with \"Premium.\" Brands
  like **Bond Pet Foods** (fermentation-based protein) and **Chippin**
  (silver carp/insect) are proving that consumers will pay a 20-30%
  premium for \"Science-backed Sustainability.\"

**Sources**

1.  **Innovative FEED Act of 2025 (H.R. 2203) Text & Status**

    - [[Congress.gov - H.R. 2203 Text &
      Actions]{.underline}](https://www.congress.gov/bill/119th-congress/house-bill/2203/text/ih)
      <https://www.congress.gov/bill/119th-congress/house-bill/2203/text/ih>

    - 

2.  **EU Green Claims Directive & Legal Update (2025)**

    - [[CMS Law - Green Claims Directive Legal
      Update]{.underline}](https://cms.law/en/int/publication/the-green-claims-directive-a-legal-update-on-developments-evolving-enforcement-and-overview-of-local-regulations-and-judgments-in-selected-juri)

    - <https://cms.law/en/int/publication/the-green-claims-directive-a-legal-update-on-developments-evolving-enforcement-and-overview-of-local-regulations-and-judgments-in-selected-juri>

    - 

    - [[European Commission - Green Claims
      Proposals]{.underline}](https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en)

    - <https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en>

    - 

3.  **EU Feed Labelling Code & FEFAC (Dec 2025)**

    - [[FEFAC - EU Member States Endorse Code for Green
      Labelling]{.underline}](https://fefac.eu/newsroom/news/eu-member-states-endorse-updated-code-for-green-labelling-for-feed-to-drive-sustainable-animal-feed-production/)

    - <https://fefac.eu/newsroom/news/eu-member-states-endorse-updated-code-for-green-labelling-for-feed-to-drive-sustainable-animal-feed-production/>

    - 

    - [[PEFCR Feed for Food Producing Animals
      Methodology]{.underline}](https://fefac.eu/wp-content/uploads/2020/08/PEFCR_feed.pdf)

    - <https://fefac.eu/wp-content/uploads/2020/08/PEFCR_feed.pdf>

    - 

4.  **Upcycled & Emerging Market Trends**

    - [[Intent Market Research - Upcycled Animal Feed Market
      Forecast]{.underline}](https://intentmarketresearch.com/press-release/upcycled-animal-feed-market-82)

    - <https://intentmarketresearch.com/press-release/upcycled-animal-feed-market-82>

    - 

    - [[Global Market Insights - Upcycled Food Products Market
      Size]{.underline}](https://www.gminsights.com/industry-analysis/upcycled-food-products-market)

    - <https://www.gminsights.com/industry-analysis/upcycled-food-products-market>

    - 

5.  **Pet Industry Trends & Sustainability (2025-2026)**

    - [[NIQ - SuperZoo 2025 Innovation
      Trends]{.underline}](https://nielseniq.com/global/en/insights/analysis/2025/superzoo-2025-innovation-trends-shaping-the-future-of-pet-care/)

    - <https://nielseniq.com/global/en/insights/analysis/2025/superzoo-2025-innovation-trends-shaping-the-future-of-pet-care/>

    - 

    - [[Arjuna Natural - Nutraceutical Trends
      2025-26]{.underline}](https://arjunanatural.com/nutraceutical-trends/)

    - <https://arjunanatural.com/nutraceutical-trends/>

    - 


---

# Source: GreenLabels_gemini.docx

**Strategic Intelligence Report: The Institutionalization of Green
Labels (2026)**

**Executive Summary:** The \"Green Label\" trend is rapidly hardening
from a marketing advantage into a regulatory \"license to operate.\" The
era of self-declared eco-friendliness is ending. By 2026, we are
witnessing the **bifurcation** of the market:

1.  **Livestock (B2B):** Green labels are becoming **standardized
    compliance metrics** (Scope 3, Nitrogen efficiency) required to sell
    to major integrators.

2.  **Pet Care (B2C):** Green labels are evolving into **\"Safety &
    Ethics\" certifications** (Upcycled, No-Toxin) driven by the
    humanization trend.

**1. Will Green Labels be Institutionalized? (The \"Hard\" Shift)**

**Yes.** The transition is being driven by specific legislation in the
EU and US that forces companies to substantiate claims with hard data
(Life Cycle Assessments).

**A. The European Union: The \"Green Claims\" Directive & PEFCR**

The EU is setting the global standard for data-driven labeling.

- **The Green Claims Directive (GCD):** As of early 2026, this directive
  (currently in trilogue negotiations) bans generic terms like \"carbon
  neutral\" or \"eco-friendly\" unless backed by a recognized Life Cycle
  Assessment (LCA). It effectively outlaws \"greenwashing\" by requiring
  third-party verification before a label can appear on a package.

- **PEFCR Integration:** The EU Member States have endorsed an updated
  **Code of Good Labelling Practice for Compound Feed**. This integrates
  the **Product Environmental Footprint Category Rules (PEFCR)**,
  meaning feed labels must now use a standardized methodology (GFLI
  database) to calculate environmental impact. You can no longer just
  *say* your feed is green; you must *calculate* it using the EU\'s
  specific formula.

**B. The United States: The Innovative FEED Act of 2025**

The US is opening a new regulatory lane that institutionalizes
\"environmental performance\" as a product class.

- **The Legislation:** The **Innovative FEED Act of 2025 (H.R. 2203)**
  creates a new category for \"Zootechnical Animal Food Substances.\"

- **The Shift:** Previously, a feed additive that claimed to \"reduce
  methane\" was regulated as a drug (a 5-8 year approval process). This
  Act reclassifies them closer to food additives. This institutionalizes
  the \"Green Label\" by giving products like **3-NOP** (methane
  blockers) a legal pathway to be sold specifically for their
  environmental benefits without being called drugs.

**2. Emerging New Green Labels: The New Market Hierarchy**

New labels are emerging to capture specific value pools, split clearly
between \"Climate Compliance\" (Livestock) and \"Eco-Purity\" (Pets).

**Category A: The \"Climate Compliance\" Labels (Livestock Focus)**

*Target: Integrators (Danone, Tyson, Fonterra) who need to hit Net Zero
targets.*

- **\"Scope 3 Verified\" / \"Low Carbon Feed\":**

  - **What it is:** A label certifying the feed has a lower carbon
    footprint per kg of gain.

  - **Key Driver:** Global dairy and beef processors are now mandating
    their suppliers reduce on-farm emissions. Feed with this label acts
    as a \"carbon credit\" in the supply chain.

  - **Key Ingredients:** Methane inhibitors (3-NOP, Red
    Seaweed/Asparagopsis), Rumen modifiers.

- **\"Nitrogen Smart\" / \"Water Safe\":**

  - **What it is:** Certifies that the feed reduces nitrogen excretion
    in manure (preventing algae blooms/water pollution).

  - **Key Driver:** Strict nitrate regulations in the Netherlands,
    Ireland, and increasingly the US Midwest.

  - **Key Ingredients:** High-efficiency Phytase, Protease enzymes, and
    crystalline amino acids.

**Category B: The \"Eco-Purity\" Labels (Pet Focus)**

*Target: Millennial/Gen Z owners who equate \"Green\" with \"Safe\" and
\"Moral\".*

- **\"Upcycled Certified\" (The Big Winner):**

  - **What it is:** A rapidly growing certification for products using
    \"waste\" streams (e.g., \"ugly\" vegetables, spent brewer\'s
    grains, salmon trimmings).

  - **Why it\'s winning:** It solves the \"food vs. feed\" moral
    conflict. Owners feel good that their pet isn\'t competing with
    humans for prime meat.

  - **Market Projection:** The upcycled animal feed market is projected
    to grow significantly (some estimates point toward \$42B+ by 2030
    for the broader sector).

- **\"Insect Protein\" / \"Planet Friendly Protein\":**

  - **What it is:** Dog food and treats made from Black Soldier Fly
    Larvae (BSFL) or Mealworms.

  - **The Pitch:** \"Hypoallergenic AND Sustainable.\" It uses a
    fraction of the water and land compared to beef or chicken.

- **\"No-Neurotoxin\" / \"Natural Defense\":**

  - **What it is:** While not strictly \"green,\" this label appeals to
    the same \"natural\" demographic. It markets essential oil-based
    flea/tick prevention (Cedarwood, Peppermint) as an eco-friendly
    alternative to chemical isoxazolines.

**3. Strategic Conclusion: How Far Will It Go?**

The trend will go as far as **Auditability**.

- **For Livestock:** If you cannot digitally prove your carbon reduction
  (via blockchain or verified LCA), you will eventually be de-listed by
  major food processors. The label is no longer a sticker; it is a data
  packet.

- **For Pets:** The \"Green\" label is merging with \"Premium.\" Brands
  like **Bond Pet Foods** (fermentation-based protein) and **Chippin**
  (silver carp/insect) are proving that consumers will pay a 20-30%
  premium for \"Science-backed Sustainability.\"

**Sources**

1.  **Innovative FEED Act of 2025 (H.R. 2203) Text & Status**

    - [[Congress.gov - H.R. 2203 Text &
      Actions]{.underline}](https://www.congress.gov/bill/119th-congress/house-bill/2203/text/ih)
      <https://www.congress.gov/bill/119th-congress/house-bill/2203/text/ih>

2.  **EU Green Claims Directive & Legal Update (2025)**

    - [[CMS Law - Green Claims Directive Legal
      Update]{.underline}](https://cms.law/en/int/publication/the-green-claims-directive-a-legal-update-on-developments-evolving-enforcement-and-overview-of-local-regulations-and-judgments-in-selected-juri)
      <https://cms.law/en/int/publication/the-green-claims-directive-a-legal-update-on-developments-evolving-enforcement-and-overview-of-local-regulations-and-judgments-in-selected-juri>

    - [[European Commission - Green Claims
      Proposals]{.underline}](https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en)
      <https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en>

3.  **EU Feed Labelling Code & FEFAC (Dec 2025)**

    - [[FEFAC - EU Member States Endorse Code for Green
      Labelling]{.underline}](https://fefac.eu/newsroom/news/eu-member-states-endorse-updated-code-for-green-labelling-for-feed-to-drive-sustainable-animal-feed-production/)
      <https://fefac.eu/newsroom/news/eu-member-states-endorse-updated-code-for-green-labelling-for-feed-to-drive-sustainable-animal-feed-production/>

    - 

    - [[PEFCR Feed for Food Producing Animals
      Methodology]{.underline}](https://fefac.eu/wp-content/uploads/2020/08/PEFCR_feed.pdf)
      <https://fefac.eu/wp-content/uploads/2020/08/PEFCR_feed.pdf>

    - 

4.  **Upcycled & Emerging Market Trends**

    - [[Intent Market Research - Upcycled Animal Feed Market
      Forecast]{.underline}](https://intentmarketresearch.com/press-release/upcycled-animal-feed-market-82)
      <https://intentmarketresearch.com/press-release/upcycled-animal-feed-market-82>

    - 

    - [[Global Market Insights - Upcycled Food Products Market
      Size]{.underline}](https://www.gminsights.com/industry-analysis/upcycled-food-products-market)
      <https://www.gminsights.com/industry-analysis/upcycled-food-products-market>

    - 

5.  **Pet Industry Trends & Sustainability (2025-2026)**

    - [[NIQ - SuperZoo 2025 Innovation
      Trends]{.underline}](https://nielseniq.com/global/en/insights/analysis/2025/superzoo-2025-innovation-trends-shaping-the-future-of-pet-care/)
      <https://nielseniq.com/global/en/insights/analysis/2025/superzoo-2025-innovation-trends-shaping-the-future-of-pet-care/>

    - [[Arjuna Natural - Nutraceutical Trends
      2025-26]{.underline}](https://arjunanatural.com/nutraceutical-trends/)
      <https://arjunanatural.com/nutraceutical-trends/>

    - 

### Global Strategic Report: The Regulatory & Market Impact of Green Labels (2026)

**Core Thesis:** The \"Green Label\" is fragmenting the global
regulatory landscape.

- **The West (EU/UK/US)** is using regulations to **verify** claims
  (preventing greenwashing).

- **The South & East (LATAM/APAC)** are using regulations to
  **incentivize** production (efficiency & export compliance).

### 1. United States (US): The \"Innovation\" Market

The Regulatory Shift: The Innovative FEED Act (H.R. 2203)

This is the single biggest deregulation event in the history of US
animal nutrition.

- **Before:** If a feed additive claimed to \"reduce emissions\" or
  \"alter the microbiome,\" the FDA classified it as a **Drug**. This
  required 8+ years and \$20M+ for approval.

- **Now (Institutionalized):** The Act creates a new category:
  **\"Zootechnical Animal Food Substances.\"** These products can now
  make environmental claims (e.g., \"Reduces Methane,\" \"Improves Gut
  Efficiency\") while being regulated as **Food Additives** (faster,
  cheaper approval).

**Market Impact:**

- **The \"Carbon Inset\" Boom:** It unleashes a flood of
  methane-reducing products (like *3-NOP*, *Mootral*, *Asparagopsis*)
  onto the US market.

- **Dairy Integration:** US Dairy cooperatives will immediately
  integrate these additives to sell \"Low Carbon Milk\" to processors
  like Starbucks or Nestlé, who need to lower their Scope 3 emissions.

### 2. European Union (EU): The \"Compliance\" Market

The Regulatory Shift: The Green Claims Directive (GCD) & PEFCR

The EU is moving from \"voluntary\" to \"mandatory evidence.\"

- **The Ban:** The GCD effectively bans generic terms like
  \"Eco-friendly,\" \"Green,\" or \"Climate Neutral\" on packaging
  unless they are backed by a **Product Environmental Footprint (PEF)**
  calculation.

- **The Method:** You must use the **PEFCR (Product Environmental
  Footprint Category Rules)** for Feed. This is a complex Life Cycle
  Assessment (LCA) verifying the impact from \"cradle to farm gate.\"

**Market Impact:**

- **\"Green\" Consolidation:** Small pet food brands that cannot afford
  expensive LCAs will stop making green claims. The market will
  consolidate around large players (Royal Canin, Purina) who have the
  data infrastructure to prove compliance.

- **Nitrogen Quotas:** In countries like the Netherlands and Denmark,
  \"Green Labels\" on feed will focus on **Nitrogen Efficiency** (low
  protein, high amino acid) to allow farmers to legally keep their herds
  under strict nitrate pollution limits.

### 3. United Kingdom (UK): The \"Anti-Greenwashing\" Market

The Regulatory Shift: CMA Green Claims Code

The Competition and Markets Authority (CMA) has launched a crackdown
specifically targeting the \"humanization\" sector (Pet Food).

- **The Check:** The CMA is aggressively auditing claims like
  \"Sustainable\" or \"Ocean Friendly.\" If a pet food brand claims
  \"Recyclable Packaging\" but the liner isn\'t recyclable in 100% of UK
  councils, they face fines.

- **Post-Brexit Divergence:** The UK is exploring a fast-track for
  \"Precision Breeding\" (Gene Editing). This could allow **Gene-Edited
  Green Crops** (e.g., soy with higher protein/lower land use) to enter
  the UK feed supply before the EU.

**Market Impact:**

- **B2C Caution:** Pet food marketing will become clinical and precise.
  Expect labels to shift from \"Eco-Friendly\" (vague) to \"Made with
  30% Solar Energy\" (specific).

### 4. Asia-Pacific (APAC): The \"Security & Efficiency\" Market

The Regulatory Shift: Food Security as \"Green\"

In APAC, \"Green\" is often a synonym for \"Efficient\" (reducing
reliance on imported soy).

- **China:** The Ministry of Agriculture\'s new **\"Feed Reduction and
  Substitution\"** guidelines (2025) incentivize low-protein diets to
  reduce soy imports. A \"Green\" label here means \"Low Soy / High
  Tech.\"

- **Australia/New Zealand:** These are the world leaders in **Carbon
  Farming**. The government has approved methodologies where feeding
  methane-reducers to cattle generates **Australian Carbon Credit Units
  (ACCUs)**.

**Market Impact:**

- **Feed as Finance:** In Australia/NZ, feed additives are financial
  instruments. Farmers buy the additive not just for animal health, but
  to generate carbon credits they can sell to miners or airlines.

- **China Pet Market:** The new 2025 Pet Feed Labeling regulations are
  strict on ingredient transparency. \"Green\" claims will likely focus
  on **\"Local Sourcing\"** (reducing food miles/imports) rather than
  carbon footprints.

### 5. Latin America (LATAM): The \"Export Visa\" Market

The Regulatory Shift: EU Deforestation Regulation (EUDR)

LATAM\'s \"Green Label\" market is entirely shaped by external pressure
from Europe.

- **The Mandate:** To sell beef or soy to Europe, Brazilian and
  Argentine producers must prove their supply chain is
  **Deforestation-Free**.

- **Brazil\'s Response:** The **\"Carbon Neutral Brazilian Beef\"** and
  **\"Low Carbon Beef\"** brands developed by Embrapa (Brazilian
  Agricultural Research Corp) are now quasi-official certifications.

**Market Impact:**

- **The \"Green Visa\":** A green label in LATAM is a \"license to
  export.\" Feedlots are adopting \"intensification\" technologies
  (producing more beef on less land) to qualify for these labels.

- **Biologicals Boom:** Brazil is the fastest-growing market for
  **Bio-pesticides** and **Bio-fertilizers** for feed crops, driven by a
  desire to reduce chemical residues and meet \"Clean Label\" demands
  from global buyers.

### Summary Table: Regional Winners & Losers

  -----------------------------------------------------------------------------------------
  **Region**   **The \"Green\" Definition** **Winner (Product        **Loser (Product
                                            Type)**                  Type)**
  ------------ ---------------------------- ------------------------ ----------------------
  **US**       **\"Scope 3 Reducer\"**      Methane Inhibitors       Generic Probiotics
                                            (3-NOP)                  (unproven claims)

  **EU**       **\"LCA Verified\"**         Nitrogen-Smart Enzymes   Vague \"Eco-Friendly\"
                                                                     Brands

  **UK**       **\"Precise & Honest\"**     Insect Protein (proven   \"Ocean Safe\"
                                            data)                    Whitefish (hard to
                                                                     prove)

  **APAC**     **\"Efficient/Credit\"**     Low-Soy Diets & Yield    Imported Premium
                                            Boosters                 Grains

  **LATAM**    **\"Deforestation-Free\"**   Intensification Tools    Extensive Grazing
                                            (Growth Promoters)       (Land heavy)
  -----------------------------------------------------------------------------------------

### 

### 

### Sources

1.  **US - Innovative FEED Act:** [Congress.gov H.R. 2203
    Status](https://www.congress.gov/bill/119th-congress/house-bill/2203)
    <https://www.congress.gov/bill/119th-congress/house-bill/2203>

2.  **EU - Green Claims Directive:** [European Commission - Green
    Claims](https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en)
    <https://environment.ec.europa.eu/topics/circular-economy-topics/green-claims_en>

3.  

4.  **UK - CMA Green Claims:** [Gov.uk - Green Claims
    Code](https://www.gov.uk/government/publications/green-claims-code-making-environmental-claims)
    <https://www.gov.uk/government/publications/green-claims-code-making-environmental-claims>

5.  

6.  **Australia - Carbon Credits for Feed:** [Clean Energy Regulator -
    Beef Cattle Herd
    Management](https://www.cleanenergyregulator.gov.au/)
    <https://cer.gov.au/>

7.  **Brazil - Carbon Neutral Beef:** [Embrapa - Carbon Neutral Meat
    Brand](https://www.google.com/search?q=https://www.embrapa.br/en/carne-carbono-neutro)
    <https://www.google.com/search?q=https://www.embrapa.br/en/carne-carbono-neutro>

8.  


---

# Source: GreenLabels_report_exhaustive_fixed_v2.docx

**The Institutionalization of Green Labels\
in Animal Nutrition and Pet Care**

Updated: 21 January 2026

Prepared for: \[Client\]

Prepared by: \[Analyst\]

# Disclaimer

This report is for general informational purposes only. It is not legal
advice. Regulatory requirements can differ by jurisdiction, product
category, claim wording, and distribution channel. Consult qualified
legal and regulatory counsel before making or substantiating
environmental, sustainability, health, or performance claims.

# Table of contents

1\. Executive summary

2\. Scope, definitions, and methodology

3\. Why green labels are being institutionalized

4\. Regulatory and standards landscape

5\. Green label taxonomy for feed and pet care

6\. Auditability, data, and assurance requirements

7\. Segment implications: livestock feed

8\. Segment implications: pet food and pet care

9\. Competitive landscape and illustrative case studies

10\. Implementation playbook for a defensible green label program

11\. Scenarios and early warning indicators

12\. Recommendations

Appendix A. Evidence hierarchy and claim substantiation checklist

Appendix B. Reference standards and schemes

Appendix C. Glossary

Appendix D. Sources

# 1. Executive summary

**Draft fixes implemented in this version:**

- Expanded the report into an implementation-ready playbook with
  governance, evidence tiers, templates, and a detailed sources
  appendix.

- Added the postponed application dates for the EU Deforestation
  Regulation and implications for deforestation-risk claims and due
  diligence.

- Aligned the EU feed sector section to the published Copa-Cogeca/FEFAC
  Code of Good Labelling Practices v1.2 (2024-12) and its linkage to
  PEFCR Feed and GFLI.

- Corrected the status of the US Innovative FEED Act: introduced bills
  (H.R. 2203 and S. 1906) rather than enacted law.

- Updated EU regulatory landscape: EmpCo Directive timing and
  implications; EU Green Claims directive proposal described as paused
  rather than actively in trilogue.

Green labels are moving from optional marketing assets to
quasi-regulatory instruments. Across animal nutrition and pet care,
sustainability claims are increasingly constrained by (1) tighter
consumer protection rules, (2) procurement requirements that translate
Scope 3 emissions targets into supplier scorecards, and (3) industry
codes that standardize how environmental performance must be calculated
and communicated.

The practical effect is institutionalization: in the EU, the combination
of the Empowering Consumers for the Green Transition Directive (EmpCo)
and feed-sector initiatives (for example, the Copa-Cogeca and FEFAC Code
of Good Labelling Practices integrating PEFCR Feed and GFLI data) is
creating a de facto baseline for what counts as a legitimate
environmental claim. In the US, environmental marketing is still
primarily enforced through the FTC Act and state consumer protection
laws, but sector-specific policy efforts such as the Innovative FEED Act
illustrate a push to modernize the regulatory pathway for certain feed
ingredients intended to deliver animal performance, food safety, or
environmental benefits.

A two-speed market is emerging. In livestock feed, green labels are
becoming procurement signals tied to emissions reduction and compliance.
In pet care, green labels remain consumer-facing trust signals, but are
increasingly bounded by legal restrictions on generic claims, self-made
labels, and carbon-neutral style statements.

For manufacturers, the winning strategy is not to add more labels, but
to build a claims system: a governed portfolio of claims mapped to
evidence tiers, supported by auditable data, aligned with accepted
methodologies, and designed for multi-jurisdiction deployment.

**Key takeaways:**

- Regulation is increasingly focused on claim substantiation, not just
  label presence. Claim wording, scope, and proof matter more than the
  badge itself.

- Industry codes and databases (PEFCR Feed and GFLI) are becoming
  default references for feed environmental footprint communication in
  Europe.

- Offset-based product climate claims are being restricted or banned in
  the EU consumer context, pushing brands toward lifecycle-based product
  footprint evidence.

- Green labels will increasingly be evaluated in the context of
  farm-level and value-chain emissions reporting (Scope 3), accelerating
  demand for ingredient- and feed-level data.

- Companies should implement a defensible claims governance process now
  (inventory, evidence standards, verification, and packaging controls)
  before enforcement escalates.

# 2. Scope, definitions, and methodology

## 2.1 Scope

This report focuses on the institutionalization of environmental and
sustainability labels and claims (\"green labels\") in two adjacent
sectors:\
• Animal nutrition for food-producing animals (compound feed, premixes,
and feed additives)\
• Pet food and pet care products (food, treats, supplements, and
selected care categories where sustainability claims are common)

## 2.2 Geographic lens

The regulatory deep dive prioritizes the European Union and the United
States, because these markets are both large and highly influential in
setting labeling expectations. Where useful, the report also references
the United Kingdom, Canada, and other jurisdictions to highlight
convergence and divergence.

## 2.3 Definitions

**Green label:** Any symbol, badge, statement, or on-pack/off-pack
communication that signals an environmental or sustainability attribute,
performance, or commitment.

**Environmental claim:** A message or representation that states or
implies a product, ingredient, brand, or business has a positive,
reduced, or neutral environmental impact (for example, low-carbon,
recyclable, climate friendly).

**Sustainability label:** A label that distinguishes or promotes a
product, process, or business with reference to environmental or social
characteristics, often linked to a certification scheme.

**Certification scheme:** A structured program with defined criteria,
governance, and independent verification leading to the right to use a
mark or make a verified claim.

**Institutionalization:** The shift from voluntary, marketing-led use of
green labels to a system where labels are governed by regulation,
industry codes, procurement requirements, and audit expectations.

## 2.4 Methodology

The analysis combines:\
• Review of applicable or proposed regulatory instruments and guidance\
• Review of sector-specific codes and methodologies used for
environmental footprint communication\
• Market signal analysis (procurement expectations, certification
programs, and innovation themes)\
• Synthesis into an implementation playbook suitable for manufacturers,
ingredient suppliers, and brand owners

# 3. Why green labels are being institutionalized

## 3.1 Converging forces

Green labels used to be driven primarily by consumer preference and
brand differentiation. They are now being shaped by four converging
forces:

**Consumer protection enforcement:** Regulators and courts are
increasingly challenging vague or unsubstantiated sustainability claims.
The standard is shifting from \"can you say it\" to \"can you prove
it\".

**Supply chain and Scope 3 pressure:** Large food and consumer goods
companies increasingly require suppliers to provide emissions and
sustainability data to support their own reporting and reduction
targets.

**Standardization of LCA methods:** Life cycle assessment methodologies,
product footprint standards, and sector databases are reducing the room
for bespoke calculation approaches.

**Digitization of product information:** QR codes, product passports,
and retailer data requirements are increasing the amount and granularity
of sustainability information associated with products.

## 3.2 A two-speed market

The same label can serve very different functions depending on the
segment:\
• Livestock feed: labels are increasingly compliance and procurement
instruments tied to measurable outcomes (emissions, nutrient efficiency,
deforestation risk).\
• Pet care: labels remain consumer trust and premiumization signals, but
are increasingly constrained by rules against generic claims,
self-created labels, and offset-based climate claims.

# 4. Regulatory and standards landscape

## 4.1 European Union cross-cutting rules affecting green labels

### 4.1.1 Empowering Consumers for the Green Transition Directive

The EU has adopted a directive aimed at reducing greenwashing and
improving consumer information on durability and reparability. For green
labels, its most consequential elements are the new restrictions on
generic environmental claims, self-created labels, and certain
offset-based product climate claims. Member states must transpose the
directive into national law by March 27, 2026, and the requirements are
expected to apply from September 27, 2026. \[Source 1\]

**Practical implications for animal nutrition and pet care include:**

- Avoid broad, undefined terms (for example, \"eco-friendly\" or
  \"green\") unless the claim can be linked to recognized excellent
  environmental performance and is not misleading.

- Treat sustainability labels as regulated assets. Labels should be
  either established by a public authority or grounded in a credible
  certification scheme with independent verification.

- Reassess any product-level climate neutrality or climate-positive
  claims that rely on offsetting outside the product value chain, which
  face heightened restrictions in an EU consumer context.

### 4.1.2 Green Claims Directive proposal

The EU also proposed a separate directive to set detailed, harmonized
rules for substantiating and communicating explicit environmental claims
and labels. However, negotiations on the proposal were paused in June
2025 after political disagreement on scope, including concerns about
expanding obligations to very small companies. As of early 2026, the
proposal has not been finalized into EU law. \[Sources 2-4\]

Implication: companies should plan for a stricter evidence regime even
if a single EU-wide Green Claims directive is delayed, because EmpCo and
existing consumer protection enforcement already increase the risk of
weak or vague claims.

### 4.1.3 Corporate reporting and value chain data demand

Corporate sustainability reporting obligations in the EU are a
structural driver of green labels becoming data-backed. The European
Commission indicates that the first companies subject to the Corporate
Sustainability Reporting Directive have to apply the new rules for the
2024 financial year, with reports published in 2025. These reporting
expectations, including value-chain information, are a major reason
buyers increasingly ask suppliers for product and ingredient emissions
data. \[Source 5\]

### 4.1.4 Digital Product Passports and data disclosure

The EU\'s Ecodesign for Sustainable Products Regulation establishes a
framework that includes a Digital Product Passport, designed to store
product sustainability and compliance information. While implementation
varies by product group, the direction of travel is toward more
standardized, machine-readable sustainability data across supply chains.
\[Source 6\]

## 4.2 EU feed-specific institutionalization

### 4.2.1 Baseline feed marketing rules

Environmental labeling in feed operates on top of existing feed
marketing and labeling requirements. In practice, feed environmental
claims must be consistent with general principles against misleading
marketing and must be substantiated.

### 4.2.2 Copa-Cogeca and FEFAC Code of Good Labelling Practices

A major institutional signal in Europe is the endorsement of the
upgraded Copa-Cogeca and FEFAC Code of Good Labelling Practices for
compound feed by the European Commission\'s Standing Committee on
Plants, Animals, Food and Feed (SCoPAFF) at its meeting of 2-3 December
(the code is published in the 2024-12 version). The updated code
provides a harmonized approach to communicating environmental
performance, integrates the PEFCR Feed for Food-Producing Animals
methodology and the Global Feed LCA Institute (GFLI) database, and
references communication across multiple environmental impact
categories. \[Source 7\]

Why this matters: even though the code is not an EU regulation, it
functions as a sector-wide playbook. For manufacturers, it effectively
defines what \"good practice\" looks like for environmental footprint
communication in B2B feed markets.

## 4.3 United States cross-cutting rules affecting green labels

### 4.3.1 FTC guidance and consumer protection enforcement

In the US, the Federal Trade Commission\'s Green Guides remain a key
reference point for environmental marketing claims. The Guides are
designed to help marketers avoid making environmental claims that
mislead consumers and are widely used as a yardstick for substantiation
and clarity. As of early 2025, reporting indicates that an updated
version had not yet been released. \[Sources 8-9\]

### 4.3.2 Industry self-regulation and litigation risk

In addition to regulator action, US green claims face scrutiny through
state consumer protection laws, class-action litigation, and advertising
self-regulation. This creates a risk landscape where even technically
accurate claims can be challenged if they are perceived as overbroad or
inadequately qualified.

## 4.4 US feed and pet-specific pathways

### 4.4.1 FDA claim boundaries for animal food substances

The FDA Center for Veterinary Medicine regulates animal food and animal
drugs. Claim wording can determine which pathway applies. In a May 21,
2024 letter, FDA noted industry interest in animal food substances that
act solely within the gut with claims related to animal production,
animal well-being, food safety, and environmental benefits, and
encouraged firms to contact FDA early in product development. \[Source
10\]

### 4.4.2 The Innovative FEED Act and zootechnical animal food substances

Bipartisan legislation has been introduced to create a defined
regulatory pathway for a new category termed \"zootechnical animal food
substances\". The House bill (H.R. 2203) was introduced March 18, 2025,
and the Senate bill (S. 1906) was introduced May 22, 2025. These bills
define the category and would regulate such substances as food additives
rather than as animal drugs under specified conditions. As of early
2026, the bills are introduced but not enacted. \[Sources 11-13\]

**Strategic relevance:**

If enacted, the Innovative FEED Act could accelerate the commercial
pathway for certain feed ingredients that deliver measurable
environmental outcomes (for example, methane reduction or nutrient
efficiency) while remaining within a food additive framework. Even
before enactment, the policy debate signals that regulators and industry
are grappling with how to handle substantiated environmental benefit
claims.

### 4.4.3 Pet care categories with unique regulatory triggers

In pet care, some product categories have claim triggers outside food
law. For example, flea and tick products are often regulated as
pesticides, and claim substantiation may fall under pesticide rules.
Brands should treat such categories as high-risk for both safety and
greenwashing claims because the combination of health-related and
environmental language can create regulatory exposure.

## 4.5 Summary table: key instruments and what they mean

  -----------------------------------------------------------------------------
  Instrument        Jurisdiction      Status and timing Implications for green
                                                        labels
  ----------------- ----------------- ----------------- -----------------------
  EmpCo Directive   EU                In force since    Restricts generic
  (EU 2024/825)                       March 2024.       claims, self-made
                                      Transposition by  sustainability labels,
                                      March 27, 2026.   and offset-based
                                      Applies from      product climate claims
                                      September 27,     in B2C contexts.
                                      2026.             

  Green Claims      EU                Proposal advanced High likelihood of
  Directive                           in Parliament     stricter substantiation
  proposal                            (first reading    expectations. Companies
  (COM(2023) 166)                     March 2024).      should build
                                      Negotiations      pre-approval ready
                                      paused June 2025; evidence dossiers.
                                      not finalized.    

  Copa-Cogeca and   EU feed sector    Endorsed by       De facto standard for
  FEFAC Code of                       SCoPAFF at 2-3    feed environmental
  Good Labelling                      December meeting; footprint communication
  Practices v1.2                      published version using PEFCR Feed and
                                      dated 2024-12.    GFLI.

  FTC Green Guides  US                Guidance          Primary reference for
                                      framework; update substantiation,
                                      process discussed clarity, and
                                      publicly, but     qualifications for
                                      updates still     environmental marketing
                                      pending as of     claims.
                                      early 2025.       

  Innovative FEED   US                Introduced in     Potential pathway for
  Act (H.R. 2203 /                    2025; not enacted substantiated
  S. 1906)                            as of early 2026. environmental-benefit
                                                        feed substances under
                                                        food additive
                                                        regulation.
  -----------------------------------------------------------------------------

# 5. Green label taxonomy for feed and pet care

## 5.1 A practical hierarchy of green labels

For implementation, it is useful to treat green labels as a hierarchy
with increasing evidentiary burden:

**Tier 0: Silent sustainability features:** Internal sustainability
improvements with no external claim. Lowest legal risk, but no market
signaling.

**Tier 1: Specific attribute claims:** Narrow, verifiable statements
about a defined attribute (for example, \"made with 30% recycled
plastic\"), supported by documentation.

**Tier 2: Comparative claims:** Claims that compare to a baseline or
competitor (for example, \"20% lower carbon footprint vs 2023 recipe\").
Requires strict methodological controls.

**Tier 3: Aggregated footprint claims:** Product footprint, lifecycle,
or environmental score claims (for example, PEF-based metrics). Requires
LCA competence, data quality controls, and often third-party review.

**Tier 4: Certified labels and seals:** Use of a certification mark (for
example, a third-party sustainability label). Requires compliance with
scheme rules and audit readiness.

**Tier 5: Multi-attribute sustainability labels:** Labels implying broad
sustainability leadership (for example, \"sustainable product\"), which
are high-risk unless backed by recognized excellent performance across
relevant categories.

## 5.2 Core claim and label categories

Across both livestock feed and pet care, most green labels cluster into
recurring categories. Understanding these categories helps brands
standardize evidence, avoid overreach, and design a portfolio that can
be scaled.

**Carbon and climate:** Product carbon footprint, low-carbon, climate
impact reduction, methane reduction related messaging.

**Circularity and waste reduction:** Upcycled ingredients, by-product
utilization, circular feed, food waste diversion.

**Deforestation and land use:** Deforestation-free sourcing, certified
soy, land-use change risk management.

**Biodiversity and regenerative practices:** Regenerative agriculture
inputs, biodiversity-friendly sourcing, soil health claims.

**Water and eutrophication:** Water use, nutrient runoff, eutrophication
footprint, nitrogen efficiency.

**Packaging sustainability:** Recyclability, recycled content, refill,
compostability, lightweighting.

**Chemical and toxicity positioning:** Claims about reduced hazardous
substances, \"no neurotoxin\" style language in care categories, and
clean label positioning.

**Animal welfare and social attributes:** Welfare-related claims and
farm assurance programs that intersect with sustainability perceptions.

## 5.3 Livestock feed: green label archetypes

In livestock systems, green labels are increasingly tied to measurable
outcomes and procurement scorecards. The most common archetypes include:

**Low-carbon feed:** A footprint claim tied to ingredient sourcing,
formulation, and processing energy; often expressed per kg feed or per
functional unit.

**Methane-reducing feed or additive:** A performance claim requiring
robust evidence of enteric methane reduction and clear definition of
conditions and expected results.

**Nutrient efficiency and eutrophication reduction:** Claims about
improved digestibility, reduced nitrogen or phosphorus excretion, or
lower eutrophication impact.

**Deforestation-risk managed feed:** Sourcing claims for soy or other
high-risk commodities backed by certification and traceability.

**Circular feed:** Use of co-products and former foodstuffs positioned
as waste reduction; requires careful messaging to avoid safety concerns.

## 5.4 Pet food and pet care: green label archetypes

In pet markets, sustainability claims are often bundled with health,
safety, and ethics. Common archetypes include:

**Upcycled ingredients:** Positioning that ingredients would otherwise
be wasted. Increasingly supported by formal certification (for example,
Upcycled Certified). \[Source 14\]

**Alternative proteins:** Insect protein, fermentation-derived
ingredients, plant-based proteins, positioned as lower-impact
alternatives.

**Sustainable seafood:** Marine sustainability certification for
fish-based diets (for example, MSC/ASC) and fishery improvement
narratives.

**Sustainable packaging:** Recyclable or recycled-content packaging
claims, often subject to evolving recyclability standards and FTC
guidance.

**Clean chemistry positioning:** Claims in care products (shampoos, flea
and tick, grooming) that avoid certain active ingredients, sometimes
framed as environmental or health safer.

## 5.5 Matrix: which categories dominate by segment

  -----------------------------------------------------------------------
  Category                Livestock feed emphasis Pet food and pet care
                                                  emphasis
  ----------------------- ----------------------- -----------------------
  Carbon and climate      High. Often linked to   Medium to high.
                          Scope 3 reporting,      Increasing interest,
                          emissions reduction     but consumer-facing
                          targets, and farm-level restrictions on
                          outcomes.               offset-based neutrality
                                                  language are rising.

  Circularity and waste   Medium. Co-products and High. Upcycled and
  reduction               former foodstuffs are   zero-waste narratives
                          established but require are prominent in
                          careful messaging.      premium brands and
                                                  innovation showcases.

  Deforestation and land  High for soy and        Medium. Present in
  use                     high-risk commodities.  premium sourcing
                                                  stories, especially for
                                                  animal proteins.

  Packaging               Medium. More B2B than   High. One of the most
  sustainability          consumer-facing for     visible consumer cues
                          feed.                   in pet aisles.

  Chemical and toxicity   Low to medium. More     High in care products
  positioning             relevant for additives  and some food \"clean
                          and processing aids.    label\" narratives.
  -----------------------------------------------------------------------

# 6. Auditability, data, and assurance requirements

## 6.1 The new expectation: substantiation as a product

As green labels become institutionalized, the substantiation package
becomes as important as the product. Across jurisdictions, regulators
and customers increasingly expect claims to be:

- Specific (clear about what is being claimed and what is not).

- Quantified where possible (especially for footprint, reduction, or
  comparative statements).

- Methodologically grounded (using accepted standards and sector rules).

- Documented (traceable evidence that can be produced during an audit or
  challenge).

- Kept current (updated when formulations, suppliers, processes, or
  markets change).

## 6.2 Life cycle assessment frameworks relevant to green labels

Most robust green label programs are built on life cycle assessment
(LCA). Depending on geography and buyer expectations, the dominant
frameworks include:

**EU Product Environmental Footprint (PEF):** The EU recommends
LCA-based methods to quantify environmental impacts of products and
organizations. PEF typically evaluates multiple impact categories and
relies on Product Environmental Footprint Category Rules (PEFCRs) for
product-specific rules. \[Sources 15-16\]

**PEFCR Feed for Food-Producing Animals:** The feed sector has a
dedicated PEFCR that sets rules for calculating the environmental
footprint of compound feed for food-producing animals. \[Source 17\]

**GFLI feed ingredient datasets:** The Global Feed LCA Institute
maintains a feed LCA database of ingredient datasets built using LCA
methodology, supporting more consistent feed footprint calculations.
\[Source 18\]

**ISO 14067:** An international standard specifying principles,
requirements, and guidelines for quantification and reporting of the
carbon footprint of a product. \[Source 19\]

**GHG Protocol Product Standard:** A global standard for product life
cycle greenhouse gas accounting and reporting used to understand full
life cycle emissions and identify reduction opportunities. \[Source 20\]

## 6.3 Data architecture for defensible claims

A scalable green label system requires a data architecture that links
claims to underlying datasets. At minimum, companies should expect to
manage:

- Ingredient identity, sourcing geography, and chain-of-custody
  documentation.

- Supplier certifications and audit documents (for example,
  deforestation-risk programs, recycled content attestations).

- Recipe and formulation version control (so claims can be tied to a
  specific BOM and time period).

- Energy, transport, and manufacturing data used in LCA models.

- Allocation rules and functional units (especially for co-products and
  by-products).

- Assurance artifacts (internal review sign-off, third-party
  verification statements, and versioned calculation files).

## 6.4 Assurance and verification models

Verification can range from internal review to full third-party
certification. The right model depends on claim risk, customer
expectations, and jurisdiction.

**Internal controls:** Appropriate for narrow, low-risk attribute claims
when evidence is clear and retrievable.

**Independent expert review:** Useful for footprint and comparative
claims, especially when methodologies are complex.

**Third-party verification to a standard:** Common for product carbon
footprint and for certification labels; can increase credibility and
reduce litigation risk.

**Full certification schemes:** Necessary when using a program\'s label
or seal. Requires audit readiness and adherence to governance rules.

## 6.5 Evidence table: minimum substantiation by claim type

  -------------------------------------------------------------------------
  Claim type        Typical example   Minimum evidence    Common failure
                                                          modes
  ----------------- ----------------- ------------------- -----------------
  Specific          "Made with 30%    Supplier            Unclear scope
  attribute         recycled plastic" declaration + test  (packaging vs
                                      method or           product);
                                      certification; spec outdated supplier
                                      sheet; batch-level  statements
                                      traceability        

  Upcycled          "Contains         Supplier            Treating normal
  ingredient        upcycled          chain-of-custody;   co-products as
                    ingredients"      certification (if   "waste"; lack of
                                      used); definition   documented
                                      of "upcycled" and   diversion from
                                      mass balance        waste

  Footprint claim   "Product carbon   LCA model with      Opaque
                    footprint: X kg   defined boundary +  boundaries;
                    CO2e"             functional unit;    inconsistent
                                      emission factors;   allocation;
                                      QA review; update   mixing primary
                                      triggers            and secondary
                                                          data without
                                                          controls

  Reduction claim   "20% lower carbon Baseline            Changing
                    vs 2023 recipe"   definition;         functional unit;
                                      like-for-like       cherry-picked
                                      comparison;         baseline;
                                      consistent method;  ignoring rebound
                                      change log;         effects
                                      verification        

  Certification     Third-party seal  Valid certificate,  Misuse outside
  label             on pack           scope statement,    scope; expired
                                      audit record, and   certificates;
                                      correct usage       altered logo or
                                      rights              wording
  -------------------------------------------------------------------------

# 7. Segment implications: livestock feed

## 7.1 The role of feed in agricultural footprint accounting

In most livestock systems, feed production is a major contributor to the
environmental footprint of animal products. This makes feed a primary
lever for processors, retailers, and brands seeking to reduce Scope 3
emissions. As a result, green labels in feed are increasingly less about
consumer marketing and more about measurable inputs into downstream
product footprints.

## 7.2 How procurement turns sustainability targets into feed requirements

Procurement teams increasingly translate sustainability targets into
supplier requirements. In practice, this looks like:

- Supplier scorecards requiring product carbon footprint data per
  ingredient and per finished feed.

- Requirements for deforestation-risk mitigation for commodities such as
  soy and palm-derived ingredients.

- Documentation of co-product use, circular feed ingredients, and waste
  diversion metrics.

- Evidence of animal performance improvements that reduce emissions
  intensity (for example, improved feed conversion ratios).

## 7.3 Deforestation risk and soy: a label that becomes a license to operate

Deforestation-related sourcing is likely to remain a high-stakes
dimension of green labeling, especially for soy. The EU Deforestation
Regulation has been amended and its entry into application is now set
for large and medium operators on December 30, 2026, and for micro and
small operators on June 30, 2027. This timeline increases the urgency
for traceability systems and credible sourcing programs that can support
both due diligence and claims. \[Sources 21-22\]

For feed companies, deforestation-free sourcing claims should be treated
as compliance-adjacent. Even when a claim is made in B2B contexts, it
may be audited through customer due diligence or challenged under
misleading marketing standards.

## 7.4 Product innovation pathways that can support defensible labels

The following innovation pathways are most likely to produce labels that
matter in procurement and can be substantiated:

**Reformulation and sourcing shifts:** Lower-impact ingredients,
improved sourcing geographies, renewable energy in manufacturing, and
optimized logistics.

**Additives with measurable outcomes:** Substances that improve feed
efficiency, reduce enteric methane, or reduce nutrient excretion,
provided evidence and regulatory positioning are aligned.

**Circular feed inputs:** Former foodstuffs and co-products that
demonstrably divert waste and maintain safety, supported by traceability
and clear scope limitations.

**Data-enabled services:** Footprint calculators, formulation tools, and
reporting services that package sustainability data for customers,
increasing switching costs and loyalty.

## 7.5 Commercial implications and pricing models

As labels become tied to measurable outcomes, commercial models can
evolve beyond simple price premiums:

- Pay-for-performance models linked to verified outcomes (for example,
  emissions reduction per ton of output).

- Shared value contracts where a portion of downstream emissions-value
  is shared with feed suppliers.

- Bundling of product plus data, where the sustainability data package
  becomes part of the SKU value.

# 8. Segment implications: pet food and pet care

## 8.1 Consumer sustainability is real, but trust is fragile

In pet categories, sustainability is often expressed through packaging
cues, ingredient stories, and brand purpose narratives. Innovation trend
coverage from industry analysts highlights themes such as sustainable
packaging and upcycled ingredients in pet retail showcases. \[Sources
23-24\]

However, consumer trust is fragile. Generic green terms and self-created
labels can backfire as enforcement against greenwashing increases.
Brands need to shift from aspirational language to specific, verifiable
statements and credible third-party programs.

## 8.2 Upcycled ingredients and circularity: from niche to mainstream signal

Upcycled claims are particularly prominent in pet treats and specialty
diets because they combine sustainability with \"ingredient story\"
appeal. The Upcycled Certified program, created by the Upcycled Food
Association and now operated within the Where Food Comes From family of
standards, is a notable institutional mechanism that can help
substantiate upcycled claims and reduce greenwashing risk. \[Sources 14,
25-27\]

Implementation caution: a credible upcycled claim should establish that
the input stream would have gone to waste in a relevant market context,
and should avoid implying that all co-products are automatically waste.

## 8.3 Alternative proteins: insect and novel inputs

Insect protein and other alternative proteins are used as sustainability
narratives in pet food. A 2022 Reuters report describes efforts to scale
insect protein for pet diets, noting both footprint advantages and
evolving regulatory acceptance. \[Source 28\]

For green labels, alternative proteins create a double requirement: the
sustainability case must be evidence-based, and the ingredient must be
compliant with animal food rules (ingredient definitions, safety, and
permissible claims).

## 8.4 Product footprint approaches for pet food in Europe

Europe is also moving toward standardized footprinting approaches in pet
food. The European pet food industry has published information on a
PEFCR for pet food that establishes a standardized framework for
assessing environmental impacts of prepared pet food sold in the EU
market. \[Source 29\]

## 8.5 Packaging: the most visible sustainability cue

Packaging remains the most visible sustainability cue in pet aisles.
However, recyclability and recycled content claims are high-risk when
local recycling infrastructure does not match claim language. Brands
should align packaging claims with accepted guidance (for example, FTC
Green Guides in the US and national packaging rules in Europe) and avoid
overpromising.

## 8.6 Care products: beware of overlapping health and green claims

Pet care categories such as flea and tick, grooming, and household
products often intersect with pesticide, biocide, or chemical safety
regimes. When a brand combines \"natural\" or \"non-toxic\" messaging
with environmental benefit claims, the claim burden increases and
regulatory triggers can change. These categories should be treated as
high-risk for both compliance and reputation.

# 9. Competitive landscape and illustrative case studies

## 9.1 What "competitive landscape" means for green labels

The competitive landscape for green labels is less about who has the
most badges, and more about who can operationalize defensible claims at
scale. Three differentiators are increasingly decisive:\
• Evidence strength: ability to produce an auditable substantiation
dossier\
• Method alignment: use of accepted standards and sector rules, enabling
comparability\
• Deployment capability: integration into product development,
procurement, labeling, and customer reporting

## 9.2 Case study: methane-reducing feed additives as a new claim frontier

Methane-reducing additives illustrate how environmental benefit claims
can move from R&D to regulated authorization and then into market
labeling. For example, the EU has authorized a preparation of
3-nitrooxypropanol as a feed additive for dairy cows and cows for
reproduction under Commission Implementing Regulation (EU) 2022/565.
This authorization is frequently cited in public discussion of
environmental-benefit feed additives. \[Sources 30-32\]

Implementation lessons:\
• Evidence must cover efficacy under defined use conditions and safety
for animals, users, and consumers.\
• Claims should be tightly scoped (species, diet, dose, expected
performance range).\
• Downstream labeling (for example, \"lower methane milk\") usually
requires additional value-chain accounting and governance.

## 9.3 Case study: Upcycled Certified as an institutional mechanism in pet markets

Upcycled certification demonstrates how a voluntary concept becomes
institutionalized through standards and governance. The Upcycled
Certified program provides a definition and certification mechanism for
upcycled claims, and is promoted as a way to bring consistency to a
category that otherwise risks vague marketing. \[Sources 14, 25-27\]

Implementation lessons:\
• Define what qualifies as \"upcycled\" in the relevant context.\
• Maintain chain-of-custody evidence and recipe-level mass balance.\
• Avoid broad claims that imply an entire product is upcycled unless
this is true.

## 9.4 Case study: carbon-neutral product messaging under rising scrutiny

Carbon neutrality claims for consumer products face rising scrutiny in
Europe, especially when they rely on offsetting. Coverage of European
developments highlights that the Empowering Consumers directive
framework is expected to restrict certain offset-based product climate
claims, pushing brands toward lifecycle-based substantiation and away
from simple offset narratives. \[Sources 1, 33\]

# 10. Implementation playbook for a defensible green label program

## 10.1 Design principle: treat claims like regulated products

A green label program should be managed like a regulated product
portfolio. Each claim should have an owner, a defined scope, an evidence
package, a review cadence, and clear rules for use across channels.

## 10.2 Governance model

Recommended governance structure:

**Green Claims Steering Committee:** Sets policy, approves high-risk
claims, and arbitrates trade-offs between marketing and compliance.

**Claims Owner:** Accountable for each claim\'s definition, scope, and
evidence package; typically product management or sustainability.

**Regulatory and Legal:** Defines claim risk, ensures compliance by
jurisdiction, and approves final language.

**Science and LCA:** Owns calculation methodologies, data quality
controls, and update triggers.

**Quality and Procurement:** Maintains supplier documentation, audits,
and traceability evidence.

**Commercial and Marketing:** Deploys claims in packaging, sales
materials, and digital channels within approved guardrails.

## 10.3 Step-by-step implementation process

**Step 1. Build a claims inventory:** Collect every
sustainability-related statement used across packaging, websites, sales
decks, tender responses, and retailer content. Include implied claims
embedded in imagery and icons.

**Step 2. Classify claims by risk and jurisdiction:** Assign each claim
a risk rating based on breadth, quantification, comparative nature,
reliance on offsets, and whether it triggers a regulated category (for
example, pesticides, drugs).

**Step 3. Define evidence requirements per claim type:** Use an evidence
hierarchy (Appendix A) to define what documentation is mandatory,
optional, and unacceptable.

**Step 4. Build the data backbone:** Implement recipe version control,
supplier documentation management, and an LCA workflow aligned to
PEF/ISO/GHG Protocol expectations as required.

**Step 5. Select verification and certification strategy:** Decide where
independent verification is required (for example, footprint claims,
reduction claims, and high-visibility consumer claims).

**Step 6. Establish packaging and content controls:** Implement an
approval workflow that prevents unapproved claims from appearing on pack
or online. Maintain a single source of truth for approved claim
language.

**Step 7. Engage suppliers with contractual data requirements:** Embed
data and documentation obligations into supplier contracts, including
update triggers when suppliers change processes or sourcing.

**Step 8. Implement monitoring and refresh cadence:** Set a review cycle
(for example, quarterly for high-risk claims, annually for footprint
models) and define triggers that require immediate review.

## 10.4 Timeline: what to do in 0-24 months

  ------------------------------------------------------------------------
  Time horizon      Primary objective  Key deliverables  Common pitfalls
  ----------------- ------------------ ----------------- -----------------
  0-90 days         Control risk and   Claims inventory; Ignoring off-pack
                    create visibility  risk rating;      claims; letting
                                       temporary         marketing
                                       moratorium on     continue without
                                       high-risk claims; controls
                                       first governance  
                                       meeting           

  3-6 months        Build core         Evidence          Overbuilding a
                    evidence and data  templates;        perfect model;
                    processes          supplier          failing to define
                                       documentation     functional units
                                       plan; pilot LCA   and boundaries
                                       model for 1-2     
                                       products;         
                                       verification      
                                       partner shortlist 

  6-12 months       Scale defensible   Standardized      Inconsistent
                    claims             claim library;    claims across
                                       LCA coverage      regions; missing
                                       across priority   update triggers
                                       SKUs; third-party when formulation
                                       verification for  changes
                                       flagship claims;  
                                       customer          
                                       reporting         
                                       packages          

  12-24 months      Institutionalize   Audit-ready claim Treating
                    and optimize       dossiers;         compliance as a
                                       automated data    one-time project
                                       pipelines;        rather than an
                                       integration into  operating system
                                       product           
                                       development stage 
                                       gates; KPI        
                                       dashboard         
  ------------------------------------------------------------------------

# 11. Scenarios and early warning indicators

## 11.1 Scenario planning logic

Because green label institutionalization depends on political,
regulatory, and market dynamics, scenario planning helps avoid
overfitting to a single path. The scenarios below are not predictions.
They are structured possibilities that can be monitored through early
warning indicators.

## 11.2 Scenario A: Harmonized EU substantiation returns

The EU revives or replaces the paused Green Claims directive proposal
with a harmonized substantiation regime. Pre-approval or formal
verification requirements become more explicit, and national enforcement
becomes more consistent.

**What it would mean:**

- Higher upfront compliance costs for consumer-facing claims.

- Greater comparability across products, increasing competitive
  pressure.

- Advantages for companies with mature LCA and verification systems.

## 11.3 Scenario B: Fragmentation plus enforcement

The EU Green Claims proposal remains stalled, but EmpCo is transposed
and enforced aggressively. Member states and courts apply consumer
protection law more actively, and national guidance diverges.

**What it would mean:**

- Need for country-specific claim playbooks and legal review.

- Higher risk for generic and aspirational claims, even without an
  EU-wide Green Claims directive.

- Value of robust evidence remains high, but claims must be tailored by
  jurisdiction.

## 11.4 Scenario C: US pathway modernization and tougher marketing scrutiny

US policy evolves in two directions: (1) a clearer pathway for certain
feed substances that deliver environmental benefits, and (2) increased
scrutiny of consumer-facing environmental marketing through FTC, state
actions, and litigation.

**What it would mean:**

- Faster commercialization for substantiated feed performance solutions
  if legislation advances.

- Greater need to harmonize claim substantiation across digital commerce
  and packaging.

- Potential for large financial exposure from class actions if claims
  are ambiguous.

## 11.5 Early warning indicators

  -----------------------------------------------------------------------
  Indicator               Why it matters          What to watch
  ----------------------- ----------------------- -----------------------
  EU transposition        Shows how strict the EU National authority
  guidance and            consumer-claims regime  guidance, early court
  enforcement actions on  becomes in practice     cases, and actions
  EmpCo                                           against generic claims

  Status signals on the   Determines whether an   Council position,
  EU Green Claims         EU-wide pre-approval    Commission actions,
  directive proposal      regime emerges          trilogue restart or
                                                  formal withdrawal

  Buyer procurement       Accelerates B2B         Tender requirements,
  scorecards requiring    institutionalization    supplier portals, and
  PEF or GFLI-aligned     independent of          audit demands
  footprints              regulation              

  US FTC Green Guides     Affects the baseline    FTC workshops, draft
  revision progress       for claim               revisions, enforcement
                          substantiation          priorities
                          expectations            

  Retail and e-commerce   Platforms can enforce   Marketplace listing
  platform claim policies stricter standards than requirements, claim
                          law                     audits, and prohibited
                                                  terms lists
  -----------------------------------------------------------------------

# 12. Recommendations

## 12.1 Immediate priorities

- Freeze high-risk claims until substantiation is reviewed, especially
  broad or generic terms and any climate-neutral language that relies on
  offsetting in EU consumer contexts.

- Create a single, governed library of approved claim language and
  prohibited terms by jurisdiction.

- Launch a claims inventory and risk assessment across all channels
  (packaging, web, retailer content, sales materials).

- Select a reference methodology for footprint claims (PEF/PEFCR where
  relevant in Europe, ISO 14067 and GHG Protocol Product Standard as
  global anchors) and standardize functional units.

- Identify 1-2 pilot products or customer accounts to build an
  end-to-end substantiation dossier and verification workflow.

## 12.2 Medium-term priorities

- Scale data collection through supplier contracts, requesting
  ingredient-level footprints, certification documents, and update
  triggers.

- Implement LCA governance with version control so that claims remain
  tied to specific formulations and time periods.

- Build a verification strategy: decide which claims require independent
  review and which can remain internal.

- Develop a product innovation pipeline aligned to defensible label
  archetypes, prioritizing measurable outcomes and procurement relevance
  in livestock feed and trust-building certifications in pet markets.

- Prepare for EU enforcement by building documentation that can
  withstand audits and challenges from regulators, customers, and
  competitors.

## 12.3 Long-term priorities

- Integrate sustainability data and claim review into product
  development stage gates, so claims are designed in, not retrofitted.

- Automate data pipelines for footprint reporting, enabling faster
  customer responses and reduced manual error.

- Use digital channels (QR codes and online product pages) to provide
  qualified, transparent information that supports on-pack brevity
  without sacrificing substantiation.

- Continuously monitor regulatory changes and enforcement patterns, and
  refresh claim language accordingly.

# Appendix A. Evidence hierarchy and claim substantiation checklist

## A1. Evidence hierarchy

Use this hierarchy to set minimum substantiation requirements. Higher
tiers include the requirements of lower tiers.

**Tier 1 evidence:** Supplier specs, certificates of analysis, recycled
content attestations, chain-of-custody documents.

**Tier 2 evidence:** Structured calculations with documented
assumptions, controlled baselines, and internal QA sign-off.

**Tier 3 evidence:** LCA study or footprint model aligned to a
recognized standard (PEF/PEFCR, ISO 14067, GHG Product Standard) with
version control.

**Tier 4 evidence:** Independent verification statement or certification
audit record.

**Tier 5 evidence:** Ongoing surveillance audits, governance documents
for label use, and public-facing methodology disclosure where required.

## A2. Claim substantiation checklist

- Claim text and context: exact wording, images, and implied meanings.

- Jurisdictions and channels: where the claim will appear (pack, web,
  retailer listing, B2B tender).

- Claim type classification: attribute, comparative, footprint, future
  commitment, certification label.

- Scope and boundary: what is included and excluded; functional unit;
  geography; time period.

- Methodology: standard or program used; key assumptions; allocation
  rules.

- Data sources: primary vs secondary; supplier data quality; update
  triggers.

- Evidence file set: documents, model files, certificates, and approvals
  stored in a controlled repository.

- Review and approval: legal, regulatory, science/LCA, quality, and
  marketing sign-off recorded.

- Monitoring plan: cadence and triggers for review when suppliers,
  formulations, processes, or regulations change.

## A3. Template: Green claim substantiation dossier contents

A practical dossier package for each high-visibility claim should
include:

- One-page claim summary (claim text, products/SKUs covered,
  jurisdictions, and limitations).

- Methodology note (standard used, boundary, functional unit,
  allocation, and data year).

- Calculation workbook or model file with version number and change log.

- Supplier evidence (certificates, declarations, chain-of-custody, audit
  summaries).

- Verification or review statement (if applicable).

- Packaging and digital copy approvals.

- Customer-facing FAQ and qualified disclosure text.

# Appendix B. Reference standards and schemes

## B1. Cross-cutting footprinting standards

- EU Product Environmental Footprint (PEF) and product-category rules
  (PEFCR).

- PEFCR Feed for Food-Producing Animals.

- PEFCR Pet Food (EU market).

- ISO 14040 and ISO 14044 (LCA principles and requirements).

- ISO 14067 (carbon footprint of products).

- GHG Protocol Product Standard.

## B2. Examples of relevant certification and sourcing schemes

The following list is illustrative, not exhaustive. Applicability
depends on ingredient category, geography, and customer expectations.

- Upcycled Certified (Upcycled Food Association / Where Food Comes
  From).

- Marine sustainability: MSC and ASC.

- Responsible soy and deforestation-risk: RTRS, ProTerra, and other
  benchmarked schemes; plus company-specific due diligence aligned with
  EUDR.

- Palm oil: RSPO.

- Forestry and paper: FSC and PEFC.

- Mass balance and circularity systems: ISCC (various scopes) where
  relevant.

- Corporate purpose and ESG signals: B Corp, 1% for the Planet (not
  product substantiation, but brand positioning).

# Appendix C. Glossary

**B2B:** Business-to-business.

**B2C:** Business-to-consumer.

**BOM:** Bill of materials, the full ingredient and packaging
specification for a SKU.

**EmpCo:** EU Empowering Consumers for the Green Transition Directive
(Directive (EU) 2024/825).

**EUDR:** EU Deforestation Regulation.

**GFLI:** Global Feed LCA Institute.

**GHG:** Greenhouse gas.

**LCA:** Life cycle assessment.

**MRV:** Measurement, reporting, and verification.

**PEF:** Product Environmental Footprint.

**PEFCR:** Product Environmental Footprint Category Rules.

**Scope 3:** Indirect emissions across a value chain, as defined in the
GHG Protocol.

# Appendix D. Sources

Source list corresponding to bracketed citations used in the report
text.

**Source 1:** European Commission, \"New EU rules to empower consumers
for the green transition enter into force\", 27 March 2024.
https://energy.ec.europa.eu/news/new-eu-rules-empower-consumers-green-transition-enter-force-2024-03-27_en

**Source 2:** Reuters, \"EU halts talks on Green Claims law\", 23 June
2025. (News report)

**Source 3:** European Parliament, press release, \"Council must break
deadlock after Commission announced withdrawal of Green Claims
Directive\", 20 June 2025.

**Source 4:** European Parliament Legislative Observatory, Procedure
file 2023/0085(COD) \"Substantiation and communication of explicit
environmental claims\" (status page).

**Source 5:** European Commission, Corporate sustainability reporting
(CSRD overview).
https://finance.ec.europa.eu/capital-markets-union-and-financial-markets/company-reporting-and-auditing/company-reporting/corporate-sustainability-reporting_en

**Source 6:** European Commission, Ecodesign for Sustainable Products
Regulation (ESPR) overview.
https://commission.europa.eu/energy-climate-change-environment/standards-tools-and-labels/products-labelling-rules-and-requirements/ecodesign-sustainable-products-regulation_en

**Source 7:** FEFAC, \"Endorsement of the upgraded Copa-Cogeca/FEFAC
Code of good labelling practices for compound feed\", with link to Code
v1.2 (2024-12).
https://fefac.eu/newsroom/news/endoresement-of-the-upgraded-copa-cogeca-fefac-code-of-good-labelling-practices-for-compound-feed-2/

**Source 8:** US Federal Trade Commission, \"Guides for the Use of
Environmental Marketing Claims\" (Green Guides).
https://www.ftc.gov/business-guidance/resources/green-guides

**Source 9:** Packaging Dive, \"FTC says no timeline for Green Guides
update\", 21 Feb 2025.

**Source 10:** US FDA Center for Veterinary Medicine, letter \"Approach
to Certain Novel Animal Food Substances\" (May 21, 2024).
https://www.fda.gov/animal-veterinary/product-safety-information/approach-certain-novel-animal-food-substances

**Source 11:** US Congress, H.R. 2203, Innovative Feed Enhancement and
Economic Development Act of 2025 (Congress.gov).
https://www.congress.gov/bill/119th-congress/house-bill/2203

**Source 12:** US Congress, S. 1906, Innovative Feed Enhancement and
Economic Development Act of 2025 (Congress.gov).
https://www.congress.gov/bill/119th-congress/senate-bill/1906

**Source 13:** American Feed Industry Association (AFIA), press release
or advocacy page on the Innovative FEED Act (2025).

**Source 14:** Upcycled Food Association, Upcycled Certified program
overview. https://upcycledfood.org/certification/

**Source 15:** European Commission, Environmental Footprint methods.
https://environment.ec.europa.eu/topics/circular-economy/environmental-footprint-methods_en

**Source 16:** European Commission, Product Environmental Footprint
resources and methodology references (linked from Environmental
Footprint methods).

**Source 17:** FEFAC, Environmental footprint information and references
to PEF and PEFCR Feed.
https://fefac.eu/priorities/sustainability/environmental-footprint/

**Source 18:** Global Feed LCA Institute (GFLI), official
downloads/resources (ingredient database). https://globalfeedlca.org/

**Source 19:** International Organization for Standardization, ISO
14067:2018 Carbon footprint of products.
https://www.iso.org/standard/71206.html

**Source 20:** GHG Protocol, Product Standard.
https://ghgprotocol.org/product-standard

**Source 21:** European Commission, Deforestation Regulation: Parliament
and Council agree on new date of application, 4 December 2025.
https://environment.ec.europa.eu/news/deforestation-regulation-parliament-and-council-agree-new-date-application-2025-12-04_en

**Source 22:** Council of the EU, press release, Deforestation
regulation: Council and Parliament agree on new date of application, 3
December 2025.
https://www.consilium.europa.eu/en/press/press-releases/2025/12/03/deforestation-regulation-council-and-parliament-agree-on-new-date-of-application/

**Source 23:** NielsenIQ, SuperZoo 2025 Innovation Trends coverage (pet
industry trends).

**Source 24:** Petfood Processing, coverage of sustainability trends in
pet food (industry trends).

**Source 25:** Food Business News, \"Where Food Comes From acquires
Upcycled Foods\", 27 Dec 2023.

**Source 26:** Where Food Comes From, announcement about acquiring
Upcycled Foods/Upcycled Certified program (2023).

**Source 27:** Specialty Food Association, news about Upcycled Certified
acquisition (2023).

**Source 28:** Reuters, \"ADM, InnovaFeed partner to meet demand for
insect protein for pet food\", 10 Nov 2022.

**Source 29:** FEDIAF / European Pet Food Industry Federation, PEFCR pet
food information page. https://europeanpetfood.org/sustainability/pefcr/

**Source 30:** Commission Implementing Regulation (EU) 2022/565
(authorisation of 3-nitrooxypropanol as a feed additive).
https://eur-lex.europa.eu/eli/reg_impl/2022/565/oj/eng

**Source 31:** Reuters Fact Check, \"Feed additive Bovaer is approved in
EU, contrary to online claims\", 13 Dec 2024.

**Source 32:** dsm-firmenich press release, \"receives landmark EU
market approval for Bovaer\", 24 Feb 2022.

**Source 33:** ESG Dive, coverage of carbon neutral product claim
scrutiny in Europe (Sep 2025).


---

# Source: New regulations_ChatGPT.docx

**Animal Nutraceuticals Regulatory Playbook (2026 update)**

**Pharmaceuticalization, zootechnical pathways, and how to build a
defensible regulatory moat (2025 to 2030 outlook)**

**Important note**

This document is business and regulatory strategy guidance, not legal
advice. Always validate final positions and claims with specialized
regulatory counsel for each target jurisdiction and species.

**Table of contents**

1.  Executive summary

2.  What "pharmaceuticalization" means in animal nutrition and why it is
    accelerating

3.  Definitions: nutraceutical vs animal food vs feed additive vs
    veterinary drug vs biologic

4.  How regulators decide classification (the "intended use engine")

5.  United States: today's reality plus what is changing (2024 to 2026)

6.  European Union: feed additive authorizations and zootechnical claims

7.  UK, Canada, and other major markets: practical notes

8.  Case study 1: Multimin 90 (trace minerals) moving from supplement
    positioning to FDA-approved Rx drug

9.  Case study 2: environmental claims as the catalyst (Experior and
    Bovaer)

10. Case study 3: bacteriophages as authorized zootechnical additives
    (EU Bafasal)

11. Claim-to-pathway decision matrix (with red flags and safer
    alternatives)

12. Evidence and dossier strategy by pathway

13. Manufacturing, quality, and supply chain requirements (what
    investors will probe)

14. Go-to-market and compliance operations (labeling, digital marketing,
    post-market)

15. Investment implications: diligence questions, deal structures, and
    "regulatory moat" valuation logic

16. 2025 to 2030 outlook: scenarios, triggers, and how to stay ahead\
    Appendix A: Regulatory strategy one-pager template\
    Appendix B: Claim review checklist (website, label, sales scripts)\
    Appendix C: Dossier checklists (US food additive/GRAS, US NADA, EU
    feed additive)\
    Appendix D: Due diligence questionnaire for investors/acquirers\
    Appendix E: Glossary

**1. Executive summary**

**The core shift**

Animal nutraceuticals and functional feed products are moving from
"marketing-claims-first" to "authorization-first." This is driven by:

- tighter enforcement against drug claims (especially online marketing
  and testimonials),

- growing demand for measurable outcomes (food safety, performance,
  environment),

- and the rise of novel modalities (microbiome, phage, enzymes, methane
  inhibitors) that do not fit legacy "nutrition only" buckets.

A clear signal is the FDA approval pathway being used by products
historically positioned as "supplements," plus the expansion of feed
additive approvals for explicit environmental outcomes (methane,
ammonia).

**The practical implication**

If you are building, investing in, or acquiring an animal nutraceutical
company, you need to decide early:

- Are we a commodity ingredient with limited claims and limited pricing
  power?

- Or are we building a regulated, claim-backed product with defensible
  differentiation (data, authorization, exclusivity, distribution
  restrictions, and quality systems)?

Trying to sit in the middle often creates the worst risk profile:
drug-claim exposure without the protection of approval.

**The "missing middle" is evolving in the US**

Historically, FDA CVM treated many structure/function or production
claims in animal food as drug claims. In May 2024, FDA withdrew the old
internal policy manual (PPM 1240.3605) and has been signaling new
guidance and a possible new pathway for "zootechnical substances."

Congress has repeatedly introduced the Innovative FEED Act concept to
create "zootechnical animal food substances" as a food additive
category. As of January 2026:

- H.R. 2203 (introduced March 18, 2025) is still in "Introduced" status.

- S. 1906 (introduced May 22, 2025) is still in "Introduced" status.

**Why the Multimin 90 precedent matters (and what it does not mean)**

Multimin 90 is FDA-approved as a new animal drug with a defined
indication: "to provide a supplemental source of zinc, copper,
manganese, and selenium in cattle," plus significant labeling
restrictions (pregnancy first trimester restriction, age restrictions)
and a withdrawal period.

This is powerful commercially (regulated status, labeling clarity,
quality expectations, potential exclusivity and patent positioning), but
it does not automatically permit broad "immune optimization" or
"reproductive efficiency" promotional claims unless they are supported
and included within approved labeling or are otherwise compliant
communications. The moat is the approval and its legal boundaries, not
marketing creativity.

**2. What "pharmaceuticalization" means in animal nutrition and why it
is accelerating**

**Working definition**

"Pharmaceuticalization" in animal nutraceuticals is the shift from:

- broad, loosely substantiated wellness claims and commodity-like
  selling\
  to

- products that look and behave more like regulated animal health
  interventions: defined indication, validated outcomes, controlled
  dosing, quality-controlled manufacturing, and increasingly formal
  premarket authorization.

**Why now**

1.  **Enforcement risk has moved to the front office**\
    Online claims (your site, distributor pages, reseller listings,
    social posts, PDFs, testimonials, "protocol charts," and even
    customer service scripts) create "intended use." FDA enforcement
    letters show that "we are not FDA approved so we cannot make claims"
    does not immunize you if your marketing still communicates disease
    treatment or structure/function drug intent.

2.  **Outcome-driven value creation**\
    Environmental claims and food safety claims (methane reduction,
    ammonia reduction, pathogen reduction) are increasingly monetizable
    through procurement standards, carbon programs, and retailer
    pressure, but they require measurable endpoints that regulators can
    evaluate.

3.  **Novel modalities do not map cleanly to "nutrition"**\
    Microbiome modulators, bacteriophages, and methane inhibitors are
    functional by design. Jurisdictions that provide an explicit feed
    additive authorization channel (EU) are ahead, and the US is trying
    to define clearer routes.

**3. Definitions: nutraceutical vs animal food vs feed additive vs
veterinary drug vs biologic**

**A. Animal nutraceutical (industry term)**

Not a universally consistent legal category. Often means:

- supplements, functional feed ingredients, additives, and wellness
  products positioned between "feed" and "drug."

**B. Animal food / feed (legal concept in many jurisdictions)**

Generally: products intended to provide nutrition. Claims must remain
within what the jurisdiction considers permissible for food.

**C. Feed additive (EU formal concept; US concept via food additive
approval)**

A substance added to animal feed to achieve a function (on the feed, the
animal, the environment, or the resulting food product), often requiring
premarket authorization depending on the jurisdiction.

**D. Veterinary drug / new animal drug (US)**

Products intended for diagnosis, cure, mitigation, treatment, or
prevention of disease, and also products intended to affect structure or
function of the body (depending on intended use and regulatory
interpretation). FDA warning letters illustrate this in practice.

**E. Veterinary biologic (US)**

Typically under USDA APHIS Center for Veterinary Biologics (vaccines,
certain immunological products). This matters when a "nutraceutical"
starts to look like an immune-modulating biologic.

**4. How regulators decide classification (the "intended use engine")**

**The single most important rule**

**Classification follows intended use, and intended use is inferred from
your total communications and product context.**

Sources of intended use include:

- label claims and directions,

- website claims and blog content,

- distributor and reseller copy,

- testimonials and reviews you highlight,

- "protocol posters" and comparison charts,

- social media posts and influencer campaigns,

- technical sheets and "whitepapers" used for selling,

- and even your customer support scripts.

A cautionary example: the FDA warning letter to Synergy Animal Products
describes how disease and structure/function claims on a website and
labeling drove the "unapproved new animal drug" conclusion, and the
firm's attempt to disclaim FDA approval did not prevent enforcement.

**Practical takeaway**

Compliance is not a label exercise. It is a cross-functional system:

- claim governance,

- content review process,

- channel partner controls,

- and documentation (substantiation files, version control).

**5. United States: today's reality plus what is changing (2024 to
2026)**

**5.1 The US "lane structure" (simplified)**

You generally operate in one of these lanes:

1.  **Animal food ingredient lane**

- Typically relies on GRAS (self or notification), AAFCO ingredient
  definitions (state acceptance), or food additive approvals depending
  on the ingredient and intended use.

- Many claims are constrained. "Structure/function" style claims have
  been a key friction point.

2.  **Food additive approval lane**

- For additives not GRAS and not otherwise lawful.

- Emerging focus: substances acting in the gut with effects related to
  digestion byproducts, microbiome, foodborne pathogens, or
  environmental outcomes (this is exactly what the Innovative FEED Act
  proposals try to formalize).

3.  **New animal drug lane (NADA, conditional approval, indexing in
    limited cases)**

- Highest regulatory burden and highest moat potential.

- Enables defined indications and stronger commercialization
  defensibility if executed well.

**5.2 Key US changes you must account for**

**A. Withdrawal of PPM 1240.3605 (May 2024)**

FDA withdrew CVM's old manual on regulating animal foods with drug
claims because it no longer reflected current thinking.

This matters because many companies (and investors) relied on the old
policy assumptions. The post-withdrawal period is transitional and
policy is still evolving.

**B. FDA is actively encouraging early engagement on "novel animal foods
with drug claims"**

FDA's May 2024 "letter to industry" encourages firms developing
gut-acting substances with claims related to production, wellbeing, food
safety, and environmental benefits to contact the agency early.

**C. Draft guidance under development: zootechnical substances and
structure/function animal food**

FDA's list of guidances under development includes:

- Draft GFI #289: Use of Zootechnical Substances in Animal Food

- Draft GFI #291: Animal Food Intended to Affect the Structure or
  Function of the Animal

Even before final publication, their existence is a major signal for
strategic planning.

**D. FDA's enforcement posture on AAFCO-defined ingredients (GFI 293,
Oct 2024)**

CVM GFI #293 states FDA generally does not intend to initiate
enforcement action for food additive approval requirements for
ingredients listed in the AAFCO 2024 Official Publication chapter six,
under specified conditions.

This is not "approval," but it is a real compliance lever for companies
using ingredients within that scope.

**5.3 Legislative watch: Innovative FEED Act (not enacted as of Jan
2026)**

The Innovative FEED Act concept aims to create a defined pathway for
"zootechnical animal food substances" as food additives (not animal
drugs), focusing on substances that act solely within the GI tract and
intended to:

- affect digestive byproducts,

- reduce foodborne pathogens of human health significance,

- or alter the GI microbiome.

As of January 2026, both 2025 versions are still introduced (not
passed).

**6. European Union: feed additive authorizations and zootechnical
claims**

**6.1 The EU's key advantage: an explicit feed additive authorization
system**

Regulation (EC) No 1831/2003 defines feed additive categories, including
zootechnical additives (additives used to affect favorably performance
of animals in good health or affect favorably the environment).

This is not a loophole. It is a formal system with:

- defined functional groups,

- premarket evaluation and authorization,

- conditions of use and labeling,

- and, in some cases, post-market monitoring requirements.

**6.2 Example: methane reduction as a zootechnical environmental claim
(3-NOP)**

Commission Implementing Regulation (EU) 2022/565 authorizes
3-nitrooxypropanol as a feed additive for dairy cows and cows for
reproduction, classified as:

- category: zootechnical additives

- functional group: substances which favorably affect the environment\
  and recognizes the potential to reduce enteric methane production.

**7. UK, Canada, and other major markets: practical notes**

**UK**

The UK often mirrors EU-style frameworks for feed additive authorization
concepts and has publicly addressed Bovaer approvals and misinformation
dynamics.

**Canada**

Public UK materials note Bovaer authorization in Canada (January 2024)
and in the US (May 2024). Use this as a signal to verify the exact
Canadian pathway for your product class early in planning.

**Practical point for multi-market launches**

Do not assume you can "port" a US claims set into the EU or vice versa.
The EU often allows explicit zootechnical claims under authorization,
while the US historically forced similar claims toward drug
classification (and is now evolving policy).

**8. Case study 1: Multimin 90 and what it proves**

**8.1 What Multimin 90 is (regulatory facts)**

FDA approval details (primary sources):

- NADA 141-582, approval date April 26, 2024, Rx status.

- Indication: "To provide a supplemental source of zinc, copper,
  manganese, and selenium in cattle."

- Key restrictions include: not for use in pregnant cows/heifers during
  first trimester, and restrictions in young calves (safety not
  established).

- FDA FOI summary describes safety, effectiveness rationale, and human
  food safety evaluation, including a withdrawal period of 14 days and
  milk discard time of 0 days.

- Green Book update lists exclusivity (5 years) and patents with listed
  expirations in 2029.

Axiota's public communication frames the business transition: moving a
historically marketed product through the FDA drug approval process and
emphasizing the completion of transition to FDA-approved labeling.

**8.2 What this case study means for "pharmaceuticalization"**

Multimin 90 demonstrates a path where:

- a nutrition-adjacent product category can be commercialized with
  drug-like regulatory rigor,

- enabling a clearer compliance posture and a differentiated market
  position (Rx distribution, defined indication, stronger quality
  expectations).

**8.3 What it does not mean (critical corrections)**

- The approved indication is a supplemental source of trace minerals. It
  is not a blanket approval for broad wellness or disease-adjacent
  claims (immune optimization, reproductive efficiency) unless those
  claims are supported, appropriately framed, and compliant with
  applicable promotional rules.

**8.4 Investor-grade lessons from Multimin 90**

1.  **Regulatory work can convert "trust" into enforceable
    differentiation**\
    Approval anchors what can be said and how it is distributed.

2.  **Quality systems become part of the moat**\
    FOI summaries often highlight safety, residue work, and
    manufacturing controls that commodity products lack.

3.  **Labeling restrictions matter commercially**\
    Restrictions and withdrawal times change adoption patterns and
    channel strategies.

**9. Case study 2: environmental claims as the catalyst (Experior and
Bovaer)**

**9.1 Experior (lubabegron): FDA-approved drug claim tied to ammonia
emissions**

DailyMed labeling lists an indication for reduction of ammonia gas
emissions per pound of live weight and hot carcass weight in beef steers
and heifers during the last 14 to 91 days on feed, and notes
effectiveness not demonstrated for less than 14 days.

This illustrates a key point:

- environmental claims can be regulated with drug-like rigor when the
  claim is specific and measurable.

**9.2 Bovaer (3-NOP): methane reduction with regulatory approvals**

- EU: authorized via Commission Implementing Regulation (EU) 2022/565 as
  a zootechnical additive (environment functional group), with
  EFSA-based conclusions referenced in the regulation.

- US: Reuters reported FDA approval for Elanco's Bovaer as a feed
  ingredient to reduce methane emissions in lactating dairy cows (May
  2024).

- DSM-firmenich stated FDA completed its review and determined safety
  and efficacy requirements were met for lactating dairy cattle, paving
  the way for market launch with partner Elanco.

**9.3 What this means for 2025 to 2030**

Environmental outcomes are a new "authorization wedge":

- They create measurable endpoints regulators can evaluate.

- They create monetization paths (procurement, carbon programs,
  sustainability reporting).

- They raise the bar for evidence and post-market defensibility.

**10. Case study 3: bacteriophages as authorized zootechnical additives
(EU Bafasal)**

**10.1 The early science and regulatory problem**

Earlier EFSA-related documentation (available via PubMed Central) shows
the FEEDAP panel concluded Bafasal was safe for target species,
consumers, and environment, but initially could not conclude efficacy
due to insufficient data.

This captures a recurring pattern for novel modalities:

- safety can be established earlier than efficacy for a specific claim.

- "efficacy for claim X" is the gating item.

**10.2 The authorization milestone (July 2025)**

Commission Implementing Regulation (EU) 2025/1390 authorizes a
preparation of specific bacteriophages as a feed additive for poultry,
classified as:

- category: zootechnical additives

- functional group: other zootechnical additives\
  and it references EFSA opinions including conclusions about potential
  to reduce environmental contamination with Salmonella Enteritidis
  under specified uses.

It also explicitly notes a need for specific post-market monitoring to
address potential selection and spread of resistant variants.

**10.3 Why this matters**

This is a concrete example that:

- phage-based interventions can achieve formal authorization,

- but may carry post-market monitoring obligations that you must
  operationalize.

**11. Claim-to-pathway decision matrix (with red flags and safer
alternatives)**

**11.1 US and EU: high-level mapping**

  ----------------------------------------------------------------------------
  **Claim type             **US likely lane   **EU likely     **Risk level if
  (examples)**             (today)**          lane**          you "wing it"**
  ------------------------ ------------------ --------------- ----------------
  Pure nutrition (source   Animal food        Feed materials  Low
  of vitamins, minerals)   ingredient         / nutritional   
                                              additive        

  "Supports digestive      Often still risky  Potentially     Medium
  health" without disease  depending on       zootechnical    
  language                 substantiation and additive        
                           framing; may       depending on    
                           require careful    claim and       
                           strategy; policy   ingredient      
                           evolving                           

  Production/performance   Historically high  Zootechnical    High (US),
  (feed efficiency, weight risk of drug       additive        Medium (EU with
  gain, milk yield)        classification;    pathway is      authorization)
                           evolving under FDA designed for    
                           initiatives and    performance     
                           proposed           claims          
                           legislation                        

  Foodborne pathogen       High scrutiny;     Zootechnical    High
  reduction (reduces       could be drug      additive        
  Salmonella, E. coli      unless clear       possible with   
  shedding)                pathway and        authorization   
                           authorization      (example:       
                                              phages)         

  Environmental outcomes   Can be food        Zootechnical    Medium to High
  (methane reduction,      additive or drug   additive        
  ammonia emissions)       depending on       environment     
                           mechanism and      functional      
                           claim; examples    group exists    
                           exist                              

  Disease                  New animal drug    Veterinary      Very high
  treatment/prevention     (approval          medicinal       
  (treats scours, prevents required)          product         
  mastitis)                                   (approval       
                                              required)       
  ----------------------------------------------------------------------------

**11.2 "Red flag" claim words that frequently trigger drug
classification**

- treat, prevent, cure, mitigate

- anti-inflammatory, antibacterial (when framed as therapeutic for
  disease)

- "for mastitis," "for scours," "for respiratory disease," etc

- dosing protocols tied to diseases

The Synergy Animal Products warning letter provides concrete examples of
claims FDA viewed as establishing drug intent, including references to
mastitis, scours, and high somatic cell count.

**11.3 Safer alternative phrasing (not a guarantee)**

If you want to stay in an animal food lane, favor:

- nutritional role language,

- normal function support language,

- and avoid disease endpoints.

But do not assume "supports" is a magic shield. Classification still
depends on context, substantiation, and overall messaging.

**12. Evidence and dossier strategy by pathway**

**12.1 US animal food ingredient strategy (GRAS / AAFCO / enforcement
discretion)**

Core components investors expect to see:

- identity and specifications (what is it, how is it made, what is in
  it),

- safety basis (target species safety, contaminants, margins of
  exposure),

- manufacturing controls and supplier qualification,

- intended use statement that aligns with lawful claims,

- substantiation file for every marketing statement.

Operational lever: if your ingredient is in AAFCO 2024 chapter six,
understand the scope of FDA's enforcement policy described in CVM GFI
293.

**12.2 US food additive strategy (including proposed "zootechnical
substances" direction)**

Plan around:

- early FDA engagement (premarket consult),

- clear mechanism and site of action (gut-only vs systemic),

- measurable endpoints and study designs,

- and conservative claim governance until policy is finalized.

FDA explicitly encourages early contact for novel animal foods with
gut-only action and substantiated claims related to production,
wellbeing, food safety, and environmental benefits.

**12.3 US new animal drug strategy (NADA)**

Expect to build:

- Safety package: target animal safety; user safety; human food safety
  (residues) for food animals; environmental assessment.

- Effectiveness package: "substantial evidence" with appropriate study
  design, endpoints, and controls.

- CMC: drug substance and drug product controls, stability, batch
  consistency, release testing.

- Labeling: exact indication wording, warnings, restrictions, withdrawal
  times.

Multimin 90's FOI summary shows the breadth of considerations FDA
evaluated, including overdose toxicity concerns and human food safety
risk characterization.

**12.4 EU feed additive authorization strategy**

A typical EFSA-aligned dossier includes:

- characterization and manufacturing process,

- safety for target species, consumers, users, environment,

- efficacy for the proposed functional group,

- stability and homogeneity,

- analytical methods and reference lab considerations.

EU implementing regulations (3-NOP and phages) show how authorizations
explicitly encode functional groups, use conditions, and sometimes
post-market monitoring.

**13. Manufacturing, quality, and supply chain requirements (what
investors will probe)**

**13.1 Why quality is now valuation-relevant**

As products move toward regulated claims, "quality" stops being a
back-office activity and becomes:

- a regulatory requirement,

- a customer requirement (integrators, veterinarians, retailers),

- and an enforcement risk reducer.

The Synergy warning letter highlights how FDA tied unapproved drug
status to CGMP failures (no quality unit, no testing, no batch records).
That is a strong diligence signal for investors.

**13.2 Practical quality system elements to implement**

- Supplier qualification and incoming testing

- Written specifications and COA verification

- Batch records and traceability

- Stability program (real-time and accelerated)

- Label control and content review workflow

- Complaint handling and adverse event reporting where applicable

- Channel partner compliance controls (distributors, affiliates,
  resellers)

**14. Go-to-market and compliance operations**

**14.1 The "claims governance" operating model (minimum viable)**

- Single owner of claims library (regulatory or quality)

- Pre-approved claims bank by product and jurisdiction

- Mandatory review of all marketing assets (web, reseller copy, PDFs)

- Training for sales and customer support

- Auditing of distributor and affiliate pages quarterly

- Written corrective action process when violations occur

**14.2 Post-market monitoring is becoming normal**

EU phage authorization shows post-market monitoring requirements can be
embedded in authorization conditions, especially for resistance-related
concerns.

**15. Investment implications: diligence questions, deal structures, and
"regulatory moat" logic**

**15.1 What a "regulatory moat" looks like in diligence**

Investors will ask:

- What exact claims are being made, and where (including third parties)?

- Which lane are you in (food, additive, drug), and what is the written
  basis?

- Do you have a substantiation dossier for every claim?

- Have you had any FDA, state, or other regulatory inquiries?

- Is manufacturing audit-ready (batch records, testing, CAPA,
  stability)?

- Are you exposed on residues or withdrawal times if food animals?

- What is your defensibility: approvals, exclusivity, patents, trade
  secrets, data?

Multimin 90 is a case study in how approvals and exclusivity/patent
listings can change defensibility and competitive posture.

**15.2 Deal structuring recommendations (practical)**

- Tie earnouts to regulatory milestones (submission accepted,
  authorization granted, label claim granted).

- Include reps/warranties on marketing claims and channel partner
  controls.

- Require disclosure of all marketing assets and reseller pages in
  diligence.

- Add covenants requiring a claim governance system within 60 to 90 days
  post-close.

**16. 2025 to 2030 outlook: scenarios, triggers, and playbook actions**

**Scenario A: Innovative FEED Act passes (or FDA creates a strong de
facto pathway via guidance)**

Trigger signals:

- movement of H.R.2203 or S.1906 beyond "introduced,"

- publication of Draft GFI 289/291 and subsequent enforcement approach,

- increased use of food additive petitions for gut-only functional
  substances.

Action:

- design studies and claims now to align with "gut-only" mechanisms and
  measurable endpoints.

- build an early FDA engagement plan.

Current status remains introduced (not enacted).

**Scenario B: EU continues authorizing high-impact functionals with
explicit conditions**

Trigger signals:

- more implementing regulations with post-market monitoring
  requirements,

- accelerated authorizations for environmental and food safety outcomes.

Action:

- build EU-first claim strategy when your product fits a functional
  group.

- treat post-market monitoring as a core capability, not an
  afterthought.

**Scenario C: Environmental claims become mainstream, and misinformation
risk rises**

Trigger signals:

- more public controversies similar to Bovaer, heightened scrutiny on
  "chemicals in food chain," and reputational risks.

Action:

- pre-build a transparent science communication package:

  - safety narrative,

  - handling guidance,

  - residue and food safety summaries,

  - and third-party validation where possible.

**Appendix A: Regulatory strategy one-pager template (copy and paste)**

**Product name:**\
**Species / lifecycle stage:**\
**Form:** (premix, top-dress, bolus, water additive, injectable, etc)\
**Active(s):**\
**Mechanism of action:** (gut-only vs systemic; key pathways)\
**Primary outcome:** (performance, food safety, environmental,
nutritional)\
**Intended claims (exact wording):**\
**Jurisdiction targets:** US / EU / UK / Canada / etc\
**Proposed regulatory lane per jurisdiction:**\
**Evidence plan:** (studies, endpoints, timelines)\
**Manufacturing plan:** (site, quality system, release specs)\
**Risk register:** (claims risk, residues, user safety, resistance,
labeling)\
**Regulatory engagement plan:** (pre-sub meetings, dossier milestones)

**Appendix B: Claim review checklist (website, label, sales scripts)**

1.  Do any claims mention diseases or disease proxies (mastitis, scours,
    pneumonia, etc)?

2.  Do testimonials mention disease outcomes you are implicitly
    endorsing?

3.  Do protocol charts recommend use "when sick" or "for outbreak
    control"?

4.  Are you implying antimicrobial or therapeutic action?

5.  Do distributors or resellers use prohibited language?

6.  Are disclaimers being used as a substitute for compliant claims
    (high risk)?

**Appendix C: Dossier checklists (high level)**

**US animal food ingredient file (GRAS / AAFCO style)**

- Identity/specs

- Manufacturing process

- Contaminant profile

- Safety basis and margins

- Intended use statement aligned to lawful claims

- Substantiation for every claim

- Label and marketing governance SOP

**US NADA-style file**

- Target animal safety

- Effectiveness (substantial evidence)

- Human food safety (residues, withdrawal)

- User safety

- Environmental

- CMC and stability

- Labeling and Rx/OTC decisions\
  (Multimin FOI summary illustrates these components in practice.)

**EU feed additive authorization file**

- Characterization and manufacturing

- Safety: animal, consumer, user, environment

- Efficacy for functional group

- Stability/homogeneity

- Methods of analysis

- Post-market monitoring plan where required

**Appendix D: Investor/acquirer diligence questionnaire (condensed)**

1.  List every claim in market (label, web, reseller, social).

2.  Provide substantiation files per claim.

3.  Provide regulatory classification memo per jurisdiction.

4.  Provide manufacturing documentation (specs, COAs, batch records,
    stability).

5.  Provide complaint history and adverse events (if tracked).

6.  Provide any regulator correspondence, inspections, warnings.

7.  Provide IP and exclusivity position (patents, data, approvals).

**Appendix E: Glossary (selected)**

- **Intended use:** the regulator-inferred purpose of the product,
  derived from total communications.

- **Zootechnical additive (EU):** feed additive category under
  Regulation 1831/2003 aimed at performance/environment outcomes.

- **Zootechnical animal food substance (proposed US):** category
  proposed in Innovative FEED Act bills for gut-only functional
  substances to be regulated as food additives.

**Multimin 90 and the Axiota precedent**

FDA Animal Drugs @ FDA - FOI Summary for the Original Approval of NADA
141-582 (MULTIMIN 90) (PDF)

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/15347

FDA Animal Drugs @ FDA - Green Book Monthly Update (May 2024) (PDF)

https://animaldrugsatfda.fda.gov/adafda/app/search/public/monthlyUpdates/downloadMonthlyUpdate/1801

FDA Animal Drugs @ FDA - Green Book Section 4: Exclusivity Periods (PDF)

https://animaldrugsatfda.fda.gov/adafda/app/search/public/exclusivityInformationPdf/Section4ExclusivityPeriods

FDA Animal Drugs @ FDA - Green Book Section 3: Patent Information (PDF)

https://animaldrugsatfda.fda.gov/adafda/app/search/public/patentInformationPdf/Section3PatentInformation

DailyMed (NIH) - MULTIMIN 90 label

https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c1d76049-a036-48f7-bf3a-0aab5ddfff7c

Axiota - Press release: FDA Approval of Multimin 90

https://axiota.com/axiota-animal-health-announces-fda-approval-of-multimin-90/

Axiota - Multimin 90 patent listing page

https://axiota.com/patent/

FDA - Approved Animal Drug Products (Green Book) overview page

https://www.fda.gov/animal-veterinary/products/approved-animal-drug-products-green-book

FDA Animal Drugs @ FDA portal (search tool that hosts Green Book PDFs,
FOI summaries, etc.)

https://animaldrugsatfda.fda.gov/adafda/views/

**FDA policy shift on animal food claims and "gut-only" products**

FDA - Letter to Industry (Novel Animal Foods with Drug Claims) (May 21,
2024)

https://www.fda.gov/animal-veterinary/resources-you/fda-letter-industry-industry-encouraged-contact-fda-regarding-novel-animal-foods-drug-claims

Federal Register - Withdrawal of PPM 1240.3605 (May 20, 2024)

https://www.federalregister.gov/documents/2024/05/20/2024-10936/program-policy-and-procedures-manual-guide-12403605-regulating-animal-foods-with-drug-claims

FDA - PPM 1240.3605 "Regulating Animal Foods with Drug Claims" (PDF)

https://www.fda.gov/media/69982/download

FDA - "Guidances Under Development" (lists draft GFI 289 and draft GFI
291)

https://www.fda.gov/animal-veterinary/guidance-industry/guidances-under-development

FDA - CVM GFI #293 (final) "FDA Enforcement Policy for AAFCO-Defined
Animal Feed Ingredients"

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cvm-gfi-293-fda-enforcement-policy-aafco-defined-animal-feed-ingredients

AAFCO - 2024 Official Publication Chapter 6 (PDF)

https://www.aafco.org/wp-content/uploads/2025/04/2024_OP_Chapter_6_enc.pdf

FDA - Animal and Veterinary Innovation Agenda (AVIA)

https://www.fda.gov/animal-veterinary/products/animal-and-veterinary-innovation-agenda

FDA - Virtual listening session page (Animal foods with certain types of
claims, 10/18/2022)

https://www.fda.gov/animal-veterinary/workshops-conferences-meetings/fda-virtual-listening-session-regulation-animal-foods-certain-types-claims-10182022

**Innovative FEED Act links (Congress.gov)**

H.R. 2203 (119th Congress) - Innovative FEED Act of 2025 (bill page)

https://www.congress.gov/bill/119th-congress/house-bill/2203

H.R. 2203 (119th Congress) - bill text

https://www.congress.gov/bill/119th-congress/house-bill/2203/text/ih

S. 1906 (119th Congress) - Innovative FEED Act of 2025 (bill page)

https://www.congress.gov/bill/119th-congress/senate-bill/1906

S. 1906 (119th Congress) - bill text

https://www.congress.gov/bill/119th-congress/senate-bill/1906/text

S. 1842 (118th Congress) - Innovative FEED Act (bill page)

https://www.congress.gov/bill/118th-congress/senate-bill/1842

S. 1842 (118th Congress) - bill text

https://www.congress.gov/bill/118th-congress/senate-bill/1842/text

**Experior (lubabegron) sources**

FDA - FDA Brief (Nov 6, 2018): approval of Experior, first animal drug
reducing gas emissions from an animal or its waste

https://www.fda.gov/news-events/fda-brief/fda-brief-fda-approves-first-animal-drug-reduces-gas-emissions-animal-or-its-waste

DailyMed (NIH) - EXPERIOR 50 (lubabegron) label

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=631a7444-8652-4bbd-907e-87f6b32cbac7

DailyMed (NIH) - EXPERIOR 10 (lubabegron) label

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0c09fde-ee94-4ab4-9bd8-854eb96ec598

**EU regulatory framework and approvals**

EUR-Lex - Regulation (EC) No 1831/2003 (feed additives framework)

https://eur-lex.europa.eu/eli/reg/2003/1831/oj/eng

EUR-Lex - Commission Implementing Regulation (EU) 2022/565 (3-NOP
authorisation) (ELI page)

https://eur-lex.europa.eu/eli/reg_impl/2022/565/oj/eng

EUR-Lex - Commission Implementing Regulation (EU) 2022/565 (PDF)

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX%3A32022R0565

EUR-Lex - Commission Implementing Regulation (EU) 2025/1390
(bacteriophage preparation authorisation for poultry) (ELI page)

https://eur-lex.europa.eu/eli/reg_impl/2025/1390/oj/eng

EUR-Lex - Commission Implementing Regulation (EU) 2025/1390 (PDF)

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=OJ%3AL_202501390

**EFSA and bacteriophage example (Bafasal) used to illustrate the
"zootechnical" pathway**

PubMed Central (PMC) - EFSA Journal (2023): Safety and efficacy of
Bafasal for all avian species (contains discussion of earlier data gaps
and post-market monitoring)

https://pmc.ncbi.nlm.nih.gov/articles/PMC9978957/

PubMed Central (PMC) - 2020 paper: Comprehensive Evaluation of the
Safety and Efficacy of BAFASAL bacteriophage preparation

https://pmc.ncbi.nlm.nih.gov/articles/PMC7412135/

**Bovaer (3-NOP) sources used in the report**

FDA - CVM File: G-150438 (PDF letter including "at this time we do not
intend to initiate enforcement action..." language and mixing
directions)

https://www.fda.gov/media/178913/download

Elanco Investor Relations - press release (May 28, 2024): FDA has
completed review of Bovaer for U.S. dairy

https://investor.elanco.com/press-releases/press-releases-details/2024/Elanco-Announces-FDA-Has-Completed-Review-of-Bovaer-First-in-Class-Methane-Reducing-Feed-Ingredient-for-U.S.-Dairy-Industry/default.aspx

DSM-firmenich - press release (May 29, 2024): Bovaer ready for U.S.
market launch after FDA review completion

https://our-company.dsm-firmenich.com/en/our-company/news/press-releases/2024/methane-reducing-feed-ingredient-bovaer-ready-for-us-market-launch.html

Reuters - US FDA approves Elanco feed ingredient to cut methane
emissions in dairy cows (May 28, 2024)

https://www.reuters.com/business/environment/us-fda-approves-elancos-feed-ingredient-cut-methane-emissions-dairy-cows-2024-05-28/

UK Food Standards Agency blog - "Bovaer cow feed additive explained"
(Dec 5, 2024)

https://food.blog.gov.uk/2024/12/05/bovaer-cow-feed-additive-explained/

Reuters Fact Check - "Bovaer's active ingredient not detected in dairy
products..." (Jan 17, 2025)

https://www.reuters.com/fact-check/bovaers-active-ingredient-not-detected-dairy-products-2025-01-17/

Reuters Fact Check - "Feed additive Bovaer is approved in EU..." (Dec
13, 2024)

https://www.reuters.com/fact-check/feed-additive-bovaer-is-approved-eu-contrary-online-claims-2024-12-13/

DSM-firmenich - statement page: "Misinformation about Bovaer" (2025)

https://our-company.dsm-firmenich.com/en/our-company/news/updates-and-statements/2025/misinformation-about-bovaer.html

**FDA enforcement example used (warning letter)**

FDA - Warning Letter: Synergy Animal Products, Inc. (Re: 712860, July
16, 2025)

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synergy-animal-products-inc-712860-07162025

FDA - CVM Warning Letters landing page

https://www.fda.gov/animal-veterinary/compliance-enforcement/cvm-warning-letters

FDA - Regulatory Actions page (Unapproved Animal Drugs)

https://www.fda.gov/animal-veterinary/unapproved-animal-drugs/regulatory-actions


---

# Source: Nutraceuticals_Whitepaper.xlsx

### Sheet: PE VC

| Country | Fund | Company Name | Classification | Detailed Summary of Operations | Pet Food? | Nutraceuticals? | In the list ? |
| --- | --- | --- | --- | --- | --- | --- | --- |
| USA | Digitalis Ventures | Astra Therapeutics | Veterinary | A biotechnology firm developing the next generation of small molecule anti-parasitic drugs. By harnessing comparative structural data and advanced computational chemistry, Astra targets parasites that have developed resistance to current treatments, addressing a critical unmet need in veterinary medicine. | No | No |  |
| USA | Digitalis Ventures | Dandylion | Other (Consumer) | A consumer brand focused on "skin-first" dog grooming products. Dandylion formulates gentle, pH-balanced hygiene solutions designed to make dog care easier and safer, responding to the trend of pet owners scrutinizing ingredient labels for topical products much like they do for their own cosmetics. | No | No |  |
| USA | Digitalis Ventures | Gallant Therapeutics | Veterinary | A clinical-stage biotech pioneering off-the-shelf (allogeneic) stem cell therapies. Gallant targets the root causes of chronic diseases such as feline chronic gingivostomatitis (FCGS) and canine osteoarthritis. Their approach utilizes uterine-derived mesenchymal stromal cells (MSCs) to regulate the immune system and promote tissue repair, moving beyond symptom management to curative intent. | No | No (Therapeutic) |  |
| USA | Digitalis Ventures | Honor Pet | Other (Services) | A service provider reimagining the end-of-life experience for pets. Honor Pet offers modern, transparent, and compassionate aftercare and cremation services, addressing the emotional needs of pet owners during the grieving process with a focus on dignity and trust. | No | No |  |
| USA | Digitalis Ventures | Napo | Other (Insurance) | A UK-based "insurtech" startup that integrates preventative wellness into pet insurance policies. Napo offers comprehensive coverage that includes access to veterinary video consultations and behaviorist advice, incentivizing proactive health management to reduce long-term claims costs. | No | No |  |
| USA | Digitalis Ventures | Oncura | Veterinary | A medical technology company democratizing access to advanced imaging. Oncura provides a platform that connects general practice veterinarians with board-certified radiologists via real-time tele-ultrasound. This allows GPs to perform complex scans with remote guidance, keeping revenue and patient care within the primary clinic. | No | No |  |
| USA | Digitalis Ventures | Made by Nacho | Other (Consumer) | A premium cat food brand co-founded by celebrity chef Bobby Flay. The company is dedicated exclusively to feline nutrition, offering high-protein wet and dry foods, treats, and toppers. The brand leverages culinary expertise to solve the "palatability gap" often found in high-quality cat foods. | Yes (Primary) | No | No |
| USA | Digitalis Ventures | MoeGo | Other (Software) | A vertical SaaS platform for the pet grooming industry. MoeGo provides an all-in-one business management solution for mobile groomers and salons, handling scheduling, routing, payments, and client communications, thereby digitizing a traditionally pen-and-paper industry. | No | No |  |
| USA | Digitalis Ventures | Mollybox | Other (Retail) | A subscription-based e-commerce platform serving the Chinese pet market. Mollybox delivers curated boxes of pet food, treats, and toys, capitalizing on the rapid growth of pet ownership and the desire for convenience among China's urban middle class. | Yes (Retailer) | No | No |
| USA | Digitalis Ventures | Native Pet | Other (Consumer) | A functional supplement company bridging the gap between "treats" and "medicine." Native Pet utilizes whole-food ingredients (e.g., pumpkin, bone broth, wild-caught salmon) to create effective nutraceuticals for digestive health, allergy relief, and calming. Their "clean label" approach appeals to health-conscious owners. | Yes (Toppers) | Yes (Core Business) | Yes |
| USA | Digitalis Ventures | Pacagen | Veterinary | A biotechnology company developing treatments to neutralize pet allergens. Their research focuses on modifying or neutralizing the proteins (like Fel d 1) in cat and dog dander that cause allergic reactions in humans, potentially allowing allergic individuals to own pets without symptoms. | No | No |  |
| USA | Digitalis Ventures | Pawp | Other (Services) | A digital health clinic and membership platform offering 24/7 access to veterinary professionals via text and video. Pawp differentiates itself with an "emergency fund" model, providing financial coverage for life-threatening emergencies without the premiums or exclusions of traditional insurance. | No | No |  |
| USA | Digitalis Ventures | PetMedix | Veterinary | Acquired by Zoetis. A biotech company that developed a transgenic mouse platform to produce fully species-specific monoclonal antibodies for dogs and cats. This technology enables the creation of highly targeted, low-immunogenicity therapeutics for chronic diseases like atopic dermatitis and cancer. | No | No |  |
| USA | Digitalis Ventures | Rejuvenate Bio | Veterinary | A spinout from the Wyss Institute at Harvard developing gene therapies to reverse age-related diseases. Their lead programs target conditions like mitral valve disease in dogs, with the long-term goal of translating these longevity technologies to human medicine. | No | No |  |
| USA | Digitalis Ventures | RiverDog | Other (Services) | An operator of premium dog daycare, boarding, and training facilities. RiverDog emphasizes enrichment-based care and crate-free environments, catering to owners who view their dogs as family members requiring socialization and mental stimulation. | No | No |  |
| USA | Digitalis Ventures | ScoutBio | Veterinary | Acquired by Ceva Santé Animale. A biotechnology company focused on "one-time" AAV-vectored gene therapies. ScoutBio developed therapeutics that enable a patient's own cells to produce therapeutic proteins, targeting chronic conditions like anemia and osteoarthritis pain. | No | No |  |
| USA | Digitalis Ventures | Scratchpay | Other (Fintech) | A financial technology company offering "Care Now, Pay Later" solutions for veterinary costs. Scratchpay integrates with practice management systems to provide instant loan approvals for pet owners, reducing economic euthanasia and enabling access to necessary medical care. | No | No |  |
| USA | Digitalis Ventures | Smalls | Other (Consumer) | A direct-to-consumer (DTC) cat food brand specializing in fresh, human-grade meat recipes. Smalls disrupts the "kibble" market by offering high-protein, high-moisture diets that mimic a cat's ancestral nutritional requirements, delivered via a subscription model. | Yes (Primary) | No | No |
| USA | Digitalis Ventures | Tuft + Paw | Other (Consumer) | A modern cat furniture brand focusing on aesthetics and design. Tuft + Paw creates litter boxes, scratching posts, and beds that function as high-end home decor, addressing the "ugly pet furniture" problem for design-conscious cat owners. | No | No |  |
| USA | Digitalis Ventures | Vedi | Veterinary | A health data platform that creates a universal medical record for animals. Vedi automates the capture of health data (vaccinations, pathology) and links it to a microchip, ensuring accurate, portable health records for veterinarians and owners. | No | No |  |
| USA | Ani.VC | The Cat Health Company | Veterinary | A longevity startup dedicated exclusively to extending the healthy lifespan of cats. The company focuses on identifying and developing new therapeutics for age-related feline diseases, utilizing both computational biology and wet-lab approaches to achieve "nine lives extension." | No | No (Therapeutic) |  |
| USA | Ani.VC | MI:RNA | Veterinary | A diagnostics company pioneering the use of microRNA biomarkers for early disease detection. MI:RNA’s technology allows veterinarians to detect conditions like heart disease, kidney failure, and cancer at a molecular level before clinical symptoms manifest, enabling earlier and more effective intervention. | No | No |  |
| USA | Ani.VC | DOG PPL | Other (Services) | A "canine social club" that merges a rigorously maintained dog park with a members-only social lounge for humans. The concept addresses the safety concerns of public dog parks by requiring behavioral assessments and vaccination proof, creating a safe "third place" for millennials and their dogs. | No | No |  |
| USA | Ani.VC | Vetmab Biosciences | Veterinary | A biopharmaceutical company focused on the discovery and development of monoclonal antibody therapies for companion animals. Vetmab aims to treat chronic veterinary diseases with biologic drugs that offer high specificity and fewer side effects than traditional small-molecule drugs. | No | No |  |
| USA | Ani.VC | RetrievAir | Other (Tech) | While public details are limited, the company operates in the retrieval technology space. In the context of Ani.VC's portfolio, this likely pertains to advanced pet tracking, safety retrieval systems, or medical sample logistics for veterinary diagnostics. | No | No |  |
| USA | Ani.VC | Lil Luv Dog | Other (Consumer) | A consumer-facing brand within the pet care sector. Given the fund's focus, this entity likely operates in the consumables or accessories market, potentially focusing on wellness or lifestyle products for small dogs. | Unclear | Unclear |  |
| USA | Stray Dog Capital | Bond Pet Foods | Other (Biotech) | A biotechnology leader using precision fermentation to produce animal-identical meat proteins without slaughter. Bond "brews" chicken protein using yeast and DNA, creating a high-purity, sustainable protein source specifically for pet food manufacturers. | Yes (Ingredients) | No | No |
| USA | Stray Dog Capital | Wild Earth | Other (Consumer) | A pioneering pet food company that utilizes yeast protein (koji) as a primary ingredient. Wild Earth produces high-protein, plant-based dog food that is complete and balanced, challenging the necessity of meat in canine diets. They also market functional supplements. | Yes (Primary) | Yes | No |
| USA | Stray Dog Capital | Because Animals | Other (Biotech) | Now evolving into new entities. This company focused on developing cultured meat specifically for pets. They famously worked on growing mouse meat for cat food, arguing that a species-appropriate ancestral diet could be produced without killing animals. | Yes | No | No |
| USA | Stray Dog Capital | BlueNalu | Other (Food) | A cellular aquaculture company producing seafood directly from fish cells. While currently focused on high-value human markets (e.g., Bluefin Tuna toro), the technology holds long-term potential for producing mercury-free, sustainable fish protein for premium pet foods. | No | No |  |
| USA | Stray Dog Capital | Upside Foods (Memphis Meats) | Other (Food) | A frontrunner in the cultivated meat revolution, producing chicken from animal cells. Tyson Ventures is also an investor. Upside’s regulatory wins pave the way for cultured meat across the entire food system, including pet nutrition. | No | No |  |
| USA | Stray Dog Capital | SuperMeat | Other (Food) | An Israeli food-tech company growing cultured chicken meat. They operate a "The Chicken" production facility/restaurant to demonstrate the viability of growing meat without birds. | No | No |  |
| USA | Stray Dog Capital | Mosa Meat | Other (Food) | A Dutch food technology company that created the world's first lab-grown hamburger. Their advancements in serum-free media are critical for reducing the cost of cultured meat to levels viable for pet food applications. | No | No |  |
| USA | Stray Dog Capital | Meatless Farm | Other (Food) | Exited. A producer of plant-based meat alternatives (mince, burgers). While human-focused, their ingredients (pea/soy protein blends) are representative of the inputs used in plant-based pet diets. | No | No |  |
| USA | Stray Dog Capital | Miyoko's Creamery | Other (Food) | A dairy-free creamery producing artisan vegan cheeses and butters using traditional fermentation techniques. Their focus on simple, whole-food ingredients mirrors the "clean label" trend in pet treats. | No | No |  |
| USA | Borealis Ventures | Embark Veterinary | Veterinary | The "23andMe" of the canine world. Embark offers the most advanced DNA testing service for dogs, providing breed identification and screening for over 200 genetic health risks. Their massive database drives research into canine hereditary diseases. | No | No |  |
| USA | Borealis Ventures | Fidocure (The One Health Company) | Veterinary | A precision medicine company for dogs with cancer. Fidocure uses genomic sequencing of canine tumors to identify specific mutations, then recommends targeted human cancer drugs (like PARP inhibitors) that can treat those mutations, bridging the gap between human and veterinary oncology. | No | No |  |
| USA | Borealis Ventures | Vetcove | Veterinary | A B2B purchasing platform for veterinary hospitals. Vetcove aggregates catalogs from all major distributors (Covetrus, MWI, etc.), allowing clinics to compare prices, track inventory, and manage purchasing from a single dashboard, significantly increasing practice efficiency. | No | No |  |
| USA | Borealis Ventures | Astra Therapeutics | Veterinary | Co-invested with Digitalis. Developing novel small molecule therapeutics for parasitic infections in animals. | No | No |  |
| USA | Borealis Ventures | Triveni Bio | Other (Biotech) | A biotechnology company utilizing genetics to develop therapeutics for immunological and inflammatory disorders. While primarily human-focused, the foundational science of I&I (Inflammation & Immunology) often crosses over into veterinary applications (e.g., atopic dermatitis). | No | No |  |
| USA | S2G Investments  | Enthos | Other (AgTech) | A circular economy company using Black Soldier Fly (BSF) larvae to upcycle organic waste into high-quality protein meal and oil. These insect-based ingredients are premium inputs for pet food and aquaculture feed, offering a sustainable alternative to fishmeal. | Yes (Ingredients) | No | No |
| USA | S2G Investments  | Sentera | Other (AgTech) | A digital agriculture company providing drone-based analytics and sensors to measure crop health and yield. Sentera's technology optimizes the production of row crops (corn, soy) that form the baseload of the animal feed supply chain. | No | No |  |
| USA | S2G Investments  | EarthOptics | Other (AgTech) | A soil data measurement company using ground-penetrating radar and machine learning to map soil health and carbon. Their technology enables farmers to verify carbon sequestration, incentivizing regenerative practices for crops used in food and feed. | No | No |  |
| USA | S2G Investments  | Pasture Bio | Veterinary/Ag | A biotechnology company developing vaccines to reduce enteric methane emissions in cattle. By mitigating the climate impact of livestock, they aim to make traditional animal protein production more sustainable. | No | No |  |
| USA | S2G Investments  | Wildtype | Other (Food) | A cultivated seafood company focusing on salmon. Wildtype grows sushi-grade salmon from cells. While currently targeting high-end human culinary markets, the technology is a precursor to sustainable fish ingredients for premium pet diets. | No | No |  |
| USA | S2G Investments  | Trace Genomics | Other (AgTech) | A soil science company using genomics to identify pathogens and beneficial microbes in the soil. This "soil DNA" testing helps farmers prevent crop disease and optimize yields without excessive chemical inputs. | No | No |  |
| USA | S2G Investments  | Kingdom Supercultures | Other (Food Tech) | A biodesign company designing microbial communities (cultures) to transform food ingredients. Their technology can create novel flavors, textures, and preservatives for the food and pet food industries naturally. | Yes (Ingredients) | No | No |
| USA | Tyson Ventures | Protix | Other (AgTech) | A leading Dutch insect ingredients company. Tyson acquired a minority stake to form a joint venture for building a massive insect ingredient facility in the US. Protix produces insect protein specifically for pet food and aquaculture, capitalizing on the hypoallergenic and sustainable properties of bugs. | Yes (Ingredients) | No | Yes  |
| USA | Tyson Ventures | Upside Foods | Other (Food) | A pioneer in the cultivated meat industry. Tyson was an early investor, supporting their mission to grow chicken from cells. This investment hedges Tyson's core poultry business against future disruption by slaughter-free meat. | No | No |  |
| USA | Tyson Ventures | Soft Robotics | Other (Tech) | A robotics company developing soft grippers and 3D vision systems for food processing. Their technology automates the handling of delicate food items (like raw meat or produce) in sanitary environments, relevant for pet food manufacturing. | No | No |  |
| USA | Tyson Ventures | Future Meat (Believer Meats) | Other (Food) | An Israeli cultivated meat company focused on reducing the cost of production to reach price parity with conventional meat. They utilize a unique media rejuvenation process to increase efficiency. | No | No |  |
| USA | Tyson Ventures | MycoTechnology | Other (Food Tech) | A food technology company using mycelium fermentation to process plant proteins (like pea and rice). Their fermentation process improves taste by removing bitter off-notes and enhances nutritional bioavailability, applicable to both human and pet food formulations. | Yes (Ingredients) | No | No |
| USA | Tyson Ventures | Clear Labs | Other (Tech) | A food safety platform using Next-Generation Sequencing (NGS) to detect pathogens like Salmonella and Listeria. This technology is critical for ensuring the safety of the meat supply chain, including raw materials for pet food. | No | No |  |
| France | Seventure Partners  | ViroVet | Veterinary | A Belgian biopharmaceutical company developing novel antiviral therapies for livestock. They utilize unique technology based on VHH (single-domain antibodies) to control viral diseases, aiming to reduce the reliance on antibiotics in animal agriculture. | No | No |  |
| France | Seventure Partners  | Proteon Pharmaceuticals | Veterinary | A company using bacteriophages (viruses that kill specific bacteria) as an alternative to antibiotics in aquaculture and poultry farming. Their products improve animal health and production efficiency without contributing to antimicrobial resistance. | No | No (Therapeutic) |  |
| France | Seventure Partners  | String Bio | Other (Biotech) | A biotech firm that converts methane gas into single-cell protein ingredients via fermentation. This "PRO-DG" protein is a sustainable, traceable ingredient used in animal feed and aquaculture, with applications for pet food. | Yes (Ingredients) | No | No |
| France | Seventure Partners  | Tibot | Veterinary/Ag | A robotics company developing autonomous robots (Spoutnic) for poultry farming. These robots move randomly to encourage bird movement, reducing floor eggs and improving animal welfare and productivity. | No | No |  |
| France | Seventure Partners  | Inspecto | Other (AgTech) | A technology company that developed a portable device for the early detection of chemical residues (pesticides) and contaminants in food and crops. This ensures the safety of raw materials entering the food and feed chain. | No | No |  |
| France | Seventure Partners  | Microbiotica | Other (Biotech) | A leader in microbiome-based therapeutics discovery. They use a proprietary platform to identify gut bacteria linked to specific phenotypes. While human-focused, the science of microbiome modulation translates directly to animal health. | No | No |  |
| France | Seventure Partners  | Enterome | Other (Biotech) | A clinical-stage biopharmaceutical company developing immunotherapies for cancer and immune diseases based on the gut microbiome. They focus on "OncoMimics" and "EndoMimics" derived from gut bacteria. | No | No |  |
| France | Seventure Partners  | LiMM Therapeutics | Other (Biotech) | A biopharmaceutical company bridging the gap between neuroscience and immunology. They focus on the neuronal regulation of innate immunity cells to treat inflammatory and metabolic diseases. | No | No |  |
| France | Seventure Partners  | Peptobiotics | Other (AgTech) | A synthetic biology company producing recombinant antimicrobial peptides. These peptides serve as a direct replacement for antibiotics in livestock feed, promoting growth and health without resistance risks. | No | No |  |
| France | Seventure Partners  | Kapsera | Other (AgTech) | A company specializing in the formulation and delivery of bio-inputs. They use microfluidics to encapsulate active ingredients (like biopesticides or probiotics) in biodegradable alginate capsules, enhancing their stability and efficacy in the field. | No | No |  |
| USA | Gryphon Investors | Vetnique Labs | Other (Consumer) | A leading pet health and wellness platform founded by a veterinarian. Vetnique is famous for Glandex, a patented supplement for anal gland health. Under Gryphon, they have expanded into a multi-brand platform, recently acquiring Lintbells (see below). | No | Yes (Core Business) | No |
| USA | Gryphon Investors | Heartland Veterinary Partners | Veterinary | A Veterinary Support Organization (VSO) supporting a network of over 300 veterinary practices across the Midwest and Southern US. Heartland provides non-clinical administrative support (HR, finance, marketing) to allow vets to focus on medicine. | No | No |  |
| USA | Gryphon Investors | Lintbells (YuMOVE) | Other (Consumer) | Acquired by Vetnique. A UK-based leader in natural joint supplements for dogs and cats. Their flagship brand, YuMOVE, is the #1 veterinary joint supplement in the UK. This acquisition creates a trans-Atlantic nutraceutical giant. | No | Yes (Core Business) | Yes |
| USA | Gryphon Investors | Fleet Labs | Other (Consumer) | Exited. A manufacturer of personal care and over-the-counter (OTC) products. While primarily human-focused (Summer's Eve, Fleet Enema), the investment demonstrates Gryphon's expertise in consumer health manufacturing and branding. | No | No |  |
| USA | Morgan Stanley Capital Partners  | FoodScience Corporation | Other (Consumer) | A formulator and manufacturer of nutritional supplements for humans and pets. FoodScience owns the trusted brands VetriScience (veterinary exclusive) and Pet Naturals (retail). They also operate a massive private label manufacturing division, producing supplements for many other brands. | No | Yes (Core Business) | Yes |
| USA | Morgan Stanley Capital Partners  | Manna Pro (Compana) | Other (Consumer) | Exited. A diversified pet care and nutrition company. Under MSCP, it grew from a farm-focused brand into a consumer pet powerhouse, acquiring brands like Fruitables (treats) and Espree (grooming) before being sold to The Carlyle Group. | Yes (Treats) | Yes | No |
| USA | Morgan Stanley Capital Partners  | Pathway Vet Alliance (Thrive) | Veterinary | Exited. A leading veterinary hospital network. MSCP partnered with founders to scale this into one of the largest networks in the US (now known as Thrive Pet Healthcare), focusing on professionalizing operations and expanding specialty care. | No | No |  |
| USA | Morgan Stanley Capital Partners  | Sebela Pharmaceuticals | Other (Pharma) | A specialty pharmaceutical company focused on gastroenterology, dermatology, and women's health. While human-focused, it underscores MSCP's competency in building specialty pharma platforms. | No | No |  |
| Sweden | EQT Group | IVC Evidensia | Veterinary | Europe's largest veterinary care provider, operating a network of over 2,500 clinics and hospitals across 20 countries. EQT drives value through procurement scale, digital transformation, and the implementation of high clinical standards. | No | Yes (Sells/Prescribes) | No |
| Sweden | EQT Group | Zooplus | Other (Retail) | The leading online retailer of pet food and supplies in Europe, operating in 30 countries. EQT took Zooplus private to accelerate its transition into a holistic pet care platform, integrating commerce with services. | Yes (Retailer) | Yes (Retailer) | No |
| Sweden | EQT Group | Dechra Pharmaceuticals | Veterinary | A global specialist in veterinary pharmaceuticals acquired by EQT in 2024. Dechra focuses on high-quality endocrinology (e.g., Vetoryl for Cushing's), dermatology, and analgesia products for companion animals. | No | Yes (Specific lines) | NOO ?? |
| Sweden | EQT Group | VetPartners | Veterinary | The leading network of veterinary clinics in Australia and New Zealand. Acquired by EQT to replicate the successful IVC Evidensia model in the Asia-Pacific region. | No | No |  |
| Sweden | EQT Group | ManyPets | Other (Insurance) | A digital-first pet insurance provider offering policies in the UK, Sweden, and the US. ManyPets is known for its user-friendly tech stack and innovative coverage options, such as covering pre-existing conditions in certain markets. | No | No |  |
| Sweden | EQT Group | Musti Group | Other (Retail) | The leading Nordic pet care specialist. Musti operates an omnichannel model combining physical retail stores with grooming services and veterinary care, dominating the pet market in Finland, Sweden, and Norway. | Yes (Retailer) | Yes (Retailer) |  |
| Sweden | EQT Group | Bespak | Other (Pharma) | A contract development and manufacturing organization (CDMO) specializing in drug delivery devices, particularly inhalers. While broadly pharma, delivery devices are increasingly relevant for veterinary asthma and respiratory treatments. | No | No |  |
| Netherlands | Aqua-Spark | Protix | Other (AgTech) | The world's leading insect protein company (Black Soldier Fly). Protix converts organic waste into protein meal and lipids. They are a major supplier to the pet food industry (partnering with Tyson) for hypoallergenic, sustainable protein ingredients. | Yes (Ingredients) | No | Yes |
| Netherlands | Aqua-Spark | Calysta | Other (Biotech) | A biotechnology company producing "FeedKind" protein using gas fermentation (methanotrophs) to convert methane into single-cell protein. This creates a sustainable, non-animal protein source for aquaculture and pet food. | Yes (Ingredients) | No | No |
| Netherlands | Aqua-Spark | eFishery | Other (AgTech) | An Indonesian IoT technology company providing smart feeding systems for fish and shrimp farming. Their technology optimizes feed usage, reducing waste and improving the economics of aquaculture. | No | No |  |
| Netherlands | Aqua-Spark | Ace Aquatec | Other (AgTech) | A welfare technology company for aquaculture. They develop acoustic predator deterrents and electric stunning systems to ensure humane harvesting of fish, aligning with high-welfare standards. | No | No |  |
| Netherlands | Aqua-Spark | Sea6 Energy | Other (AgTech) | A company mechanizing ocean farming of tropical seaweed. Seaweed is processed into biostimulants for agriculture, functional ingredients for animal feed (including pet food), and renewable fuels. | Yes (Ingredients) | Yes (Ingredients) | No |
| Netherlands | Aqua-Spark | BioFishency | Other (AgTech) | Provides advanced water treatment systems for land-based aquaculture (RAS). Their electrochemical technology removes ammonia from water, enabling higher stocking densities and cleaner fish production. | No | No |  |
| Netherlands | Aqua-Spark | Chicoa Fish Farm | Other (Food) | A vertically integrated tilapia farm in Mozambique. It aims to build a scalable model for sustainable protein production in Sub-Saharan Africa. | No | No |  |
| USA | WP Global Partners | PetVet365 | Veterinary | A network of veterinary hospitals focused on a "Fear-Free" experience. Unlike traditional rollups that buy existing clinics, PetVet365 executes a de novo strategy, building new, modern hospitals from the ground up with a standardized, pet-friendly design (e.g., no exam tables, glass doors). | No | No |  |
| USA | WP Global Partners | Monogram Foods | Other (Food) | A major manufacturer of value-added meat products (jerky, bacon, corn dogs). While primarily a human food company, Monogram has significant co-manufacturing capabilities that extend to premium meat-based pet treats. | Yes (Treats) | No | No |
| USA | WP Global Partners | Medi-Tech | Other (Health) | A medical device manufacturer. This investment underscores WP Global's broader interest in healthcare manufacturing and supply chain. | No | No |  |
| UK | Inflexion | Medivet | Veterinary | Partially Exited. A major UK veterinary group operating a "hub-and-spoke" model with 24-hour hospitals supporting smaller satellite clinics. Inflexion helped them double their footprint before selling a majority stake to CVC Capital Partners. | No | No |  |
| UK | Inflexion | Lintbells (YuMOVE) | Other (Consumer) | Realized. A leader in natural joint supplements for dogs. Inflexion supported their expansion into the US market and D2C channels before selling the business to Gryphon Investors' Vetnique Labs in 2024. | No | Yes (Core Business) | Yes |
| UK | Inflexion | Kynetec | Other (Data) | Exited. A global leader in market research and data for the animal health and agriculture sectors. Kynetec provides critical data to pharma companies about vet prescription behaviors and farmer purchasing habits. | No | No |  |
| UK | Inflexion | Tierarzt Plus Partner (TPP) | Veterinary | A rapidly growing network of veterinary practices in Germany. Inflexion partnered with the founders to consolidate the fragmented German market, focusing on digitization and training to attract talent. | No | No |  |
| UK | Inflexion | Village Vets | Veterinary | A veterinary group based in Ireland. Inflexion provides capital to facilitate the expansion of existing sites and the opening of new locations, bringing corporatized veterinary care to the Irish market. | No | No |  |
| USA | NovaQuest Capital Management | Gallant Therapeutics | Veterinary | Co-invested with Digitalis. NovaQuest participated in the Series B financing to support the commercialization of Gallant’s off-the-shelf stem cell therapies for feline gingivostomatitis and canine osteoarthritis. | No | No (Therapeutic) |  |
| USA | NovaQuest Capital Management | Mileutis | Veterinary | An Israeli biopharmaceutical company developing residue-free, peptide-based immunotherapies. Their lead product aims to treat bovine mastitis (udder infection) in dairy cows without antibiotics, addressing a major cause of milk loss and antibiotic overuse. | No | No |  |
| USA | NovaQuest Capital Management | Arvelle Therapeutics | Other (Pharma) | A biopharmaceutical company focused on developing treatments for CNS disorders, specifically epilepsy. (Human health). | No | No |  |
| USA | NovaQuest Capital Management | Mycovia Pharmaceuticals | Other (Pharma) | A pharmaceutical company dedicated to women's health, specifically developing oral treatments for recurrent vulvovaginal candidiasis (yeast infections). | No | No |  |
| USA | NovaQuest Capital Management | Zoetis (Product Finance) | Veterinary | NovaQuest has historically provided product financing to Zoetis (and its predecessor Pfizer Animal Health) to fund the development of specific blockbuster animal health assets (details often confidential but typically involve late-stage R&D funding in exchange for royalties). | No | No |  |
| UK | Ocean 14 Capital | Enthos | Other (AgTech) | (Also in S2G portfolio). Uses insects to upcycle waste into protein for aquafeed and pet food. | Yes (Ingredients) | No | No |
| UK | Ocean 14 Capital | The Kingfish Company | Other (Food) | A land-based Recirculating Aquaculture System (RAS) producer of Yellowtail Kingfish in the Netherlands and US. Demonstrates high-tech, sustainable fish farming. | No | No |  |
| UK | Ocean 14 Capital | SyAqua | Other (AgTech) | A leader in shrimp genetics and nutrition. SyAqua uses advanced breeding programs to improve the growth rates and disease resistance of shrimp stocks globally. | No | No |  |
| UK | Ocean 14 Capital | AION | Other (Sustainability) | A spin-out from Aker BioMarine that provides circular plastic solutions. They help maritime industries recycle plastic waste into new products, reducing ocean pollution. | No | No |  |
| UK | Ocean 14 Capital | Novelplast | Other (Sustainability) | A plastics recycling company. They process PET plastic waste into high-quality pellets that can be reused in manufacturing, contributing to a circular economy. | No | No |  |
| UK | Ocean 14 Capital | Ava Ocean | Other (Food) | A Norwegian company harvesting scallops using a unique, non-invasive seabed harvesting technology that protects the ocean floor ecosystem. | No | No |  |
| UK | Fulcrum Global Capital  | P&P Optica | Other (Tech) | Provides hyperspectral imaging systems for meat processing to detect foreign materials and assess quality (fat/lean ratio). Ensures safety of meat entering food/pet food supply. | No | No |  |
| UK | Fulcrum Global Capital  | Green Dot Bioplastics | Other (Biotech) | Produces bio-based, compostable plastics using recycled agricultural feedstock. Used in packaging and durable goods. | No | No |  |
| UK | Fulcrum Global Capital  | NanoGuard Technologies | Other (AgTech) | Uses cold plasma technology to sterilize food and feed, reducing mycotoxins and spoilage without chemicals. Applicable to pet food safety. | No | No |  |
| UK | Fulcrum Global Capital  | Resilient Biotics | Veterinary | Developing microbiome-based therapeutics (LBPs) for respiratory diseases in livestock, replacing antibiotics. | No | No (Therapeutic) |  |
| UK | Fulcrum Global Capital  | Vytelle | Veterinary/Ag | Precision livestock company offering hormone-free IVF and individual animal data capture for cattle breeding. | No | No |  |
| UK | Fulcrum Global Capital  | WeedOUT | Other (AgTech) | Develops bioherbicides that exploit sterility to combat resistant weeds. | No | No |  |
| UK | Fulcrum Global Capital  | Talam Biotech | Other (AgTech) | Uses microbes to block heavy metal uptake in crops, improving food safety. | No | No |  |
| USA | Cavallo Ventures | Bond Pet Foods | Other (Biotech) | Uses precision fermentation to produce animal-identical meat proteins (e.g., chicken) for pet food without slaughter. | Yes (Ingredients) | No | No |
| USA | Cavallo Ventures | Omeat | Other (Food) | Cultivated meat company using regenerative factors from cow plasma to grow meat. Focused on cost-effective scalability. | No | No |  |
| USA | Cavallo Ventures | Vestaron | Other (AgTech) | Develops peptide-based bio-insecticides that are safe for humans/animals but effective against pests. | No | No |  |
| USA | Cavallo Ventures | Native Microbials | Veterinary/Ag | Develops endomicrobial supplements (microbiome) for livestock to improve feed efficiency and health. | No | Yes (Livestock) | No |
| USA | Cavallo Ventures | Soma Detect | Other (AgTech) | Sensors for dairy cows measuring milk quality and health indicators in real-time. | No | No |  |
| USA | Cavallo Ventures | Pasture Bio | Veterinary/Ag | Developing vaccines to reduce methane emissions in cattle. | No | No |  |
| Netherlands | Anterra Capital | BiomEdit | Veterinary | Spin-out from Elanco. Develops microbiome-based therapeutics and novel probiotics for animal health (livestock and pets). | No | Yes (Therapeutic/Probiotic) | No |
| Netherlands | Anterra Capital | Enko | Other (AgTech) | Discovers novel small molecule crop protection products using DNA-encoded libraries (drug discovery tech applied to ag). | No | No |  |
| Netherlands | Anterra Capital | Invetx | Veterinary | Exited. Biopharma developing monoclonal antibodies for chronic diseases in companion animals. | No | No |  |
| Netherlands | Anterra Capital | Animol | Veterinary | Incubated. Focused on discovering novel small molecule drugs for animal health using accelerated discovery platforms. | No | No |  |
| Netherlands | Anterra Capital | Caribou Biosciences | Other (Biotech) | CRISPR genome editing company (IPO). Technology applicable to agriculture and therapeutics. | No | No |  |
| Netherlands | Anterra Capital | ProducePay | Other (Fintech) | Financial and data platform for the fresh produce supply chain. | No | No |  |
| Netherlands | NuFrontiers (Nutreco)  | BlueNalu | Other (Food) | Cellular aquaculture producing seafood from cells. Nutreco collaborates on supply chain/feed for cells. | No | No |  |
| Netherlands | NuFrontiers (Nutreco)  | Mosa Meat | Other (Food) | Cultivated meat pioneer (beef). Nutreco provides expertise in feed components for cell media. | No | No |  |
| Netherlands | NuFrontiers (Nutreco)  | Proteon Pharmaceuticals | Veterinary | Bacteriophage technology to combat bacteria in aquaculture and livestock, reducing antibiotic use. | No | No (Therapeutic) |  |
| Netherlands | NuFrontiers (Nutreco)  | ViAqua | Veterinary | RNA-particle platform for aquaculture health, specifically targeting viral diseases like White Spot Syndrome in shrimp. | No | No |  |
| Netherlands | NuFrontiers (Nutreco)  | Eruvaka | Other (AgTech) | IoT and cloud-based aquaculture pond management solutions (smart feeding). | No | No |  |
| Netherlands | NuFrontiers (Nutreco)  | Enough (formerly 3F Bio) | Other (Food) | Produces mycoprotein (fungi-based) via fermentation for sustainable protein. | Yes (Ingredients) | No | No |
| Switzerland | Blue Horizon | Beyond Meat | Other (Food) | Exited. Plant-based meat giant. | No | No |  |
| Switzerland | Blue Horizon | Mosa Meat | Other (Food) | Cultivated beef. | No | No |  |
| Switzerland | Blue Horizon | Wild Earth | Other (Consumer) | Plant-based pet food company using koji (fungi) protein. Offers high-protein dog food and supplements. | Yes (Primary) | Yes | No |
| Switzerland | Blue Horizon | The EVERY Company | Other (Biotech) | Precision fermentation to create animal-free egg proteins (pepsin, egg white). | No | No |  |
| Switzerland | Blue Horizon | Geltor | Other (Biotech) | Designer proteins (collagen, elastin) via fermentation for beauty and nutrition markets. | No | Yes (Ingredients) |  |
| Switzerland | Blue Horizon | Alpha Foods | Other (Food) | Plant-based convenience foods (burritos, nuggets). | No | No |  |
| UK | Cibus Capital (Cibus Fund) | 4AG Robotics | Other (AgTech) | Autonomous mushroom harvesting robots to address labor shortages. | No | No |  |
| UK | Cibus Capital (Cibus Fund) | Growers Edge | Other (Fintech) | Financial technology/warranty products for farmers to de-risk adoption of new ag technologies. | No | No |  |
| UK | Cibus Capital (Cibus Fund) | The Kingfish Company | Other (Food) | Land-based RAS aquaculture producing Yellowtail Kingfish. | No | No |  |
| UK | Cibus Capital (Cibus Fund) | Ecorobotix | Other (AgTech) | Ultra-high precision smart spraying systems for crops to reduce chemical usage. | No | No |  |
| UK | Cibus Capital (Cibus Fund) | Withcott Seedlings | Other (Ag) | Australian producer of vegetable tree seedlings. | No | No |  |
| UK | Cibus Capital (Cibus Fund) | Inscentinel (BeeHero) | Other (AgTech) | Precision pollination services using IoT sensors in beehives. | No | No |  |
| USA | Vestar Capital Partners | PetHonesty | Other (Consumer) | Premium natural pet health supplements (soft chews) for joint, digestion, and allergy health. | No | Yes (Core Business) | Yes  |
| USA | Vestar Capital Partners | Big Heart Pet Brands | Other (Consumer) | Exited (to Smucker). Major pet food company (Milk-Bone, Meow Mix). | Yes (Primary) | No | No |
| USA | Vestar Capital Partners | Manna Pro | Other (Consumer) | Exited (to Carlyle). Health and wellness products for pets (supplements, care). | Yes (Treats) | Yes | No |
| USA | Vestar Capital Partners | Sun Products | Other (Consumer) | Exited. Laundry and household cleaning products. | No | No |  |
| UK | Shore Capital | Mission Pet Health | Veterinary | The newly formed entity resulting from the merger of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP), creating a massive network of 700+ hospitals. | No | No |  |
| UK | Bridgepoint  | Identicare | Other (Services) | UK pet microchipping and pet owner services company. | No | No |  |
| USA | Roark Capital  | Pet Valu | Other (Retail) | Exited. Major Canadian pet specialty retailer. | Yes (Retailer) | Yes (Retailer) | No |
| USA | Roark Capital | Pet Supermarket | Other (Retail) | Pet specialty retailer in the SE United States. | Yes (Retailer) | Yes (Retailer) | No |
| USA | TSG Consumer  | Thrive Pet Healthcare | Veterinary | Formerly Pathway Vet Alliance. A comprehensive veterinary network including primary care, specialty, and urgent care clinics. | No | No |  |
| USA | TSG Consumer  | Dogswell | Other (Consumer) | Manufacturer of dog treats with functional benefits. | Yes (Treats) | Yes (Functional) | No |
| USA | KKR | PetVet Care Centers | Veterinary | Acquirer/operator of general and specialty vet hospitals. | No | No |  |
| UK | BC Partners | Gambol Pet Group | Other (Consumer) | Major Chinese pet food manufacturer (Myfoodie brand). | Yes (Primary) | No | No |
| UK | BC Partners | PetSmart | Other (Retail) | Leading North American pet retailer (Products + Services). | Yes (Retailer) | Yes (Retailer) | No |
| USA | Advent International | Seek Pet Food | Other (Consumer) | Leading 3rd party manufacturer of pet food/kibble in China. | Yes (Mfg) | No | No |
| USA | Advent International | Felix Pharmaceuticals | Veterinary | Animal health generics manufacturer (Ireland). | No | No |  |
| USA | Hellman & Friedman | Zooplus | Other (Retail) | Leading European online pet platform (Partnered with EQT). | Yes (Retailer) | Yes (Retailer) | No |
| UK | Mayfair Equity | TrustedHousesitters | Other (Services) | Subscription-based pet-sitting and travel community. | No | No |  |
| Belgium / Germany | Verlinvest | Tom & Co | Other (Retail) | Leading pet retailer in Belgium and France. | Yes (Retailer) | Yes (Retailer) | No |
| Belgium | Verlinvest | Nesto | Veterinary | Network of veterinary clinics in Belgium, Luxembourg, Germany. | No | No |  |
| USA | Warburg Pincus | Bond Vet | Veterinary | Urgent care and walk-in veterinary clinic chain (tech-enabled). | No | No |  |
| USA | Warburg Pincus | Mashura | Other (Tech) | Inventory intelligence/management for vets (CUBEX brand). | No | No |  |
| France | Eurazeo | Ultra Premium Direct | Other (Consumer) | Exited. French D2C premium pet food brand (sold to Inspired Pet Nutrition). | Yes (Primary) | No | Yes |
| USA | Paine Schwartz | Axiota Animal Health | Veterinary | Non-antibiotic nutritional health products for cattle (immune/stress support). | No | Yes (Livestock) |  |
| USA | Paine Schwartz | Hendrix Genetics | Other (Ag) | Multi-species animal genetics (turkeys, layers, swine, aquaculture). | No | No |  |
| USA | Main Post Partners | Nulo | Other (Consumer) | Premium high-protein, low-carb pet food brand (backed by athletes). | Yes (Primary) | No | No |
| UK | Cinven | Partner in Pet Food | Other (Consumer) | European private label pet food manufacturer (Sold majority to CVC). | Yes (Primary) | No | No |
| UK | Cinven | Arcaplanet | Other (Retail) | Leading pet store chain in Italy. | Yes (Retailer) | Yes (Retailer) | No |
| USA | Swander Pace | Merrick Pet Care | Other (Consumer) | Exited. Natural/organic pet food leader (Sold to Nestle Purina). | Yes (Primary) | No | No |
| UK | CapVest Partners | Inspired Pet Nutrition (IPN) | Other (Consumer) | The UK's largest independent pet food manufacturer. Owns mass-market brands Harringtons and Wagg. Recently acquired Butcher's Pet Care (wet food) and Ultra Premium Direct (France) to build a pan-European platform. | Yes (Primary) | Yes (Harringtons Supplements) |  |
| Sweden / Europe | Axcel | The Nutriment Company (formerly Voff) | Other (Consumer) | A leading European consolidator of premium "natural" pet food brands, specifically focusing on RAW (BARF) and air-dried diets. Portfolio includes Nutriment (UK), Leo & Wolf, Energique (Netherlands), and Dibo (Germany). | Yes (Primary) | Yes (AntiForte brand) |  |
|  | Axcel | Vetopia | Service Provider | A leading veterinary clinic group with over 220 clinics across Denmark, Norway, Sweden, Finland, Germany, Austria, and Switzerland. |  |  |  |
| USA | Clearlake Capital | Wellness Pet Company | Other (Consumer) | A global pioneer in natural pet nutrition. Formed from the merger of WellPet and other assets. Brands include Wellness, Old Mother Hubbard, Whimzees, and Sojos. Focuses on outcome-based nutrition and dental health. | Yes (Primary) | Yes (Wellness Supplements) |  |
| USA | PAI Partners | Alphia, NovaTaste | Other (Manufacturing) | The largest custom manufacturer of super-premium pet food in the U.S. Provides turnkey co-manufacturing and R&D services for leading brands and retailers, producing over 1 billion pounds of dry food and treats annually. | Yes (Manufacturer) | No |  |
| France | Astanor Ventures | Ynsect | Other (AgTech / Ingredients) | A global leader in insect farming (mealworms) to produce high-performance protein and fertilizer. Produces Sprÿng, a premium protein ingredient specifically for the pet food market, offering sustainable and hypoallergenic benefits. | Yes (Ingredients) | No |  |
| Germany | Astanor Ventures | MicroHarvest | Other (AgTech / Ingredients) | A biotechnology company utilizing precision fermentation to produce sustainable proteins from bacteria. Their technology produces protein significantly faster than animal or plant sources, targeting the pet food and aquafeed markets. | Yes (Ingredients) | No |  |
| Belgium | The Craftory | Edgard & Cooper | Other (Consumer) | A sustainable pet food challenger brand known for using 100% fresh meat (no meat meal) and biodegradable packaging. They have expanded into dental sticks and functional treats. | Yes (Primary) | No |  |
| India | The Craftory | Drools | Other (Consumer) | India’s leading domestic pet food company. It holds a dominant market share in South Asia, producing dry food, wet food, and veterinary prescription diets (VetPro) for dogs and cats. | Yes (Primary) | Yes (VetPro Line) |  |
| UK | Five Seasons Ventures | Butternut Box | Other (Consumer) | A tech-enabled Direct-to-Consumer (DTC) fresh dog food company. They cook fresh meals at low temperatures and deliver them frozen to customers on a subscription basis. Recently acquired PsiBufet (Poland). | Yes (Primary) | No |  |
| Germany | Five Seasons Ventures | Mammaly | Other (Consumer) | A pet health brand specializing in functional snacks and supplements. They focus on preventative health issues like digestion, joint mobility, and calming, delivered in a treat format rather than a pill. | No | Yes (Core Business) |  |
| UK | Five Seasons Ventures | Untamed | Other (Consumer) | A premium DTC cat food brand rejecting "junk" ingredients. They offer high-protein, human-grade whole meat recipes in tins, focusing on feline health and longevity. | Yes (Primary) | No |  |
| USA | Linden Capital | Rarebreed Veterinary Partners | Veterinary | A technology-enabled veterinary services platform in the Northeast U.S. Operates a network of general practice hospitals and PetMedic urgent care clinics, focusing on staff retention and modernizing the care experience. | No | No |  |
| USA | Linden Capital | Axiota Animal Health | Veterinary (Livestock) | A non-antibiotic animal health platform. Develops nutritional products (like Multimin 90 and Lactipro) to support immune function and transition periods in beef and dairy cattle. | No | Yes (Livestock) |  |
| Italy / Europe | NXMH | Whitebridge Pet Brands (EU) | Other (Consumer) | The European arm of Whitebridge (retained after NXMH sold the N. American business to General Mills). Includes Schesir, Stuzzy, and ADOC brands, focusing on natural, minimally processed wet food for cats and dogs. | Yes (Primary) | No |  |
| USA | JAB Holding Company | NVA (National Veterinary Associates) |  | One of the world's largest veterinary platforms operating 1,000+ general practice hospitals, equine centers, and pet resorts. | No | No |  |
| USA | JAB Holding Company | Ethos Veterinary Health |  | A network of over 140 world-class specialty and emergency veterinary hospitals (distinct from NVA's general practice). | No | No |  |
| USA | Nordic Capital | United Veterinary Care (UVC) |  | A rapidly growing chain of primary care, emergency, and specialty veterinary hospitals, primarily in the Eastern US. | No | No |  |
| UK | BC Partners | VetPartners |  | A major European veterinary group (separate from the ANZ entity) operating hundreds of practices across the UK and Continental Europe. | No | No |  |
| USA | General Atlantic | GoodVets |  | A veterinary care platform partnering with entrepreneurial veterinarians to build and operate modern, state-of-the-art care facilities. | No | No |  |
| USA | Advent International | National PetCare Centers |  | An operator of veterinary hospitals (identified in investment history). | No | No |  |


### Sheet: Regulatory

| Topic | United States (US) | European Union (EU) | United Kingdom (UK) |
| --- | --- | --- | --- |
| Is “nutraceutical” a legal category? | No. FDA does not recognize a “dietary supplement” category for animals; products are regulated as animal food or animal drugs, depending on intended use. | No. Products fall under feed law or veterinary medicinal product law (binary logic). | No. Same binary logic: feed vs veterinary medicine, assessed by presentation and function. |
| Primary authorities | FDA Center for Veterinary Medicine (CVM) for animal food and animal drugs; states enforce feed laws (often via AAFCO-aligned frameworks). | European Commission (authorisations) + EFSA (scientific risk assessment for additives); Member States enforce. | VMD for veterinary medicines; FSA/FSS for feed additives and feed safety (GB). NI has additional complexity due to EU alignment in parts of veterinary medicines. |
| Core legal split (what triggers “drug”) | Intended use / claims. If a product is intended to diagnose, cure, mitigate, treat, or prevent disease, it is an animal drug under the FD&C Act logic; “support/maintain” claims are typically used for food positioning. | Medicinal claims trigger reclassification as a Veterinary Medicinal Product under the EU medicines framework (and enforcement practice). | Medicinal by presentation (claims imply treat/prevent disease) or medicinal by function (pharmacological effect) triggers VMD control and marketing authorisation requirements. |
| Pre-market route for ingredients  | Ingredient must be lawful for use in animal food (common pathways include GRAS, food additive approval; FDA also operates consultation mechanisms for animal food ingredients). | Feed additives require an EU authorisation dossier and EFSA assessment (safety + efficacy depending on category). Feed materials follow different rules than additives. | Feed additives are assessed under UK processes (GB) via FSA/FSS; medicinal products require VMD marketing authorisation (GB). |
| “Performance / functional” claims in production animals | Historically constrained because many performance-type claims drift toward “drug intent.” A key policy debate is creating a clearer path for “zootechnical” type substances as food additives. | Explicitly structured via zootechnical additives under Reg. (EC) No 1831/2003, requiring EFSA review and authorisation (including efficacy). | Similar conceptually to EU for feed additives (GB), with national process; claims still must stay out of “medicinal” territory unless authorised as a medicine. |
| Claims regime in pets (typical market practice) | Many pet supplement players use structure/function style language (support, maintain, promote). No DSHEA-like animal supplement regime. | Disease claims are generally prohibited for feed; functional claims need substantiation; a specific dietetic framework exists for certain “particular nutritional purposes.” | Same as EU logic; VMD is strict on “medicinal” words/phrases and overall presentation (including websites and testimonials). |
| Diet-disease linkage exceptions | Limited, and highly fact-specific. Veterinary therapeutic diets can be scrutinised if positioned to treat disease (borderline). | Dietetic feed (PARNUTS) provides a “positive list” style route for specific nutritional purposes (limited set of permitted claim-types). | Similar concept exists through feed rules, but interpretation differs; also NI vs GB divergence can create additional compliance friction. |
| Post-market controls (typical) | Enforcement actions for misbranding/adulteration; additional industry self-regulation exists in pet supplements. | Strong feed safety enforcement; for additives, authorisation conditions and post-market obligations can apply. | VMD enforcement for medicines; Trading Standards can also be relevant for misleading claims outside medicines law. |
| Practical implication for go-to-market speed | Pet supplements can scale quickly if positioned as “food” with conservative claims, but the boundary is risk-sensitive (label + marketing). | Additive authorisation can be a high barrier to entry (costly dossier), but once authorised, it can create defensible moats for B2B ingredients. | Potentially agile for certain feed authorisations in GB vs EU, but dual regime issues (NI) can complicate “UK-wide” supply chains. |
| What investors should watch (2024–2026) | Fragmentation and reform debate around ingredient review and a dedicated path for functional animal food substances. | Continued emphasis on safety and substantiation; for livestock/aquaculture additives, environmental assessment expectations can be material. | GB regulatory divergence from EU can create “faster test market” dynamics, but also increases compliance complexity for pan-UK operators. |


### Sheet: Mobility 

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Mobility Segment) | Est % Use (General Supplement Market) | Est. Global Revenue (Veterinary) |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Omega 3 (EPA/DHA) | Dogs, cats (OA pain, inflammation); also used in equine performance programs as adjunct anti-inflammatory support | Adjunct to NSAIDs and multimodal OA management | Pain scores, mobility, weight bearing, activity | A: controlled canine OA data supports analgesic and anti inflammatory benefit; typically adjunct rather than replacement in moderate disease | (Roush et al., 2010; Hielm Björkman et al., 2012) | 25 - 30% | 18 - 20% | $1.2 - $1.4 Billion |  |  |
| Undenatured type II collagen (UC II) | Dogs, mobility and OA related pain. Occasional equine use. | Adjunct to NSAIDs | Owner reported function, mobility scores, pain measures | B to A: several canine studies support mobility improvement; positioning is “maintenance plus symptom reduction” | (Gupta et al., 2009; Stabile et al., 2024) | 10 - 15% | 3 - 5% | $170 - $250 Million |  |  |
| Eggshell membrane (ESM) complexes | Dogs, stiffness and mobility | Adjunct to NSAIDs | Mobility and pain questionnaires, stiffness | B: evidence supports improvements in mobility outcomes in dogs; effect sizes vary by formula | (Ragetly et al., 2025; Stabile et al., 2024) | 2 - 5% |  | $50 - $80 Million |  |  |
| Green lipped mussel (Perna canaliculus) | Dogs, joint function support | Adjunct to NSAIDs | Lameness and mobility scoring | B: supportive evidence in dogs, but outcomes depend on dose and product standardization | (Carmona et al., 2009; Vandeweerd et al., 2012) | 8 - 12% | 2 - 4% | $170 - $200 Million |  |  |
| Glucosamine and chondroitin | Dogs and horses, legacy joint category | Adjunct to NSAIDs | Mobility and pain scores | B to C: widely used, but systematic reviews and heterogeneity create uncertainty; keep as “legacy category with mixed evidence” | (Vandeweerd et al., 2012); (Kampa et al., 2023) | 45 - 55% | 12 - 15% | $1.1 - $1.3 Billion |  |  |
| MSM | Horses and dogs, soreness and mobility | Adjunct to NSAIDs | Comfort, recovery, lameness scoring | C: some supportive equine oriented evidence, but overall veterinary data is thinner than omega 3 or collagen pathways | (Barshick et al., 2025) ; (Zhang et al., 2022) | 15 - 20% | 4 - 6% | $230 - $250 Million |  |  |
| Hyaluronic acid (oral) | Horses and dogs, joint lubrication positioning | Adjunct to OA care | Lameness and performance comfort | C: injectable HA has established use, oral evidence is more variable; keep claims conservative | (Cayzer et al., 2011); (Aguado et al., 2021) ; (Carmona et al., 2009) | 3 - 5% | < 1% | Niche (<$50M) |  |  |
| Boswellia and curcumin | Dogs and horses, inflammation support | Adjunct to OA care | Pain and mobility measures | C: plausible anti inflammatory mechanisms, limited robust veterinary RCT base; acceptable as secondary stack ingredient | (Aguado et al., 2021); (Caterino et al., 2021) ; (Stabile et al., 2024) | 5 - 8% | 1 - 2% | $100 - $150 Million |  |  |


### Sheet: Gut Health

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Gut Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Probiotics (strain specific) | Dogs, acute uncomplicated diarrhea; swine and poultry performance stability | Dog: reduce unnecessary antibiotic use (example metronidazole) in selected cases; livestock: reduce reliance on AGP like functions | Dog: time to normal stool; livestock: ADG, FCR, diarrhea incidence | A: canine RCT supports probiotic credibility in acute diarrhea contexts; swine meta analysis supports performance effects with context dependence | (Shmalberg et al., 2019; Zimmermann et al., 2016) | 40 - 50% | 30 - 38% | $5.6 - $7.5 Billion (Feed + Pet) |
| Prebiotics (MOS, FOS, inulin) | Broilers and swine, pathogen binding and gut architecture | Reduce enteric instability and downstream medication | FCR, lesion scores, morbidity, shedding indicators | B: MOS has production relevant meta analytic support; effects are program and baseline dependent | (Hooge, 2004; Kiarie et al., 2012) | 25 - 35% | 10 - 15% | $500 - $800 Million |
| Synbiotics | Dogs in shelters and high density environments; production systems | Reduce diarrhea incidence and supportive of resilience | Diarrhea incidence, stool quality, performance | B: controlled shelter dog work supports reduced diarrhea incidence; translation depends on setting | (Rose et al., 2017) ; (Sahoo et al., 2022) ; (Whittemore et al., 2019) | ~25%  | ~8% | $1.25 Billion (Feed + Pet) + Pet) |
| Postbiotics and butyrate donors (tributyrin) | Piglets around weaning stress | Reduce post weaning enteric instability and treatment events | Villus height, gut morphology, growth | B: controlled piglet work supports gut morphology and growth related improvements | (Zeng et al., 2015; Chen et al., 2023) | 10 - 15% | 3 - 5% | $230 - $1,200 Million |
| Organic acids | Swine and poultry, feed hygiene and gut pH modulation | Reduce pathogen pressure and support post AGP programs | FCR, diarrhea incidence, microbial counts | B: broad evidence base, strongly context dependent, typically positioned as “toolbox component” | (Khan & Iqbal, 2016) ; (Khan et al., 2022)  | 60 - 70% (Livestock) | 25 - 30% (Feed) | $10 - $12 Billion |
| Digestive enzymes (phytase, xylanase, protease) | Poultry and swine, digestibility and performance | Reduce digestive inefficiency and downstream disease pressure | FCR, digestibility, litter quality | A: mature evidence base for performance and digestibility; strongest in monogastrics | (Selle and Ravindran, 2007; (Cowieson et al., 2020); ) ; (Kiarie et al., 2013) ; (Cowieson et al., 2020) | 80 - 90% (Livestock) | 3 - 5% (Feed Total) | $1.4 - $2.1 Billion |
| Clay binders and toxin adsorbents | Livestock, mycotoxin risk management | Reduce morbidity and productivity loss events | Performance stability, clinical signs, toxin biomarkers when available | B: established category, but binder quality varies greatly by toxin spectrum | (Döll and Dänicke, 2011) (Huwig et al., 2001) ; (EFSA, 2011) |  |  |  |
| Herbal gut soothers (slippery elm, marshmallow root) | Dogs and cats, mild GI comfort | Adjunct to symptomatic care | Stool comfort, owner reported signs | C: limited veterinary trial base; better treated as low risk supportive ingredients with conservative claims | (Finno, 2020) (Wynn, 2009) ; (Bonaterra et al., 2020) |  |  | . |


### Sheet: Immunity 

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Immunity & Resilience Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Beta 1,3 1,6 glucans (yeast) | Aquaculture, shrimp and fish resilience; poultry stress windows | Reduce infection pressure and mortality, reduce treatment events | Survival, immune markers, challenge outcomes | B: frequently studied immunostimulants in aquaculture; strongest positioning is resilience support | (Meena et al., 2013; Hauton, 2021) | 0.004 | 0.002 | ~USD 38M (2024) |
| Plasma / colostrum & Ig-rich fractions | Piglets around weaning | Reduce diarrhea, improve growth, reduce medication events | ADG, diarrhea incidence, gut integrity | B to A: widely supported in early life pig nutrition literature | (Torrallardona, 2010) | 0.255 | 0.119 | USD 2.20B (2024) |
| Nucleotides (often yeast derived) | Poultry and aquaculture, immune responsiveness | Adjunct to health programs, stress windows | Immune readouts, growth under challenge | B: controlled supplementation studies support immune and growth parameters | (Abdel Moneim et al., 2020) (Jang et al., 2019) | 0.072 | 0.034 | ~USD 622M midpoint (2024) |
| Seaweed and polysaccharides | Ruminants and monogastrics, oxidative stress and immune support | Adjunct to herd health, not a drug replacement | Immune markers, productivity, metabolic indicators | B to C: evidence exists but endpoints and effect sizes are variable | (Sweeney et al., 2022) ; (Wang et al., 2016) | 0.517 | 0.242 | USD 4.46B (2023) |
| Selenium and vitamin E | Multiple species, antioxidant defense | Reduce deficiency linked risk and oxidative stress burden | Biomarkers, fertility or immune outcomes in deficiency contexts | B: best framed as antioxidant support, especially where baseline status is limiting | (Calik et al., 2022) ; (Finch & Turner, 1996) | 0.033 | 0.015 | USD 280.7M (2024) |
| Vitamin C | Aquaculture, stress mitigation | Support resilience and survival | Survival, immune markers | B: commonly used, stronger in aquaculture and stress physiology contexts | (Meena et al., 2013) (Tavakolinasab et al., 2025) ; (Wang et al., 2016) | 0.017 | 0.008 | USD 148.4M (2023) |
| Lactoferrin and functional peptides | Calves and pets, immune and gut support | Adjunct positioning | Immune markers, clinical signs | C: promising but less standardized evidence base in animals | (Ballou et al., 2019) | 0.034 | 0.016 | USD 297.3M (2024) |
| Vaccine synergy positioning | Poultry and aquaculture | Adjunct to vaccination programs | Antibody titers, immune readouts | C to B: supportive concept, effect sizes depend on antigen and baseline nutrition | (Chen et al., 2021) | - | - | - |


### Sheet: Cognitive Support 

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est. % Use (Cognitive Support Segment) | Est. % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| MCTs (medium chain triglycerides) | Senior dogs, cognitive dysfunction support | Adjunct to medical management (example selegiline where used) | Cognitive task performance, owner reported behavior | A: controlled evidence supports cognitive benefits in aged dogs | (Pan et al., 2010) (Pan et al., 2024) | 0.349 | 0.023 | $450 Million |
| DHA (docosahexaenoic acid) | Dogs and cats, brain aging support | Adjunct | Cognitive and behavior measures, general neurologic support | B: biologically strong, clinical outcomes depend on design and baseline diet | (Pan et al., 2010) | 0.271 | 0.018 | $350 Million |
| Antioxidant enriched diets and blends | Senior dogs, oxidative stress and cognition | Adjunct | Learning, memory tasks, behavior change | B to A: canine cognitive aging literature supports antioxidant diet interventions | (Cotman et al., 2002); (Milgram et al., 2002) | 0.233 |  |  |
|  |  |  |  |  |  |  | 0.015 | $300 Million |
| Phosphatidylserine | Senior dogs and cats | Adjunct | Cognitive and behavior endpoints | C: limited veterinary specific trial base | (Finno, 2020) | 0.012 | 0.0008 | $15 Million |
| SAMe | Aging animals, often positioned for liver and brain support | Adjunct | Biomarkers, clinical signs | C: stronger for liver support narratives than cognition | (Finno, 2020); (Reme et al., 2008) ; (Hackett, 2013) | 0.078 | 0.005 | $100 Million |
| Ginkgo biloba | Senior pets | Adjunct | Behavior and cognition | C: limited veterinary evidence, careful positioning | (Finno, 2020) | 0.004 | 0.0003 | $5 Million |
| B complex vitamins | Senior pets and deficiency risk | Adjunct | Biomarkers and general vitality | C: best treated as baseline adequacy plus targeted deficiency prevention | (Finno, 2020) | 0.054 | 0.004 | $70 Million |


### Sheet: Calming

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Immunity & Resilience Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| L theanine | Dogs and cats, anxiety support | Adjunct to behavioral therapy and anxiolytics (example trazodone, SSRIs in chronic cases) | Owner reported anxiety scales, situational response | B: supportive evidence exists, heterogeneity remains | (Pike et al., 2015) ; (Eaton et al., 2021) | 0.045 | 0.003 | ~$50 Million |
| Alpha casozepine | Dogs and cats, stress modulation | Adjunct | Anxiety scales, behavior outcomes | B: controlled evidence in companion animals supports calming claims | (Beata et al., 2007) ; (Palestrini et al., 2010) | 0.027 | 0.002 | ~$30 Million |
| Tryptophan | Dogs, behavioral modulation | Adjunct | Aggression and stress related behavior outcomes | B to C: evidence exists but not uniformly strong, context matters | (DeNapoli et al., 2000); ; (Palestrini et al., 2010) | 0.073 | 0.004 | ~$80 Million |
| Magnesium and B vitamins | Dogs and horses, “stress support” stacks | Adjunct | Non specific, subjective measures | C: plausible but limited targeted veterinary RCT base | (Oddoux et al., 2022); (Finno, 2020) |  | 0.001 | ~$10 Million |
|  |  |  |  |  |  | 0.009 |  |  |
| Botanicals (valerian, passionflower, chamomile) | Dogs, cats, horses | Adjunct | Behavioral outcomes | C: limited and variable; careful claims and safety review needed | (Robinson, 2025) | 0.091 | 0.005 | ~$100 Million |
| CBD and hemp derivatives | Dogs primarily | Adjunct | Pain, anxiety related endpoints depending on product | C to B: growing evidence base, but regulatory and quality variability remains material | (Mulder et al., 2025); (Verrico et al., 2020) ; (Mejia et al., 2023)  | 0.3 |  | ~$330 Million |
|  |  |  |  |  |  |  | 0.018 |  |
| Multi ingredient calming complexes | Dogs, cats, horses | Adjunct | Owner reported signs, situational tolerance | C: evidence depends on the lead active and product substantiation | (Finno, 2020) | 0.455 | 0.027 |  |
|  |  |  |  |  |  |  |  | ~$500 Million |


### Sheet: Performance

| Nutraceutical family | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Performance Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Phytase | Poultry and swine, phosphorus digestibility | Reduces nutrient waste and supports gut efficiency | Digestibility, FCR, P excretion | A: established performance tool with deep evidence base | (Selle and Ravindran, 2007; Afsharmanesh et al., 2023) | 0.085 | 0.014 | ~$600 Million |
| Xylanase and carbohydrases | Poultry and swine | Supports digestibility and performance stability | FCR, ADG, litter quality | A: mature evidence base, strong ROI logic | (Selle and Ravindran, 2007) | 0.141 | 0.023 | ~$1.00 Billion |
| Protease | Poultry, protein utilization | Supports digestibility, reduces nitrogen waste | Digestibility, FCR | A to B: meta analysis level support exists | (Cowieson et al., 2020) | 0.028 | 0.005 | ~$200 Million |
| Phytogenics (essential oils, thymol, carvacrol, cinnamaldehyde) | Poultry and swine, gut stability and performance | Part of post AGP toolbox | FCR, lesion scores, microbial outcomes | B: broad but heterogeneous; formulation and delivery matter | (Murugesan et al., 2015; Abdelli et al., 2021) | 0.125 | 0.021 | ~$890 Million |
| Yeast culture (S. cerevisiae) | Ruminants and monogastrics | Supports rumen and gut efficiency | Milk yield or FCR depending on species | B: meta analysis support, context sensitive | (Desnoyers et al., 2009) ; (Poppy et al., 2012) | 0.282 | 0.046 | ~$2.00 Billion* |
| Organic trace minerals (chelated Zn, Cu, Mn) | Poultry and swine, hoof and skin integrity, performance | Adjunct | Growth, integrity metrics | B: supportive evidence; economics depend on baseline mineral program | (Ballou et al., 2019); (Gomez et al., 2022) ; (Ding et al., 2024) |  |  |  |
| Electrolytes | Poultry heat stress, horses performance days | Adjunct to management | Hydration markers, performance stability | B: strong practical rationale, clinical trial density varies | (Ballou et al., 2019) | 0.118 | 0.019 | ~$840 Million |
| Amino acid blends and rumen protected amino acids | Ruminants and swine | Improves efficiency, reduces waste | Yield, FCR, nitrogen efficiency | B: mature for protected AA in ruminants, but “nutraceutical” framing depends on claims | (Fleming et al., 2019); (Zanton et al., 2014) ; (Lee et al., 2019) | 0.169 | 0.028 | ~$1.20 Billion |
| Carnitine, CLA, creatine, beta alanine | Pets and horses niche | Adjunct | lean mass, energy metabolism; mainly livestock performance | C: limited veterinary specific RCT base, best framed as niche | (Finno, 2020); (Owen et al., 1996) ; (Ramanau et al., 2004) | 0.008 | 0.001 | ~$55 Million |


### Sheet: Niches

| Niche | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Niches Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dermatology: omega 6, linoleic acid | Dogs and cats, skin barrier support | Adjunct to anti pruritic drugs and topical care | Coat, pruritus scores, skin barrier outcomes | B: strongest when addressing barrier and deficiency like states | (Finno, 2020); (Saevik et al., 2004) ; (Popa et al., 2024) | 0.068 | 0.006 | ~$120 Million |
| Dermatology: biotin | Dogs and horses, hoof and coat | Adjunct | Hoof quality, coat quality | C: commonly used, mixed strength | (Finno, 2020); (Buffa et al., 1992) ; (Reilly et al., 2010) | 0.032 | 0.003 | ~$56 Million |
| Dermatology: zinc methionine | Dogs, coat and skin | Adjunct | Skin integrity outcomes | B to C: supportive evidence, baseline status matters | (Finno, 2020) | 0.1 | 0.009 | ~$175 Million |
| Urinary tract: cranberry | Dogs and cats | Adjunct | Recurrence of urinary signs, biomarkers | C: mixed evidence, careful positioning | (Finno, 2020) | 0.029 | 0.003 | ~$50 Million |
| Pigmentation: astaxanthin | Aquaculture and poultry | Adjunct | Flesh color, antioxidant outcomes | B: well established in aquaculture pigmentation economics | (Shah et al., 2016) | 0.771 | 0.07 | ~$1.35 Billion |


### Sheet: Ectoparasites

| Strategy | Primary species and use case | Drug sparing or adjunct target | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Immunity & Resilience Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Natural repellents (essential oils) | Dogs, “natural” flea and tick positioning | Competes with isoxazoline class in consumer mindshare | Parasite counts, bite incidence | C: efficacy variability plus safety and regulatory risk make this a high risk category | (Robinson, 2025) | 0.55 | 0.028 | ~$550 Million |
| Garlic based approaches | Dogs and cats | Competes with proven parasiticides | Parasite counts | C: efficacy is anecdotal and safety is a concern at higher dosing | (Part II 8 11 internal notes; Robinson, 2025) | 0.04 | 0.002 | ~$40 Million |
| Skin barrier support stacks (omega 3, quercetin blends) | Dogs with flea allergy dermatitis positioning | Adjunct | Pruritus and skin outcomes | C: more defensible as dermatitis support than as parasite control | (Finno, 2020) |  | 0.008 | ~$150 Million |
|  |  |  |  |  |  | 0.15 |  |  |


### Sheet: Nutrigenomic

| Concept | Where it shows up | Why investors care | Results | Evidence level and clinical takeaway | Key references | Est % Use (Within Nutrigenomics Segment) | Est % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Biomarker substantiation (omics, gene expression) | Livestock and premium pet brands | Creates defensibility when ingredients are not patentable | Biomarker movement plus downstream performance or clinical endpoints | B: best treated as a substantiation and differentiation layer, not a product category | (Asmelash et al., 2018; ul Haq et al., 2022) | 0.175 | 0.032 | ~$613 Million |
| Nrf2 and polyphenol pathways | Multiple species | Mechanism narrative for antioxidant and resilience claims | Biomarkers of oxidative stress and inflammation | C to B: mechanistic base is strong, but direct claims need species specific data | (Deon et al., 2025) | 0.057 | 0.01 | ~$200 Million |
| Gut integrity as antibiotic alternative infrastructure | Swine, poultry, aquaculture | Links gut tools to medication reduction and ROI | Diarrhea incidence, lesion scores, treatment incidence | B to A: strongest where it ties to field outcomes | (Kiarie et al., 2012; Zimmermann et al., 2016) | 0.62 | 0.112 | ~$2.17 Billion |
| Vaccine interaction positioning | Poultry, aquaculture | Adjunct logic without overclaiming | Antibody readouts, survival under challenge | C to B: supportive, context dependent | (Chen et al., 2021; Meena et al., 2013) | 0.086 | 0.015 | ~$300 Million |


### Sheet: Advanced formulations 

| Delivery Technology | Best Fit Species | What Problem it Solves | Results | Evidence Level & Clinical Takeaway | Key References | Est. % Use (Adv. Form) | Est. % Use (Gen. Market) | Est. Global Revenue |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Powders & Top Dress | Horses, Dogs | Precise dosing integrated into feeding routine | Intake reliability | High practical relevance; baseline format for performance | (Finno, 2020) | 0.039 | 0.015 | ~$300M |
| Nanocarriers & Microencapsulation | Poultry, Swine, Aqua | Heat stability, oxidation, and bioavailability | Dose Sparing; 85% absorption vs 15% raw | Level B: Enabling tech; critical for heat-sensitive biotics | (Noreen, 2026; Almassri, 2024) | 0.025 | 0.011 | ~$180M |
| Rumen Protection Matrices | Ruminants | Bypasses rumen; targets small intestine | Optimized yield; amino acid digestibility | Level B: Mature for AA; expanding to specialized bioactives | (Fleming, 2019; Inô, 2024) | 0.492 | 0.196 | ~$3.80B |
| Smart Monitoring Boluses | Cattle (Dairy/Beef) | Early disease & SARA detection; precision intervention | 52% reduction in antibiotics; 15hr calving alert | Level B: High clinical utility; enables "individualized" nutrition | (smaXtec, 2025; Sensors, 2024) | 0.042 | 0.021 | ~$2.58 Billion |
| Soft Chews (Premium) | Dogs, Cats | Compliance Wall and repeat purchase ritual | SaaS-like retention; reduced "pill burden" | Commercially Critical: Palatability is the binding constraint | (Finno, 2020; Sirio, 2026) | 0.317 | 0.126 | ~$2.45B |
| 3D-Printed "Printlets" | Horses, Senior Dogs | Poly-pharmacy; customized dosing | 99.9% precision; combined actives (Polypill) | Emerging: High LTV through data-driven customization | (PectaSol, 2026; Crafty Apes) | 0.008 | 0.004 | ~$120M |
| Aquafeed Coatings | Aquaculture | Prevents leaching; ensures water stability | Growth & biomass preservation under challenge | Level B: Key constraint is delivery stability in water | (Hauton, 2021) | 0.145 | 0.058 | ~$1.12B |
| Smart Monitoring Boluses | Cattle (Dairy/Beef) | Early disease & SARA detection; Precision intervention | 52% reduction in antibiotics; 15hr calving alert | Level B: High clinical utility; enables "individualized" nutrition | (smaXtec, 2025; Sensors, 2024) | 0.042 | 0.021 | ~$2.58 Billion |
| Biofilm-Carrier Probiotics | Dogs, Poultry | Manufacturing heat & extrusion loss | 92% CFU survival vs. <10% in standard kibble | Level B: Solves the "viability problem" in dry feed | (Kathayat, 2022; Rabetafika, 2023) | 0.021 | 0.009 | ~$165 Million |
| Liposomal Transdermal Gels | Cats | "Pilling" non-compliance & oral rejection | 10.7% CAGR; avoids GI-tract degradation | Level B: Critical for chronic care and stress-sensitive pets | (CPHI, 2025; Nova One, 2024) | 0.018 | 0.006 | ~$110 Million |


### Sheet: Green Claim

| Sustainability wedge | Species | Additive family | Typical measurable KPI | Evidence level and clinical takeaway | Key references | Estimated % Use (Within Green Segment) | Estimated % Use (General Market) | Est. Global Revenue (Veterinary) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Methane mitigation | Ruminants | Asparagopsis | Methane reduction, diet dependent | B: large reductions reported in controlled settings, scalability and economics remain gating | (IPCC, 2021; Roque et al., 2021) | 0.008 | <0.1% | ~$25 Million |
| Methane mitigation | Ruminants | 3 NOP | Methane reduction, production neutrality | A to B: consistent reductions reported, often around high 20 percent range; adoption depends on who pays | (Hristov et al., 2015; Pupo et al., 2025) | 0.019 | 0.001 | ~$60 Million |
| Natural methane reducers | Ruminants | Tannins and essential oils | Methane reduction | B to C: smaller reductions but practical for some systems | (Pupo et al., 2025) | 0.039 | 0.003 | ~$120 Million |
| Phosphorus excretion management | Monogastrics | Phytase | P excretion reduction | A: established tool; meta analysis support exists | (Afsharmanesh et al., 2023) | 0.207 | 0.015 | ~$640 Million |
| Nitrogen efficiency | Poultry | Protease and amino acid balancing | N excretion proxies, ammonia, litter quality | B: operational route is digestibility improvement; linkage to welfare outcomes such as footpad dermatitis often discussed | (Cowieson et al., 2020; Shepherd and Fairchild, 2010) | 0.727 | 0.052 | ~$2.25 Billion |
| Omega 3 supply chain resilience | Aquaculture and pets | Algae DHA oils (Schizochytrium) | Supply risk reduction, DHA consistency | B: strategic input story supported by aquaculture nutrition literature | (Shah et al., 2023) | 0.075 | 0.006 | ~$250 Million |



---

# Source: Nutrigenomics_Animal_Playbook_2026.docx

Version 1.1 \| January 22, 2026

Prepared from and expanding on the draft report:
Nutrigenomics_Gemini.docx (provided by the user).

# Table of contents

Word can generate an automatic TOC because this report uses heading
styles. In Word: References → Table of Contents.

# 1. Executive summary

Nutrigenomics is the study and application of how nutrients and
bioactive feed ingredients change gene expression and downstream
physiology. In animals, it enables a shift from feeding by breed or life
stage to feeding by measurable biology (genotype, phenotype, microbiome,
and metabolic state).

Investor lens: The DNA or microbiome test kit is rarely the durable
profit pool. The durable profit pools are (1) the translator that
converts biological data into actionable nutritional recommendations and
(2) the recurring interventions (food, supplements, feed additives) that
customers repurchase.

Core strategic construct: the Genomic Loop. A low- to mid-margin test is
used as customer acquisition and data collection. The company then
monetizes through a long-lived subscription or repeat purchase cycle,
often reinforced by retesting and longitudinal outcome tracking.

**Key market context (ranges reflect differences across analyst
methodologies):**

- Global nutrigenomics market estimates for 2025 cluster around roughly
  USD 0.54B to 0.80B, with many forecasts implying high teens growth
  through 2030 and beyond.

- Personalized nutrition (primarily human health and wellness) is
  materially larger: multiple analyst sources put 2025 at roughly USD
  15B to 16B and 2030 around USD 31B.

- The global pet food market is the adjacent spending base (over USD
  100B in recent estimates) and is being premiumized by pet humanization
  and by fast-growing \'fresh\' and functional subsegments.

- In livestock, the relevant spending pools are feed additives and
  functional ingredients (for example, probiotics, prebiotics,
  postbiotics, yeast fractions) that increasingly rely on \'omics\'
  evidence and antibiotic-reduction narratives.

**Most investable wedges (in animals):**

- Translator-led subscription businesses (test → recommendation →
  recurring intervention).

- B2B ingredient platforms that can prove mechanism and ROI via
  transcriptomics or other \'omics\' and then sell through feed and
  premix channels.

- Vet-channel individualized diets or protocols where the prescribing
  authority (veterinary recommendation) creates durable retention.

Implementation headline: Build the translator asset first, then wrap it
in a product that creates measurable, repeatable outcomes and repeat
purchase behavior.

# 2. Definitions and scope

Because the term \'nutrigenomics\' is used inconsistently in the market,
this report uses the following practical definitions:

- Nutrigenomics: nutrient-driven changes in gene expression (for
  example, changes in mRNA abundance, pathway activation, inflammatory
  signaling) and the use of that knowledge to design diets, supplements,
  or feed additives.

- Nutrigenetics: differences in response to nutrients driven by genetic
  variants (for example, a mutation that changes appetite regulation).

- Nutriepigenomics: nutrient-driven changes in epigenetic marks (for
  example, DNA methylation patterns) that can alter gene expression
  without changing DNA sequence.

- Multi-omics: combined measurement of genomics, transcriptomics,
  microbiomics, proteomics, metabolomics, and clinical phenotypes.

**Practical scope in this report:**

- Companion animals (primarily dogs and cats): at-home tests, microbiome
  platforms, personalized food and supplement subscriptions, and
  veterinary protocols.

- Livestock and aquaculture: functional ingredients and feed programs
  that claim to improve health, performance, resilience, and
  sustainability, sometimes supported by \'omics\' evidence.

- Platforms and enabling infrastructure: labs, bioinformatics,
  algorithms, data rights, and manufacturing.

# 3. Why now: the convergence creating nutrigenomics pull

Three forces have converged to make nutrigenomics commercially relevant
in animals:

1.  Cost curves: sequencing, genotyping, and microbiome assays have
    become cheap enough to use as customer acquisition or as part of a
    protocol rather than a luxury diagnostic.

2.  Evidence tooling: transcriptomics and related methods allow
    ingredient companies to show mechanistic signals (for example,
    immune or inflammatory pathway shifts) instead of relying only on
    proxy outcomes.

3.  Demand and regulation: premiumization in pets (owners paying for
    longevity narratives) and, in livestock, pressure to reduce
    antibiotic reliance and improve sustainability both raise
    willingness to pay for functional, evidence-backed interventions.

# 4. Scientific primer: how nutrients change biology

At a simplified level, nutrigenomics is a signal-processing story:
nutrients and bioactives are inputs; cells sense them through receptors
and metabolic sensors; those sensors change transcription factor
activity; transcription factors change gene expression; gene expression
changes proteins, metabolites, and physiology.

This section is intended to help investors and operators distinguish
high-signal mechanistic claims from low-signal marketing claims.

## 4.1 Mechanisms that frequently show up in animal nutrigenomics

- Inflammation and immune modulation: shifts in cytokine signaling,
  NF-kB related pathways, barrier integrity, and innate immune programs.

- Energy metabolism and mitochondrial function: glucose utilization,
  fatty acid oxidation, ketone utilization, and oxidative stress
  responses.

- Appetite and body composition regulation: satiety hormones,
  adipokines, and pathways that influence energy intake versus
  expenditure.

- Skin and allergy phenotypes: inflammatory mediators, epithelial
  barrier, and microbiome interactions that affect atopic dermatitis and
  pruritus.

- Microbiome mediated effects: microbial metabolites (for example,
  short-chain fatty acids) that act as signaling molecules and can
  influence host gene expression.

## 4.2 Intervention categories used as nutrigenomic levers

- Prebiotics and fibers (including yeast fractions and
  oligosaccharides): often positioned for gut integrity and immune
  support.

- Probiotics and next-generation probiotics: live organisms intended to
  modulate the microbiome, with variable engraftment and stability.

- Postbiotics: non-living microbial preparations or metabolites intended
  to deliver microbiome benefits with improved stability.

- Methyl-donor and one-carbon metabolism nutrients (for example,
  SAMe-related approaches): positioned for epigenetic and neurologic
  effects.

- Lipid interventions: omega-3s for inflammation, and medium-chain
  triglycerides or botanical oil blends as alternative fuel sources in
  aging cognition narratives.

- Nucleotide ingredients: positioned as building blocks that may support
  growth, gut development, and immune function during stress or rapid
  development.

## 4.3 Evidence types and how to interpret them

- Transcriptomic or gene expression readouts: useful mechanistic
  support, but must be connected to clinically meaningful outcomes and
  not just statistical differences.

- Biomarkers: for example, dysbiosis indices, inflammatory markers,
  stool quality scoring, pruritus scoring, body condition scoring.
  Stronger when validated and reproducible.

- Clinical outcomes: ideally controlled trials; in practice, many
  products rely on retrospective case series and real-world evidence.
  Investors should discount uncontrolled outcomes.

- Unit economics evidence: does the biology translate into retention,
  repeat purchase, and willingness to pay?

# 5. Technology stack: measurement, bioinformatics, and the translator

Commercial nutrigenomics products usually combine (a) a measurement
modality, (b) a model or ruleset that interprets measurements, and (c)
an intervention catalog that can be recommended and fulfilled. The
translator is the glue between these pieces.

## 5.1 Common measurement modalities in animals

- Genetic testing: saliva or cheek swab genotyping or sequencing used to
  infer predispositions, trait risks, or response differences.

- Microbiome testing: stool sampling (and sometimes oral sampling)
  analyzed via sequencing to infer dysbiosis and missing taxa.

- Metabolic testing: blood or urine biomarkers, metabolomics panels, or
  sensor data (rare in animals today).

- Clinical phenotyping: owner-reported symptoms, vet diagnoses, diet
  history, and longitudinal outcomes.

## 5.2 The translator: algorithmic approaches and moat formation

- Rules-based translators: deterministic mapping from markers to
  recommendations. Fast to launch, easy to copy unless combined with
  proprietary data.

- Statistical risk models: link markers to outcomes using cohort data.
  Moat depends on dataset size, phenotype quality, and rights to use the
  data.

- Machine learning translators: can learn complex interactions but
  require larger datasets and careful validation to avoid spurious
  correlations.

- Moat formation pattern: the best translators improve with time because
  each test and subscription cycle generates more labeled data (marker +
  intervention + outcome).

## 5.3 Data rights and governance

- Consent and contractual rights to use data for model improvement and
  for commercialization (for example, ingredient partnerships).

- Linkage to outcomes and longitudinal follow-up.

- Defensible barriers to data replication (distribution, vet channel
  partnerships, exclusive stool bank access, etc.).

# 6. Market sizing and segmentation

Important caveat: Most syndicated market research sizes
\'nutrigenomics\' and \'personalized nutrition\' primarily in the
context of human health. Animal nutrigenomics is usually embedded inside
adjacent markets (pet food, pet supplements, feed additives, and animal
health). Therefore, market numbers below should be treated as context,
not as direct TAM for any single animal-focused company.

## 6.1 Context markets and growth rates (selected)

  -----------------------------------------------------------------------
  **Market (global  **Selected        **Forecast /      **Notes**
  unless noted)**   estimates**       growth**          
  ----------------- ----------------- ----------------- -----------------
  Nutrigenomics     USD 0.54B to      High teens CAGR   Definitions vary;
  (overall)         0.80B (2025)      in many forecasts includes human
                                                        DTC, lab
                                                        services,
                                                        analytics

  Nutrigenomics     USD 0.58B (2025)  USD 1.14B by 2030 Testing only;
  testing                             (CAGR \~14%)      does not include
                                                        interventions

  Personalized      USD \~15B to 16B  USD \~31B by 2030 Mostly human
  nutrition         (2025)            (CAGR \~14%)      health and
  (overall)                                             wellness

  Pet food          USD 103.3B (2023) USD 139.29B by    Spending base
                                      2030              that can absorb
                                                        premium
                                                        functional claims

  Fresh pet food    Just over USD 3B  Projected \~USD   Fast-growing
  (US)              (2025)            10B in next       premium
                                      decade            subsegment

  Animal feed       USD 42.0B (2023)  USD 55.46B by     Includes many
  additives                           2030              functional
                                                        ingredients
                                                        relevant to
                                                        livestock
                                                        nutrigenomics

  Probiotics in     USD 5.18B (2023)  USD 9.18B by 2030 Proxy for gut
  animal feed                                           integrity and
                                                        antibiotic
                                                        alternative spend

  Postbiotics (all  USD 146.7M (2025) USD 224.8M by     Includes animal
  applications)                       2030              feed as an
                                                        application in
                                                        some reports
  -----------------------------------------------------------------------

## 6.2 Animal-specific segmentation framework

Instead of relying only on top-down market categories, animal
nutrigenomics is best segmented by (a) buyer, (b) decision maker, and
(c) monetization model:

- B2C pet: buyer and decision maker is the owner. Monetization is
  subscription food, supplements, and retesting.

- B2B livestock: buyer is farm, integrator, or feed mill. Decision
  makers include nutritionists and veterinarians. Monetization is
  ingredient inclusion and performance-linked ROI.

- Vet channel: veterinarian influences or controls decision.
  Monetization is prescription diets, in-clinic protocols, and repeat
  purchasing.

## 6.3 Implication for investors

Because animal nutrigenomics TAM is fragmented, the most reliable way to
size a target is bottom-up: estimate reachable populations (for example,
chronic GI dogs in a target geography), expected attach rates for
testing, subscription conversion, average monthly spend, and retention.
Top-down nutrigenomics numbers are useful only as directional context.

# 7. Value chain and profit pools

The draft correctly emphasized that the interpretation layer is often
the strategic profit pool. Below is a cleaned and expanded view of the
value chain, with typical economics and strategic notes.

  -----------------------------------------------------------------------
  **Layer**         **What happens**  **Typical         **Strategic notes
                                      economics**       / investor view**
  ----------------- ----------------- ----------------- -----------------
  1\. Collection +  Sampling kits,    Often mid gross   Avoid as
  laboratory        logistics,        margin but        standalone unless
  processing        sequencing, qPCR, commoditizes over unique assays or
  (hardware)        preprocessing     time              access

  2\.               Algorithms,       High gross        Best place to
  Interpretation    reports,          margin; value     build durable
  (the translator)  recommendation    increases with    moat; data rights
                    engine,           data scale        are critical
                    longitudinal                        
                    analytics                           

  3\. Intervention  Food,             Can be high gross Moat comes from
  manufacturing     supplements, feed margin for        formulations,
                    additive          branded           claims
                    production,       supplements;      discipline,
                    quality systems   varies for bulk   repeat purchase

  4\. Distribution  E-commerce, vet   Economics driven  Channel control
  and prescribing   clinics, feed     by CAC, channel   determines data
  influence         mills,            fees, and         accumulation and
                    integrators,      retention         thus translator
                    subscription                        moat
                    logistics                           
  -----------------------------------------------------------------------

## 7.1 The Genomic Loop (subscription flywheel)

A common pattern in the highest-performing businesses is a flywheel:
Test → Insight → Action product → Outcome tracking → Retest → Better
model → Better insight → Higher willingness to pay.

**Key design requirements for a strong loop:**

- The test must lead to a recommendation that feels specific and
  defensible.

- The recommended product must be proprietary enough to capture margin
  and retention.

- The company must capture outcomes to improve the translator and to
  justify retesting.

- Retesting should have a clear purpose (for example, verify microbiome
  shift) rather than being a generic upsell.

# 8. Business models and unit economics

This section reframes the draft\'s business model discussion into a more
complete map of monetization options. Many companies blend several
models.

## 8.1 Companion animals: personalization and longevity narratives

- Test-led subscription (Genomic Loop): at-home kit or vet-mediated
  test, followed by recurring supplements or food, then periodic
  retesting.

- Direct subscription without testing: personalized meal plans based on
  questionnaires and vet history. Lower scientific differentiation but
  simpler operations.

- Condition-specific protocols: GI health, dermatology, obesity,
  cognitive aging. Works best when the protocol has measurable endpoints
  and repeat purchase drivers.

## 8.2 Livestock and aquaculture: efficiency, resilience, and sustainability

- Ingredient inclusion model: sell a feed additive into premixes and
  diets; ROI measured by feed conversion, mortality, growth rate, and
  health events.

- Program model: integrate multiple ingredients plus advisory services
  (precision feeding) to hit genetic potential targets under stress
  conditions.

- Maternal or early-life programming: interventions targeted to breeders
  or early-life windows to change lifetime performance economics.

## 8.3 Platform and data licensing

- White-label tests and reports for brands (pet food companies, clinics,
  ingredient suppliers).

- Data partnerships where anonymized cohorts are used to validate
  ingredient claims or to develop new products.

- Clinical decision support tools for veterinarians (requires high trust
  and evidence).

## 8.4 What to measure (metrics that actually predict value)

- Test conversion to subscription or repeat purchase (attach rate).

- Retention and cohort decay (month 1, 3, 6, 12).

- Gross margin by product category and by channel (DTC vs vet vs
  wholesale).

- Evidence strength: from uncontrolled testimonials to controlled
  trials.

- Data flywheel health: percent of customers with outcome tracking,
  repeat tests, and usable labeled data.

# 9. Adoption drivers: why customers buy (pets vs livestock)

The draft included useful insight that motivations differ sharply by
buyer type. This section formalizes that insight because it directly
affects messaging, channel strategy, and retention.

## 9.1 Pet owners: fear, hope, and control

- High willingness to pay when the message frames hidden risk and
  provides an actionable protocol.

- Retention increases when owners feel the recommendations are uniquely
  tailored to their pet and validated by retesting or clinical
  improvement.

- Brand trust and veterinary endorsement materially reduce skepticism,
  especially for microbiome claims.

## 9.2 Livestock producers: ROI and risk management

- Purchase decisions are driven by measurable performance: feed
  conversion ratio, growth rate, mortality, medication use, and
  processing outcomes.

- The most persuasive claims quantify impact under specific stressors
  (heat stress, pathogen challenge, early weaning) and show repeatable
  field trial results.

- Ingredient adoption is constrained by inclusion cost and by
  operational simplicity; the best products are easy to formulate and
  stable across supply chains.

## 9.3 Implication for product design

- Pets: design for narrative plus proof. Combine a clear story (why your
  pet is unique) with a protocol that produces observable improvement.

- Livestock: design for proof plus economics. Provide ROI calculators,
  field trial data, and clear inclusion guidance.

# 10. Competitive landscape and company archetypes

The draft referenced portfolio files that were not included in the
upload. This section therefore treats company examples as illustrative
and based on publicly available information, plus the companies named in
the draft.

## 10.1 Archetype map

- Archetype A: Test-led subscription and protocols (companion animals).

- Archetype B: Ingredient and feed additive companies using \'omics\'
  for proof (livestock, aquaculture).

- Archetype C: Vet-channel individualized nutrition services
  (prescription diet adjacency).

- Archetype D: Enabling labs and sequencing providers (often
  commoditized unless differentiated).

## 10.2 Selected company snapshots (illustrative)

  -----------------------------------------------------------------------------------------------------
  **Company /     **Segment**     **Core offer**   **Business        **Strategic moat   **Notes**
  brand**                                          model**           hypothesis**       
  --------------- --------------- ---------------- ----------------- ------------------ ---------------
  AnimalBiome     Pet microbiome  Microbiome       Test → protocol → Dataset + clinical Raised Series B
                                  tests + oral FMT repeat purchase   protocol +         Aug 2024; see
                                  capsules (Gut                      fulfillment + vet  case study
                                  Restore)                           trust              

  BIOME9          Pet gut health  Gut health       DTC + cross-sell  Brand + gut health Acquisition
  (acquired by                    analysis +       food              positioning +      announced 2025
  Pooch & Mutt)                   tailored                           subscriber         
                                  supplement plan                    retention          

  Alltech         Livestock       Nutrigenomics    Ingredient        Distribution +     Opened a
                  nutrigenomics   research + feed  inclusion via     mechanistic        dedicated
                                  technologies     feed channels     proof + long-term  nutrigenomics
                                  (e.g., Actigen)                    customer           center in 2008
                                                                     relationships      

  Royal Canin     Vet-channel     Individualized   Vet-mediated      Clinical channel + US availability
  Individualis    diets           diets via        personalization   service model      changed in
                                  veterinary                                            2025; concept
                                  clinics                                               remains
                                                                                        relevant

  Virbac          Cognitive       SAMe cognitive   Vet and retail    Brand + clinical   Example of
  (Novifit)       support         supplement       distribution      evidence + vet     methyl-donor
                                                                     recommendation     narrative

  Purina Pro Plan Senior          Senior dog diet  Mass premium pet  Scale +            Example of
  Bright Mind     nutrition       positioned for   food              marketing +        functional
                                  cognitive                          proprietary        nutrition with
                                  support                            formulations       mechanistic
                                                                                        framing

  Bioiberica      Functional      High nucleotide  B2B ingredient    Ingredient         Example of
  (Nucleoforce)   ingredients     yeast products   and product lines specialization +   building blocks
                                  for pets and                       studies and        positioning
                                  aquaculture                        partnerships       
  -----------------------------------------------------------------------------------------------------

# 11. Case study: AnimalBiome (microbiome tests and oral FMT)

Why this case matters: AnimalBiome illustrates a full Genomic Loop in
practice, with a clear test-to-protocol pathway and a product that is
hard to replicate purely through marketing. It also highlights the
regulatory and scaling risks inherent in microbiome therapeutics.

## 11.1 What the company sells

- At-home microbiome tests for companion animals and veterinary-facing
  testing services.

- An oral fecal microbiota transplant (FMT) capsule product positioned
  as Gut Restore, marketed for digestive and skin issues.

- A protocolized workflow: test, interpret relative to a healthy
  reference set, intervene, and retest.

## 11.2 Funding context (public)

Public databases report that AnimalBiome raised a Series B round in
August 2024 and has raised roughly the mid-twenties (USD millions) in
total funding. Treat third-party funding databases as directional unless
confirmed by filings or company announcements.

## 11.3 Economics and loop design (illustrative)

- Entry point: gut health test (priced around USD 99 in some veterinary
  marketing).

- Recurring: Gut Restore capsules are marketed in the USD 125+ range per
  month on consumer channels, depending on pack size.

- Retention reinforcement: retesting to verify microbiome shift and to
  adjust protocol.

## 11.4 Data moat

AnimalBiome publicly states that it has collected and analyzed large
numbers of cat and dog microbiome samples and uses a curated healthy
reference set to interpret results. Publicly visible claims vary by site
and may reflect updates over time (for example, consumer pages versus
veterinary pages). The core moat thesis is that repeated testing plus
outcomes creates a proprietary microbiome-to-response dataset.

## 11.5 Evidence base (what exists, and what to look for)

- Company-level claims: the consumer product page cites improvement in
  clinical signs for a large share of dogs with IBD.

- Peer-reviewed literature: retrospective case series and trials
  exploring FMT in dogs with chronic enteropathy and chronic diarrhea,
  including work on repeated FMT and on oral lyophilized FMT capsules.

- Investor diligence: ask whether the company\'s commercial outcomes
  match published cohorts, and whether endpoints are measured with
  validated clinical indices.

## 11.6 Regulatory and safety considerations

- In humans, FDA has stated that fecal microbiota used for
  transplantation is regulated as a biological drug product and has used
  enforcement discretion only under limited circumstances (human rCDI).

- Veterinary commercialization pathways are less explicit and may
  evolve.

- Operationally, stool donor screening, batch testing, and traceability
  are critical to reduce pathogen transmission risk.

## 11.7 Strategic why a strategic investor might care

- A strategic acquirer in pet food or animal health may value the
  dataset and the ability to make credible microbiome claims at scale.

- The company can also serve as an R&D engine for future defined
  consortia (moving from donor-derived mixes to cultured strains).

- The protocol creates repeat purchase behavior and a defensible
  narrative around restoring the microbiome versus generic probiotics.

# 12. Case study: BIOME9 and Pooch & Mutt (DTC gut health and personalization)

This case matters because it demonstrates consolidation: a pet food
brand acquiring a gut health testing and science platform to strengthen
personalization and retention. It is a practical example of where exit
demand can come from.

## 12.1 Strategic logic

- Data capture: testing creates a differentiated view of the dog and
  enables more credible personalization.

- Retention: personalization makes switching brands feel like abandoning
  the dog\'s specific needs.

- Product expansion: enables a portfolio of condition-specific
  supplements, prebiotic blends, and diet plans.

- Marketing and trust: a science positioning can justify premium pricing
  and reduce price elasticity.

## 12.2 Risks

- Test commoditization: if the test does not create a unique translator,
  competitors can copy the UX and undercut pricing.

- Clinical substantiation: personalization claims without evidence can
  trigger regulatory or reputational issues.

- Data governance: if data use permissions are weak, the translator
  cannot be improved or monetized via partnerships.

# 13. Case study: Alltech (nutrigenomics-backed feed technologies)

This case matters because it illustrates how \'omics\' can be used by
incumbent ingredient companies to strengthen claims, defend margin, and
position products as antibiotic alternatives or resilience enhancers.

## 13.1 What Alltech built (publicly described)

- Alltech opened a Center for Animal Nutrigenomics and Applied Animal
  Nutrition at its Lexington, Kentucky headquarters in 2008, positioned
  as a dedicated facility for studying nutrition and gene expression.

- Alltech markets certain feed technologies, such as Actigen, as being
  developed through nutrigenomics and intended to support gut health and
  animal performance.

## 13.2 Commercial takeaway for investors

- In livestock, distribution and trust matter as much as science.
  Nutrigenomic evidence can increase sales conversion and reduce churn
  by improving perceived credibility.

- High leverage opportunities can exist in platforms that enable
  ingredient companies to produce credible mechanistic datasets
  (standardized assays, pipelines, and field-trial analytics).

# 14. Perinatal programming and early-life windows

The draft highlighted perinatal programming as a potential frontier. The
core idea is that certain nutritional interventions during pregnancy,
lactation, or early life can change long-term outcomes through
developmental biology and epigenetic mechanisms. In livestock, this can
be economically attractive because an intervention on a breeder can
affect many offspring.

## 14.1 Why it can be a strong economic lever

- Leverage: one intervention can influence multiple offspring, improving
  ROI compared with treating each offspring individually.

- Timing: early-life windows may produce larger long-term effects than
  late interventions.

- Measurable outputs: immunity, growth, resilience to weaning stress,
  and lifetime productivity.

## 14.2 Practical diligence questions

- What specific markers or endpoints show that programming occurred
  (immune markers, growth curves, morbidity)?

- Is the intervention mechanism plausible (methylation biology,
  microbiome seeding, immune training)?

- How reproducible are effects across farms, genetics, and diets?

# 15. Functional nutrition examples adjacent to nutrigenomics (cognition and epigenetic narratives)

Not every relevant product is sold as nutrigenomics. Many are marketed
as functional nutrition, but they share the core concept of targeted
biological modulation. Two examples from the draft are SAMe-based
cognitive supplements and MCT/botanical oil senior diets.

## 15.1 Virbac: SAMe (Novifit) and cognitive decline

- Virbac has marketed Novifit as a SAMe-based cognitive supplement for
  aging dogs and cats, supported by clinical trial evidence on SAMe in
  dogs.

- From a nutrigenomics lens, SAMe is relevant as part of one-carbon
  metabolism and methylation biology, which is often used in epigenetic
  narratives.

## 15.2 Purina Pro Plan Bright Mind: senior cognitive positioning

- Purina positions Bright Mind senior formulas around brain metabolism
  changes in dogs around age 7 and the use of botanical oils as an
  efficient brain fuel source.

- Commercial lesson: large incumbents can translate mechanistic
  narratives into mass-market products, which can compress
  differentiation for startups unless they own a translator or a
  protocol moat.

# 16. Regulatory and claims landscape (high-level)

Regulation varies substantially by jurisdiction and by product category.
This section is a practical risk framework, not legal advice.

## 16.1 Categories that matter in practice

- Pet food and treats: typically regulated as food. Claims are
  constrained, especially for disease treatment claims.

- Veterinary therapeutic diets: often positioned as foods but sold
  through veterinary channels; claims and substantiation are sensitive.

- Supplements: regulatory frameworks differ by country; in many markets,
  structure/function claims are allowed but disease claims are not.

- Microbiome therapeutics and FMT: in humans, FDA treats FMT as a
  biological drug product and has issued guidance about enforcement
  discretion in limited circumstances. Veterinary pathways are less
  explicit and may evolve.

## 16.2 Claim substantiation guidance for operators

- Prefer claims tied to measurable biomarkers (for example, stool
  quality indices, dysbiosis indices, validated skin scoring).

- Use mechanistic \'omics\' claims as supportive evidence, not as the
  only evidence.

- Maintain a disciplined claim vocabulary that avoids crossing into drug
  claims unless the regulatory path is planned and funded.

# 17. Risks, failure modes, and red flags

- Biological noise: microbiomes and phenotypes vary by breed, geography,
  diet, and environment. Models can overfit.

- Correlation traps: many markers correlate with disease without being
  causal; recommendations may not translate into outcomes.

- Evidence risk: testimonials and uncontrolled studies can inflate
  perceived efficacy. Demand peer-reviewed evidence where possible.

- Regulatory creep: categories such as microbiome therapeutics may face
  increasing scrutiny over time.

- Operational risk: sample logistics, contamination control, donor
  screening (for FMT), and quality systems can break the business.

- Commoditization: tests can become interchangeable. Without a
  translator moat, price competition erodes margin.

- Trust risk: consumers and veterinarians will disengage if results feel
  generic or inconsistent.

# 18. Investor due diligence checklist (animal nutrigenomics)

Use this as a structured diligence template.

## 18.1 Product and evidence

- What exact endpoint is targeted (GI, dermatology, obesity, cognitive,
  growth performance)?

- What is the primary evidence type: controlled trial, retrospective
  study, real-world evidence, or mechanistic transcriptomics?

- Are endpoints measured with validated veterinary indices or
  standardized farm metrics?

- Does efficacy replicate across breeds, diets, and environments?

## 18.2 Translator and data moat

- What is the translator (rules, statistical model, ML model)? What are
  inputs and outputs?

- How large is the proprietary dataset, and what proportion is
  longitudinal with outcomes?

- Are data rights secured for model improvement and for external
  partnerships?

- How hard is it for a competitor to replicate the dataset (channel
  control, unique partnerships, unique sample bank)?

## 18.3 Unit economics

- Test margin and cost structure: is the test a profit center or an
  acquisition tool?

- Subscription conversion and retention: what percent convert and how
  long do they stay?

- Gross margin by SKU and by channel; impact of logistics and spoilage.

- Payback period and cohort LTV: are they improving as the translator
  improves?

## 18.4 Regulatory and quality

- How is the product classified in the key launch markets (food,
  supplement, drug)?

- What claim language is used and how is it substantiated?

- Quality systems: GMP, batch testing, traceability, adverse event
  handling.

- For microbiome or FMT: donor screening protocol, pathogen testing, and
  handling of safety alerts.

## 18.5 Partnerships and exits

- Which incumbents could partner or acquire and why (data, protocol,
  distribution)?

- Is there evidence of strategic demand (for example, acquisitions like
  Pooch & Mutt buying BIOME9)?

- Does the company have a plan to defend margins when incumbents copy
  surface-level features?

# 19. Investment thesis and opportunity map

This section translates the full analysis into actionable investment
beliefs and a screening rubric.

## 19.1 Primary investment beliefs

- Belief 1: Diagnostics alone commoditize. The defensible asset is the
  translator plus the data flywheel.

- Belief 2: The best nutrition businesses monetize through repeat
  purchase. Investors should prioritize subscription conversion and
  retention over one-off kit sales.

- Belief 3: In livestock, mechanistic proof plus ROI wins.
  Transcriptomics can be a sales accelerator, but adoption still
  requires field economics and distribution.

- Belief 4: Regulatory risk is asymmetric. Microbiome therapeutics can
  create step-function value if validated, but can also face abrupt
  regulatory headwinds.

## 19.2 Screening scorecard (quick and practical)

  -----------------------------------------------------------------------
  **Dimension**     **0 (weak)**      **1 (medium)**    **2 (strong)**
  ----------------- ----------------- ----------------- -----------------
  Translator moat   Generic rules or  Some proprietary  Proprietary
                    third-party IP    logic; limited    models + large,
                                      data              outcome-linked
                                                        data rights

  Intervention      Commodity         Some formulation  Proprietary
  margin            products          differentiation   formulations +
                                                        subscription +
                                                        high margin

  Evidence strength Anecdotes only    Retrospective or  Controlled
                                      real-world data   studies +
                                                        mechanistic
                                                        support

  Channel control   Marketplace       Some direct       Vet or
                    dependent         channel           distribution
                                                        partnerships that
                                                        lock in demand

  Regulatory risk   Unclear and       Partially managed Clear
                    unmanaged                           classification
                                                        strategy +
                                                        quality system
                                                        investment
  -----------------------------------------------------------------------

## 19.3 Where to focus (today)

- Pet GI and dermatology: high owner pain, measurable outcomes, and
  strong subscription potential.

- Antibiotic alternative and gut integrity programs in livestock: large
  spend pools and strong compliance-driven demand.

- Platforms that help incumbents run standardized nutrigenomic
  validation (outsourced transcriptomics and analytics).

# 20. Implementation playbook (how to build or upgrade a nutrigenomics program)

This section translates the report into an actionable build plan for an
operator or an investing team working with a portfolio company.

## 20.1 Phase 0: choose a wedge that creates repeat purchase

4.  Pick one high-value problem with clear customer pain and measurable
    endpoints (for example, chronic diarrhea and stool quality).

5.  Define the minimum viable biomarker set and the minimum viable
    intervention catalog.

6.  Decide the channel: DTC, vet, or B2B. The channel determines data
    access and retention.

## 20.2 Phase 1: build measurement and reporting MVP

7.  Design kit logistics (sampling, shipping, stabilization, chain of
    custody).

8.  Select assay and lab partner, and define QC thresholds.

9.  Build a first translator (rules or simple model) that maps results
    to a small set of recommendations.

10. Ship reports that feel specific and include clear next steps.

## 20.3 Phase 2: design the recurring intervention and the loop

11. Build proprietary interventions where possible (unique formulations,
    subscription bundles).

12. Create retest triggers tied to the protocol timeline (for example,
    60 to 90 days).

13. Capture outcomes via structured surveys, vet feedback, and objective
    metrics where feasible.

14. Use outcomes to refine the translator and to improve conversion and
    retention.

## 20.4 Phase 3: validation, scaling, and defensibility

15. Run controlled or quasi-controlled studies in the highest-value
    cohorts to de-risk claims.

16. Establish quality systems and adverse event monitoring.

17. Expand the translator to additional endpoints only after core loop
    retention is strong.

18. Develop partnerships for distribution and for ingredient validation,
    but protect data rights.

## 20.5 Reference technical architecture (simplified)

- Ingestion: kit barcode + customer metadata + diet history + symptoms.

- LIMS / lab outputs: sequencing reads and QC metrics.

- Feature store: standardized microbiome/genotype features.

- Translator: model service that outputs risk scores and recommended
  interventions.

- Report generator: customer-facing PDF plus vet-facing clinical notes.

- Commerce: recommendation engine → cart → subscription fulfillment.

- Feedback: outcomes, retest data, churn reasons, vet notes.

# 21. Appendix: glossary

  -----------------------------------------------------------------------
  **Term**                            **Definition (practical)**
  ----------------------------------- -----------------------------------
  Translator                          The algorithm, rules, and data that
                                      convert biological measurements
                                      into specific nutritional actions
                                      (product recommendations).

  Genomic Loop                        A business flywheel where testing
                                      creates an insight that leads to a
                                      repeat-purchase intervention, plus
                                      outcome tracking and retesting that
                                      improve the translator over time.

  Dysbiosis                           A state where the gut microbiome
                                      composition is imbalanced relative
                                      to a reference, often associated
                                      with symptoms but not always
                                      causal.

  FMT (fecal microbiota transplant)   Transfer of stool-derived microbial
                                      communities from a healthy donor to
                                      a recipient to modulate the
                                      microbiome.

  Prebiotic                           A substrate selectively utilized by
                                      host microorganisms that confers a
                                      health benefit.

  Probiotic                           Live microorganisms which, when
                                      administered in adequate amounts,
                                      confer a health benefit on the
                                      host.

  Postbiotic                          Preparation of inanimate
                                      microorganisms and/or their
                                      components that confers a health
                                      benefit on the host (definitions
                                      vary).

  One-carbon metabolism / methyl      Pathways and nutrients involved in
  donors                              methylation biology; often invoked
                                      in epigenetic narratives.
  -----------------------------------------------------------------------

# 22. References (selected public sources)

R1: Precedence Research. Nutrigenomics Market Size, Share and Trends
2025 to 2034. (Published Nov 21, 2025).
https://www.precedenceresearch.com/nutrigenomics-market

R2: Fortune Business Insights. Nutrigenomics Market report.
https://www.fortunebusinessinsights.com/industry-reports/nutrigenomics-market-101099

R3: Mordor Intelligence. Nutrigenomics Testing Market.
https://www.mordorintelligence.com/industry-reports/nutrigenomics-testing-market

R4: MarketsandMarkets. Personalized Nutrition Market.
https://www.marketsandmarkets.com/Market-Reports/personalized-nutrition-market-249208030.html

R5: Mordor Intelligence. Personalized Nutrition Market.
https://www.mordorintelligence.com/industry-reports/personalized-nutrition-market

R6: Grand View Research. Pet Food Market.
https://www.grandviewresearch.com/industry-analysis/pet-food-industry

R7: Reuters. General Mills introduces \'fresh\' Blue Buffalo dog food
(fresh pet food category size and forecast). (Jun 23, 2025).
https://www.reuters.com/business/general-mills-introduces-fresh-blue-buffalo-dog-food-2025-06-23/

R8: Grand View Research. Animal Feed Additives Market.
https://www.grandviewresearch.com/industry-analysis/animal-feed-additives-market

R9: Grand View Research. Probiotics in Animal Feed Market.
https://www.grandviewresearch.com/industry-analysis/probiotics-animal-feed-market-report

R10: MarketsandMarkets press release. Postbiotics Market worth \$224.8
million by 2030.
https://www.marketsandmarkets.com/PressReleases/postbiotics.asp

R11: Food Manufacture. Pooch & Mutt acquires dog gut health business.
(Jan 31, 2025).
https://www.foodmanufacture.co.uk/Article/2025/01/31/pooch-mutt-acquires-dog-gut-health-business/

R12: Pet Worldwide. Pooch & Mutt acquires Biome9. (Feb 4, 2025).
https://www.petworldwide.net/content-1/news/2025/02/04/pooch-mutt-acquires-biome9.html

R13: AnimalBiome. Our Science - Cat and Dog Microbiome Testing (consumer
site). https://www.animalbiome.com/pages/our-science-1

R14: AnimalBiome Veterinary. Our Science (veterinary site).
https://animalbiome.vet/pages/our-science

R15: AnimalBiome. Gut Restore for Dogs product page (pricing and
claims).
https://www.animalbiome.com/products/doggybiome-gut-restore-supplement

R16: Toresson L, et al. Clinical Effects of Faecal Microbiota
Transplantation as Adjunctive Therapy in Dogs with Chronic
Enteropathies. (2023).
https://pmc.ncbi.nlm.nih.gov/articles/PMC10145442/

R17: Toresson L, et al. Repeated fecal microbiota transplantation in
dogs with chronic enteropathy. J Am Vet Med Assoc. (2025).
https://avmajournals.avma.org/view/journals/javma/aop/javma.25.08.0563/javma.25.08.0563.xml

R18: Liu S, et al. Effects and Microbiota Changes Following Oral
Lyophilized FMT Capsules in Dogs with Chronic Diarrhea. (2025).
https://pmc.ncbi.nlm.nih.gov/articles/PMC12474058/

R19: U.S. FDA. Guidance: enforcement policy regarding IND requirements
for use of fecal microbiota for transplantation. (Final guidance Nov 29,
2022).
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota

R20: WATTAgNet. USA: Alltech opens nutrigenomics facility. (May 18,
2008).
https://www.wattagnet.com/home/article/15481290/usa-alltech-opens-nutrigenomics-facility

R21: Alltech. Actigen product page.
https://www.alltech.com/our-products/actigen

R22: Royal Canin Academy. Individualized pet nutrition (Individualis).
https://academy.royalcanin.com/en/veterinary/individualized-pet-nutrition

R23: Royal Canin Individualis vet site notice (US availability).
https://vet.individualis.com/

R24: Virbac. New studies support the use of Novifit. (Apr 12, 2012).
https://us.virbac.com/home/resources/news/pagecontent/latest-announcements/new-studies-support.html

R25: Rème CA, et al. Effect of S-adenosylmethionine tablets on
age-related mental decline in dogs: a placebo-controlled trial. (2008).
https://pubmed.ncbi.nlm.nih.gov/18597245/

R26: Purina Pro Plan. Bright Mind product pages / vet materials.
https://www.proplanvetdirect.com/canine-pro-plan-bright-mind-adult-7-chicken-rice-formula

R27: Bioiberica. Nucleoforce Pets HF.
https://www.bioiberica.com/en/products/animal-health/nucleoforce-pets-hf

R28: Food Ingredients First. Bioiberica unveils animal immunity and
intestinal health Nucleoforce launch. (Oct 20, 2025).
https://www.foodingredientsfirst.com/news/bioiberica-animal-immunity-nucleoforce-launch.html

R29: Tracxn. AnimalBiome company profile (funding timeline).
<https://tracxn.com/d/companies/animalbiome/__S6-8HBaOKKcpTeIK17zSsWrWBsM7Vs7EjhoxfBaj-tQ>


---

# Source: Nutrigenomics_Gemini.docx

**1. Executive Summary: The \"Software\" of Nutrition**

Nutrigenomics is not a product; it is the **\"biological software\"**
that dictates how nutrition interacts with an animal\'s genetic
hardware. It represents a fundamental shift from feeding \"breeds\"
(e.g., Labradors) to feeding **\"Gene Expression Profiles\"**.

The sector is currently valued at **\~\$600M--\$800M (2025)** but is
unlocking a much larger **\$4B Personalized Nutrition market** (CAGR
17%). The real value for investors is not in the DNA test itself (a
commodity), but in the **\"Genomic Loop\"**---the SaaS-like ecosystem
where a genetic test locks a customer into a lifetime of high-margin,
proprietary supplements.

**Key Strategic Insight:** The most investable assets are those that own
the **\"Translator\"**---the proprietary data or algorithm that converts
a DNA read-out into a purchasable nutritional intervention.

**2. What is Nutrigenomics? (The Definition)**

Nutrigenomics is the study of how nutrients affect gene expression. It
is the science of using food to **\"switch on\"** or **\"switch off\"**
specific genes without altering the underlying DNA sequence.

- **The Old Way (Genetics):** \"Your dog has the *POMC* gene mutation,
  so he is genetically obese. Nothing we can do.\"

- **The New Way (Nutrigenomics):** \"Your dog has the *POMC* mutation.
  We will feed him a specific high-fiber, mitochondrial-boosting diet
  that **downregulates** the hunger signal expression, effectively
  \'silencing\' the obesity risk.\"

**The Two Core Business Models:**

1.  **High-Value Personalization (Pets):** selling **\"Longevity\"** to
    owners.

    - *Mechanism:* DNA Swab → Cloud Analysis → Monthly Subscription Box
      of \"Gene-Matched\" supplements.

2.  **Genotype-Specific Efficiency (Livestock):** selling **\"Yield\"**
    to farmers.

    - *Mechanism:* Feeding specific \"methyl-donor\" diets to pregnant
      sows to program the immune systems of their unborn piglets
      (Perinatal Programming).

**3. Market Sizing & Predictions**

  ------------------------------------------------------------------------------
  **Metric**          **Forecast    **CAGR           **Primary Driver**
                      (2030)**      (2025--2030)**   
  ------------------- ------------- ---------------- ---------------------------
  **Nutrigenomics     **\$1.5B --   **\~17%**        Precision Nutrition
  Core Market**       \$2.0B**                       adoption in US/EU.

  **Pet Personalized  **\$4.0B+**   **12--15%**      \"Pet Humanization\" &
  Nutrition**                                        Preventative Care.

  **Livestock         **\$2.5B+**   **8--10%**       Antibiotic replacement &
  \"Omics\" Feed**                                   Carbon reduction.
  ------------------------------------------------------------------------------

- **Margin Profile:**

  - **Tests/Diagnostics:** Low Margin (30--40%) -- *The \"Loss Leader\"*

  - **Supplements/Interventions:** High Margin (65--75%) -- *The
    \"Recurring Revenue\"*

  - **Data/IP Licensing:** Ultra-High Margin (80%+) -- *The \"Platform
    Play\"*

**4. The Value Chain: Where to Play?**

The value chain is composed of three layers. The middle layer
(Interpretation) captures the most strategic value.

**Layer 1: The Hardware (Commoditized)**

- **Players:** LabCorp, Neogen, Illumina.

- **Activity:** Sequencing the DNA (Swab → A/C/G/T Data).

- **Verdict:** **Avoid.** This is a race to the bottom on price per base
  pair.

**Layer 2: The \"Translator\" (The Moat)**

- **Players:** **Biome9**, **AnimalBiome**, **Alltech (Nutrigenomics
  Center)**.

- **Activity:** The Algorithm. Taking raw DNA data and saying, *\"This
  sequence means your dog needs more Zinc and less Starch to prevent hip
  dysplasia.\"*

- **Verdict:** **TARGET.** This layer owns the relationship and the
  prescription power.

**Layer 3: The Intervention (The Cash Flow)**

- **Players:** **Virbac (Novifit)**, **Nestlé Purina (Bright Mind)**,
  **Royal Canin (Individualis)**.

- **Activity:** Manufacturing the \"Gene-Active\" food or supplement.

- **Verdict:** **Buy.** High brand loyalty and recurring revenue.

**5. Companies & \"Hidden Gems\" in Your Portfolio**

*Analysis based on your attached files 20260115_VC_PE_Portfolio.xlsx and
Value_Chain_Companies.xlsx.*

**A. The \"Pure Play\" Targets**

1.  **Biome9 (UK) / Pooch & Mutt**

    - **In your files:** Mentioned in Value_Chain_Companies.xlsx under
      \"New Business Models.\"

    - **The Play:** They are the **\"23andMe for Dogs.\"** They use AI
      to analyze gut microbiome DNA and prescribe a personalized food
      subscription.

    - **Status:** Recently acquired/partnered with Pooch & Mutt (backed
      by white-label manufacturing).

    - **Why Watch:** They have solved the \"Loop\" -- the test sells the
      food.

2.  **Alltech (USA)**

    - **In your files:** Mentioned heavily in Value_Chain_Companies.xlsx
      (Nutrigenomics tab).

    - **The Play:** They own the **only dedicated \"Nutrigenomics
      Center\"** in the industry. They use \"Gene Chips\" to prove their
      yeast products (Actigen) physically change gene expression in the
      animal\'s gut.

    - **Strategic Value:** They are the \"Intel Inside\" for other feed
      brands.

**B. The \"Sleeping Giants\" (Portfolio Ops)**

3.  **Virbac (France)**

    - **In your files:** Value_Chain_Companies.xlsx (Cognitive tab).

    - **Product:** **Novifit® (SAMe)**.

    - **The \"Hidden\" Nutrigenomic Angle:** SAMe is a \"Methyl Donor.\"
      It works via **Epigenetics** (DNA Methylation) to improve brain
      function in seniors. Virbac is essentially selling an epigenetic
      drug as a supplement.

4.  **Nestlé Purina**

    - **In your files:** Value_Chain_Companies.xlsx (Cognitive tab).

    - **Product:** **Bright Mind® (MCTs)**.

    - **The Angle:** Their \"Neuro-Metabolic\" approach uses MCTs to
      bypass glucose metabolism genes that fail in aging dogs. They hold
      the patents on this \"metabolic hack.\"

5.  **Bioiberica**

    - **In your files:** Value_Chain_Companies.xlsx (Nutrigenomics tab).

    - **Product:** **Nucleoforce®**.

    - **The Angle:** They sell free Nucleotides (the building blocks of
      DNA/RNA). This is the \"raw material\" for rapid gene repair
      during high growth.

**6. Sources**

- **Precedence Research:** *Nutrigenomics Market Size, Share and Trends
  2025 to 2034.*
  [[Link]{.underline}](https://www.precedenceresearch.com/nutrigenomics-market)
  <https://www.precedenceresearch.com/nutrigenomics-market>

- 

- **Market Research Future:** *Nutrigenomics Market Size, Trends, Growth
  Forecast 2035.*
  [[Link]{.underline}](https://www.marketresearchfuture.com/reports/nutrigenomics-market-4009)
  <https://www.marketresearchfuture.com/reports/nutrigenomics-market-4009>

- 

- **MarketsandMarkets:** *Postbiotics Market worth \$224.8 million by
  2030.*
  [[Link]{.underline}](https://www.marketsandmarkets.com/PressReleases/postbiotics.asp)
  <https://www.marketsandmarkets.com/PressReleases/postbiotics.asp>

- 

- **Mordor Intelligence:** *Postbiotics Market Size, Share & 2030 Growth
  Trends Report.*
  [[Link]{.underline}](https://www.mordorintelligence.com/industry-reports/postbiotics-market)
  <https://www.mordorintelligence.com/industry-reports/postbiotics-market>

- 

- **Grand View Research:** *Pet Food Market Size, Share & Trends \|
  Industry Report 2030.*
  [[Link]{.underline}](https://www.grandviewresearch.com/industry-analysis/pet-food-industry)
  <https://www.grandviewresearch.com/industry-analysis/pet-food-industry>

- 

- **Mordor Intelligence:** *Nutrigenomics Testing Market Size & Share
  Analysis - Growth Trends and Forecast (2025).*
  [[Link]{.underline}](https://www.mordorintelligence.com/industry-reports/nutrigenomics-testing-market)
  <https://www.mordorintelligence.com/industry-reports/nutrigenomics-testing-market>

- 

- **Alltech:** *Nutrigenomics \| Alltech Crop Science.*
  [[Link]{.underline}](https://www.alltech.com/our-solutions/crop-science/nutrigenomics)
  <https://www.alltech.com/our-solutions/crop-science/nutrigenomics>

- 

- **Pooch & Mutt / Biome9:** *Acquiring BIOME9: Pooch & Mutt\'s venture
  into gut health science.*
  [[Link]{.underline}](https://www.poochandmutt.co.uk/blogs/gut-health/acquiring-biome9-pooch-mutts-venture-into-gut-health-science)
  <https://www.poochandmutt.co.uk/blogs/gut-health/acquiring-biome9-pooch-mutts-venture-into-gut-health-science>

- 

- **Virbac (via dvm360):** *Spotlight on Research: Cognitive Dysfunction
  Syndrome.*
  [[Link]{.underline}](https://www.dvm360.com/view/spotlight-research-cognitive-dysfunction-syndrome-sponsored-virbac-animal-health)
  <https://www.dvm360.com/view/spotlight-research-cognitive-dysfunction-syndrome-sponsored-virbac-animal-health>

- 

- **Bioiberica:** *Nucleoforce Aqua HF.*
  [[Link]{.underline}](https://www.bioiberica.com/en/products/animal-health/nucleoforce-aqua-hf)
  <https://www.bioiberica.com/en/products/animal-health/nucleoforce-aqua-hf>

**1. The Rise: Why Now? (The Convergence)**

Nutrigenomics is rising because three technologies have collided, making
the \"invisible\" visible.

- **The Cost of Sequencing:** The cost to sequence a genome has
  plummeted. It is now cheap enough (\<\$50 COGS) to be a \"customer
  acquisition cost\" rather than a luxury product.

- **The \"Omics\" Evidence:** We no longer just *guess* that Omega-3s
  help joints. Companies like **Alltech** (as noted in your Value_Chain
  file) now use **Gene Chips** to *prove* that a specific yeast fraction
  downregulates the expression of inflammatory cytokines in the gut.

  - *The Shift:* We moved from \"Trust me, it works\" to \"Here is the
    RNA transcript showing your dog\'s inflammation genes switching
    off.\"

- **The \"Epigenetic\" Awareness:** Consumers (especially
  Millennials/Gen Z) now understand that \"DNA is not destiny.\" They
  know that lifestyle (diet) can influence genes. This creates a market
  for products that claim to \"optimize\" genetic potential.

**2. Market Penetration: The \"High-Value Niche\"**

*Data Source: Nutraceuticals_Whitepaper.xlsx (Nutrigenomic Tab)*

The data shows a classic \"Premium Niche\" dynamic.

- **General Market Penetration:** extremely low (**\~0.03%** of the
  total feed market).

  - *Why?* It is too expensive for generic production.

- **Revenue Impact:** Despite low volume, it generates **\~\$613
  Million** in revenue.

  - *Insight:* This confirms an incredibly high willingness-to-pay. The
    customers buying this are not price-sensitive; they are
    performance-sensitive.

- **The \"Hidden\" Penetration:** The *Gut Integrity* segment (often
  marketed as \"antibiotic alternative\" but functionally nutrigenomic)
  is much larger (**\~\$2.17 Billion**). This is where the volume
  is---farmers using gene-active ingredients to survive without
  antibiotics.

**3. Client Attraction: The Psychology of the Sale**

Why do clients buy this? The motivation differs strictly by customer
type.

**A. The Pet Owner (B2C): \"Fear & Control\"**

- **The Hook:** \"The Silent Killer.\"

  - Owners are terrified of cancer and hidden diseases. A DNA test
    reveals \"invisible risks\" (e.g., *COL5A1* for joint failure).

- **The Sale:** **\"Actionable Hope.\"**

  - If you just tell an owner \"Your dog will get arthritis,\" they feel
    helpless.

  - If you say \"Your dog has the arthritis gene, BUT this *Epigenetic
    Chew* can delay it by 3 years,\" they will subscribe immediately.

  - *Example from File:* **Biome9** (\"Predictive AI\"). They don\'t
    sell dog food; they sell a \"health forecast\" and the tool to
    change it.

**B. The Livestock Farmer (B2B): \"Efficiency & Defense\"**

- **The Hook:** \"Lost Margins.\"

  - A farmer doesn\'t care about the pig\'s feelings. They care that the
    pig isn\'t growing as fast as its genetics say it should.

- **The Sale:** **\"Unlocking Potential.\"**

  - Genetics companies (like Aviagen) sell birds designed to grow fast.
    The farmer buys nutrigenomics (like **Alltech's Actigen**) to ensure
    the bird *actually* hits that genetic target despite heat stress or
    poor water.

  - *Example from File:* **Bioiberica** (\"Nucleoforce\"). The claim is
    \"Spare Parts.\" It provides the raw DNA/RNA blocks so the animal
    doesn\'t waste energy making them, aiming purely for faster growth
    (ROI).

**4. The \"Value Chain\" Trap & Opportunity**

*Perspective from Value_Chain_Companies.xlsx*

Most investors look at the wrong layer.

- **The Trap (Diagnostics):** Do NOT invest in the lab doing the PCR
  test. That is a commodity race to the bottom.

- **The Opportunity (The Translator):** Invest in the company that owns
  the **Algorithm**.

  - **The \"Lock-In\" Model:** Once **Royal Canin** (Individualis) or
    **Biome9** has your dog\'s DNA data, you are \"locked\" into their
    ecosystem. Switching foods feels like \"ignoring your dog\'s
    biology.\"

  - **The Moat:** The accumulated data of *Genotype + Health Outcome*
    becomes a predictive engine that no competitor can copy.

**5. Future Perspective: \"Perinatal Programming\"**

The next frontier (2026--2030) is targeting the **Mother** to program
the **Child**.

- **The Science:** Feeding the pregnant mother specific \"Methyl
  Donors\" (like **Virbac\'s Novifit** / SAMe technology) to permanently
  alter the gene expression of the offspring *in utero*.

- **The Business:** This is the Holy Grail for livestock. Instead of
  feeding expensive supplements to 1,000 piglets, you feed the sow once,
  and all 12 piglets are born with \"upgraded\" immune systems.

**Summary: What to Watch**

- **Watch** for companies pivoting from \"Breed Specific\" to
  \"Metabolic Specific.\"

- **Look for** \"Epigenetic\" claims in the Regulatory files---this is
  the new buzzword replacing \"Natural.\"

- **Valuation:** Expect high multiples (SaaS-like) for companies that
  successfully link a **Diagnostic Test** to a **Subscription Product**
  (The Biome9 model).

**1. Executive Snapshot: The \"23andMe\" of Poop**

**AnimalBiome** is not a supplement company; it is a **biological data
company** that monetizes through \"Gut Restoration.\" They have
successfully commercialized a medical procedure---**Fecal Microbiota
Transplant (FMT)**---by packaging it into a consumer-friendly oral
capsule (\"The Poop Pill\").

- **Status:** Series B (Raised \~\$26M total; \$15.5M in Aug 2024).

- **Backers:** **Cargill** (Strategic Lead), SOSV, Digitalis Ventures.

- **Key Asset:** The world's largest database of pet microbiome samples
  (\>15,000 samples), allowing them to define \"Healthy\" vs.
  \"Dysbiotic\" with proprietary precision.

**2. The Business Model: The \"Patient Owner\" Loop**

*Source: Value_Chain_Companies.xlsx (New Business Models Tab)*

They do not sell a one-off product; they sell a **Protocol**.

1.  **The Hook (The Test):** The owner buys a **\$99 Gut Health Test
    Kit** because their dog has chronic diarrhea or itchy skin (atopic
    dermatitis).

2.  **The Fear (The Report):** The results show the dog is missing key
    bacteria (e.g., *Faecalibacterium*) compared to the \"Healthy Dog
    Reference Set.\"

3.  **The Fix (The FMT):** The algorithm prescribes **\"Gut Restore
    Capsules\"** (\$125/month). This is not a generic probiotic; it is
    freeze-dried stool from \"Super-Donor\" dogs.

4.  **The Retention (The Retest):** \"Retest in 3 months to see the
    colonization.\" (SaaS-like retention).

**3. The \"Secret Sauce\": Why They Win**

*Differentiation from Generic Probiotics*

- **The Problem with Probiotics:** Most pet probiotics (*Lactobacillus*)
  are just \"tourists\"---they pass through the gut without staying.

- **The AnimalBiome Solution:** **\"Ecosystem Transplant.\"**

  - They use **FMT (Fecal Microbiota Transplant)**. They take the entire
    bacterial community from a clinically healthy dog and freeze-dry it.

  - *Claim:* \"We don\'t just add one soldier; we drop in a whole new
    army.\"

  - **The Moat:** They have patented the **Oral Capsule Delivery
    System** (US Patent App 2018, Inventor: Holly Ganz) that ensures the
    bacteria survive stomach acid without needing the \$2,000 veterinary
    colonoscopy procedure.

**4. Regulatory Strategy: The \"Wild West\" Loophole**

*Source: Value_Chain_Companies.xlsx (Microbiome Tab)*

This is their biggest risk and their biggest speed advantage.

- **The Classification:** They operate as a **\"Complementary Feed\"
  (Supplement)** company, NOT a Drug company.

- **The Hack:** Technically, FMT is a biological drug (regulated by FDA
  CVM). However, FDA has exercised \"Enforcement Discretion\" (turning a
  blind eye) for FMT in animals because there are no approved
  alternatives for life-threatening dysbiosis.

- **The Risk:** If the FDA decides to regulate FMT strictly (as they are
  starting to do in humans), AnimalBiome would need expensive NADA (New
  Animal Drug Application) trials.

- **The Defense:** They are pivoting to **\"Defined
  Consortia\"**---identifying the specific 5--10 strains that work and
  growing them in a lab (fermentation) so they stop relying on donor
  poop (which is hard to scale and regulate).

**5. Strategic Verdict: Why Cargill Invested**

**Cargill** led their Series A and B not because they want to sell poop
pills, but because they want the **Data**.

- **The End Game:** AnimalBiome is building the **\"Google Maps\" of the
  Dog Gut.**

- **The Value:** Cargill (or a potential acquirer like Mars/Royal Canin)
  will use this database to formulate mass-market kibble that claims:
  *\"Clinically proven to restore the microbiome based on 15,000 DNA
  samples.\"*

AnimalBiome is a **strong acquisition target** for a Pet Food Major
(Mars, Purina) looking to own the \"Prescription Diet\" for GI issues.
The \"Yuck Factor\" of the product is high, but the **efficacy data**
(80% improvement in IBD dogs) is undeniable.

<https://www.animalbiome.com/pages/our-science-1#:~:text=We%20can%20detect%20any%20bacterial,cat%20and%20dog%20microbiome%20samples>.

<https://tracxn.com/d/companies/animalbiome/__S6-8HBaOKKcpTeIK17zSsWrWBsM7Vs7EjhoxfBaj-tQ>

The **80% efficacy** figure for AnimalBiome is not a marketing estimate;
it is derived from specific pilot studies and retrospective clinical
data published by the company and its research partners.

Here is the source breakdown:

**1. The Primary Data Source (The \"80%\" Claim)**

- **Source:** *AnimalBiome Pilot Study (2019)*

- **Study Cohort:** 40 Dogs and 72 Cats with diagnosed or suspected
  **Inflammatory Bowel Disease (IBD)**.

- **Intervention:** 25-day course of \"Gut Restore\" (Oral FMT
  Capsules).

- **Outcome:**

  - **Dogs:** **80% (32/40)** showed improved clinical signs (better
    stool quality, reduced vomiting).

  - **Cats:** **83% (60/72)** showed improved clinical signs.

  - **Secondary Benefit:** 50% of dogs and 25% of cats showed increased
    appetite.

- **Citation:** *"The Promise of Fecal Transplants: A Microbiome
  Solution for Veterinary Practitioners" \[White Paper\], AnimalBiome
  (2019).*

**2. Supporting Clinical Evidence (Academic & Peer-Reviewed)**

- **Study:** *Use of oral FMT in dogs with Chronic Enteropathy (CE).*

- **Source:** *MDPI (Veterinary Sciences) / PMC (National Institutes of
  Health).*

- **Finding:** Oral FMT capsules (like AnimalBiome\'s) significantly
  decreased the **CIBDAI** (Canine Inflammatory Bowel Disease Activity
  Index) scores.

  - *Specific Data:* In a retrospective case series of 41 dogs, **31/41
    (75%)** responded to treatment with improved fecal quality.

- **Link:** [[Clinical Effects of Faecal Microbiota Transplantation as
  Adjunctive Therapy in Dogs with Chronic
  Enteropathies]{.underline}](https://www.mdpi.com/2306-7381/10/4/271)

**3. Customer & Veterinary Validation (Real-World Evidence)**

- **Scale:** They have analyzed over **60,000 microbiome samples** (the
  largest dataset in the industry).

- **Validation:** Over **1,000 veterinarians** worldwide actively
  recommend the product.

- **User Feedback:** In B2C channels, efficacy is often reported in
  \"rescue\" cases where metronidazole (antibiotics) failed.

  - *Quote:* \"80% of dogs will have reduced symptoms associated with
    IBD by Day 25.\" (Source: AnimalBiome Technical Product Guide).

**4. Why This Matters for Valuation**

This data moves AnimalBiome from a \"Supplement\" company to a
**\"Therapeutic\"** asset.

- **The \"Drug-Like\" Profile:** Achieving **\~80% efficacy** in IBD
  cases (a condition that usually requires steroids) is comparable to
  pharmaceutical interventions, but without the side effects.

- **The Moat:** Any competitor trying to replicate this would need to
  build a donor bank of thousands of dogs to match AnimalBiome\'s
  \"Healthy Reference Set\" to ensure safety and efficacy.


---

# Source: Value_Chain_Companies.xlsx

### Sheet: Mobility 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Nutramax | Dasuquin® | Glucosamine, Chondroitin, ASU (Avocado/Soy Unsaponifiables), Green Tea | Dogs, Cats | Nutramax (Vertical) | The US #1: The undisputed leader. Proprietary ASU outperforms standard Glucosamine. | 🔗 Nutramax Site |
| Bioiberica | Condrovet® Force HA | Chondroitin Sulfate, Glucosamine, Hyaluronic Acid, Type II Collagen | Dogs, Cats | Bioiberica (Vertical) | The EU #1: Vertical integration of Heparin/Chondroitin makes them the lowest-cost high-quality producer. | 🔗 Bioiberica Page |
| Vetoquinol | Flexadin® Advanced | UC-II® (Undenatured Type II Collagen), Omega-3, Vitamin E | Dogs, Cats | Lonza (Licensor) | Drug Replacement: Induces oral tolerance to stop inflammation (alternative to NSAIDs). | 🔗 Vetoquinol USA |
| Lintbells | YuMOVE Joint Care | ActivEase® Green Lipped Mussel, Glucosamine, Hyaluronic Acid | Dogs | Lintbells (Vertical) | Supply Chain Control: Owns the mussel bays in NZ to guarantee 4x higher potency. | 🔗 Lintbells Science |
| VetriScience | GlycoFlex® 3 | Perna canaliculus (GlycOmega™), Glucosamine, MSM, DMG | Dogs | Aroma NZ (Supplier) | Clinical Legacy: The original "Gold Standard" formula used by US vets for 40+ years. | 🔗 Drugs.com |


### Sheet: Gut Health 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Nestlé Purina | FortiFlora® | Enterococcus faecium SF68, Vitamin C, Vitamin E | Dogs, Cats | Nestlé Research | Market Dominance: The #1 prescribed probiotic globally. Proprietary microencapsulation. | 🔗 Purina SF68 |
| Protexin (ADM) | Pro-Kolin | Probiotics (E. faecium), Preplex® Prebiotic, Kaolin, Pectin | Dogs, Cats | ADM (Vertical) | The EU Standard: The reference paste for acute diarrhea (Kaolin + Probiotic synergy). | 🔗 Protexin Page |
| Zesty Paws | Probiotic Bites | Bacillus subtilis DE111®, Pumpkin, Papaya | Dogs | ADM (Licensor) | Spore Tech: Uses hardy spore-forming bacteria (DE111) that survive manufacturing heat. | 🔗 ADM Sell Sheet |
| AnimalBiome | Gut Restore | Fecal Microbiota Transplant (FMT) material (Oral Capsules) | Dogs, Cats | AnimalBiome | Restoration: Reseeds the entire ecosystem, not just adding one strain. | 🔗 Patent App |


### Sheet: Immunity 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Diamond V (Cargill) | Original XPC™ | Postbiotics (Saccharomyces cerevisiae fermentation metabolites) | Livestock, Dogs | Cargill (Vertical) | The Original Postbiotic: The global reference for "Immune Training." Optimizes gut structure without live bacteria. | 🔗 Diamond V Science |
| Swedencare | ProDen PlaqueOff® | Ascophyllum nodosum (D1070™ Kelp) | Dogs, Cats | Swedencare (Vertical) | Systemic Action: The algae is absorbed into the blood and secreted into saliva to prevent plaque (Systemic, not local). | 🔗 Swedencare Tech |
| Olmix | Algimun® | Macroalgae Extracts (MSP® - Sulfated Polysaccharides) | Livestock, Aqua | Olmix (Vertical) | Marine Immunity: Specific algae sugars (MSP) that unlock the gut's immune receptors (TLRs) better than yeast. | 🔗 Olmix MSP Page |
| Leiber GmbH | Biolex® MB40 | Beta-Glucans & MOS (Brewers' Yeast Cell Walls) | Livestock, Pets | Leiber (Vertical) | Surface Structure: Unique high-surface-area yeast hulls that bind pathogens (E. coli/Salmonella) like a magnet. | 🔗 Leiber Brewers Yeast |
| Phytobiotics | Sangrovit® | Isoquinoline Alkaloids (Macleaya cordata) | Livestock | Phytobiotics (Vertical) | Gut Integrity: Plant-based alkaloids that reduce intestinal inflammation, saving energy for growth. | 🔗 Sangrovit Page |


### Sheet: Cognitive 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Nestlé Purina | Bright Mind® | Medium Chain Triglycerides (MCTs) (C8/C10 Blend) | Senior Dogs | Nestlé (Patent) | Metabolic Fuel: Uses MCTs as an alternative energy source for the aging brain (Glucose bypass). | 🔗 US Patent 8962050 |
| Ceva | Senilife® | Phosphatidylserine, Ginkgo Biloba, Vitamin B6, Resveratrol | Senior Dogs | Ceva (Vertical) | Neuro-Protection: The reference veterinary formula for reversing "Sundowner Syndrome." | 🔗 Ceva Senilife |
| Virbac | Novifit® | SAMe (S-Adenosylmethionine) | Senior Dogs | Virbac | Dual Action: Supports both Liver function (Glutathione) and Brain function (Cognition). | 🔗 Virbac Novifit |


### Sheet: Calming 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Nestlé Purina | Calming Care | Bifidobacterium longum BL999 (Probiotic strain) | Dogs | Nestlé Research | Gut-Brain Axis: Proprietary strain proven to blunt cortisol (stress hormone) via the vagus nerve. | 🔗 ProPlanVetDirect |
| Ceva | Adaptil® Chew | Thiamine, L-Tryptophan, Green Tea Extract, Colostrum | Dogs | Ceva (Vertical) | Brand Power: Leverages the world's #1 pheromone brand (Adaptil) into an edible format. | 🔗 Adaptil.com |
| Vetoquinol | Zylkène® | Alpha-Casozepine (Lactium®), Hydrolyzed Milk Protein | Dogs, Cats | Ingredia (Licensor) | Speed: Acts on GABA receptors instantly (like Valium) without sedation. | 🔗 Vetoquinol Tech |
| Virbac | Anxitane® | L-Theanine (Suntheanine®) | Dogs, Cats | Taiyo (Licensor) | Focus: The only pure L-Theanine chew backed by global veterinary safety data. | 🔗 Virbac Profile |
| ElleVet | Calm & Comfort | CBD + CBDA (Proprietary Hemp Blend) | Dogs | ElleVet (Vertical) | Regulatory Lead: The only Cannabis strain with significant university clinical data (Cornell). | 🔗 Cornell Study |


### Sheet: Performance

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Zinpro | Availa® | Performance Minerals (Zinc, Manganese, Copper Amino Acid Complexes) | Livestock | Zinpro (Vertical) | Bioavailability: The only minerals that use amino-acid transporters to bypass digestion blocks. | 🔗 Zinpro Science |
| Adisseo | Rovabio® | Multi-Enzyme Complex (Xylanase, Glucanase) | Poultry, Swine | Adisseo (Vertical) | The Nutrient Unlocker: Dismantles plant fibers to "create" energy from cheap feed ingredients. | 🔗 Adisseo Page |
| Evonik | MetAMINO® | DL-Methionine (99% pure) | Poultry, Swine | Evonik (Vertical) | The Bottleneck: The world's purest source of the #1 limiting amino acid for muscle growth. | 🔗 Evonik Page |
| DSM | Ronozyme® | Phytase, Protease, Amylase | Poultry, Swine | DSM-Firmenich | Phosphate Replacement: Liberates bound phosphorus, eliminating the need for rock phosphate. | 🔗 DSM Page |


### Sheet: Ectoparasites

| Company (Commercial) | Product | Active Ingredients | Target Species | Mechanism of Action | The Strategic Claim |
| --- | --- | --- | --- | --- | --- |
| Anpario | Mitex | Diatomaceous Earth (Physical Action) | Poultry, Swine | Mechanical Killer: Microscopic shards pierce the insect's waxy exoskeleton, causing dehydration and death. No resistance possible. | Resistance-Proof: Unlike chemicals, mites cannot mutate to survive physical destruction. 98.5% efficacy vs. chemical standard. |
| Bioiberica | Atopivet® | Nucleotides + Hyaluronic Acid | Dogs, Cats | Skin Barrier Reinforcement: Strengthens the physical skin barrier from the inside out, making it harder for allergens/parasites to penetrate. | Systemic Shield: The only oral product proven to thicken the dermal barrier, reducing "entry points" for flea allergy dermatitis. |
| Phytobiotics | Miarom® | Essential Oils (Thyme, Anise, Peppermint) | Poultry, Swine | Repellent Scent: Systemic absorption leads to secretion of repellent volatiles through the skin/pores, making the animal "invisible" or hostile to pests. | Sensory Camouflage: Masks the animal's CO2 and heat signature, confusing parasites before they can attach. |
| Candioli | Acarene Spray | Pyrethrins (Natural) + Piperonyl | Birds, Rabbits | Natural Neurotoxin: Uses natural Chrysanthemum extract to paralyze mites without the toxicity of synthetic organophosphates. | Safe for Exotics: The standard of care for delicate species (birds/rabbits) where synthetic chemicals are lethal. |
| Farnam | Equi-Spot® | Permethrin (Botanical Analog) | Horses | Vector Control: Repels ticks (Lyme disease vectors) and flies that cause "Summer Eczema." | Vector Block: Not just a killer, but a repellent—preventing the bite from happening in the first place. |
| Earth Animal | Nature’s Protection™ | Yeast, Garlic, B-Vitamins | Dogs, Cats | Metabolic Odor: Alters the dog's blood chemistry to produce a scent undetectable to humans but repulsive to fleas/ticks. | The "Daily Pill": A chemical-free oral alternative to the "Spot-On" drops, capitalizing on the "Clean Label" trend. |


### Sheet: Nutrigenomics

| Company | Product | Active Molecule | Genomic Mechanism | The Strategic Claim |
| --- | --- | --- | --- | --- |
| Bioiberica | Nucleoforce® | Free Nucleotides (RNA/DNA fragments) | Genomic Synthesis | The "Spare Parts": Provides pre-formed nucleotides, bypassing the body's energy-intensive DNA synthesis pathway. Essential for rapid cell division (Immunity/Growth). |
| Virbac | Novifit® | SAMe (S-Adenosylmethionine) | Epigenetic Methylation | The "Master Switch": SAMe is the universal "Methyl Donor." It drives DNA methylation, which turns genes "on" or "off"—critical for cognitive repair and liver regeneration. |
| VetriScience | GlycoFlex® | DMG (Dimethylglycine) | Epigenetic Regulation | The "Metabolic Optimizer": DMG is a methyl donor that supports the methylation cycle, reducing lactic acid build-up and modulating immune response genes. |
| Alltech | Actigen® | Mannan-Rich Fraction (MRF) | Transcriptomics | The "Gene Tuner": Alltech is the only company using Gene Chips to prove their product physically down-regulates inflammation genes and up-regulates defense genes in the gut. |
| Zinpro | Availa® Zn | Zinc Amino Acid Complex | Transcription Factors | The "Barrier Builder": Proved via nutrigenomics that their specific Zinc up-regulates the genes coding for Claudin/Occludin (Tight Junction proteins), physically sealing the gut. |


### Sheet: Advanced Formulations 

| Company (Commercial) | Product | Nutraceutical Ingredients | Target Species | Technology Owner | The Strategic Claim | Proof of Relationship |
| --- | --- | --- | --- | --- | --- | --- |
| Balchem | ReaShure® | Encapsulated Choline | Dairy | Balchem (Vertical) | Precision Encapsulation: Proprietary coating ensures nutrients survive the harsh rumen environment to reach the liver. | 🔗 Balchem ReaShure |
| Nestlé Purina | FortiFlora® | E. faecium SF68 (Microencapsulated) | Dogs, Cats | Nestlé Research | Stability Assurance: Multi-layer microencapsulation guarantees the probiotic stays alive until it hits the bowl. | 🔗 Purina Institute |
| Zinpro | Availa® | Zinc/Manganese/Copper Amino Acid Complexes | Livestock | Zinpro (Vertical) | Active Transport: The only minerals that use specific amino-acid transporters to bypass digestion blocks (100% Bioavailable). | 🔗 Zinpro Science |
| Gelita | Petagile® | Bioactive Collagen Peptides (BCP®) | Dogs, Horses | Gelita (Vertical) | Molecular Tuning: Hydrolysis technology that cuts collagen into specific peptide lengths optimized for absorption into cartilage. | 🔗 Gelita Petagile |
| Swedencare | ProDen PlaqueOff® | Ascophyllum nodosum (D1070™ Kelp) | Dogs, Cats | Swedencare (Vertical) | Systemic Delivery: The only dental product that works via the bloodstream (secreted into saliva) rather than just scrubbing. | 🔗 Swedencare Tech |
| SmartPak | SmartPaks™ | Custom Supplements (Unit Dosing) | Horses, Dogs | SmartPak (Vertical) | Compliance Tech: Patented unit-dose packaging system that ensures 100% owner compliance and freshness stability. | 🔗 SmartPak Patents |
| Novus | Mintrex® | Chelated Trace Minerals (HMTBa) | Poultry, Swine | Novus Int. (Vertical) | Bidentate Chelation: Minerals are chemically clamped by two molecules, protecting them from breaking down in the gut. | 🔗 Novus Mintrex |


### Sheet: Mobility

| Technology Owner | Commercial Product | Range | Proof of Relationship | Direct Link (Where to look) |
| --- | --- | --- | --- | --- |
| Lonza (UC-II®) | Vetoquinol Flexadin® Adv. | Vet | Trademark Footer: The official Vetoquinol product page explicitly states in the legal footer: "UC-II® and logo are trademarks of Lonza." | 🔗 Vetoquinol USA |
|  |  |  |  | (Scroll to bottom of page) |
| Lintbells (ActivEase®) | YuMOVE Joint Care | Retail | Vertical Ownership: Lintbells' corporate site details their ownership of the mussel bays in NZ. | 🔗 Lintbells "Science" |
|  |  |  |  | (See "From Source to Sea") |
| Aroma NZ (GlycOmega™) | VetriScience GlycoFlex® | Vet | Brochure Footer: The official sales brochure explicitly lists: "GlycOmega™ is a trademark of Aroma New Zealand Ltd." | 🔗 GlycoFlex Brochure (PDF) |
|  |  |  |  | (See bottom of Page 2) |
| Nestlé (Patent) | Purina Bright Mind® | Food | Patent Assignment: The US Patent for "Enhancing Canine Cognitive Function" is assigned to Nestec SA (Nestlé). | 🔗 US Patent 8962050 |
|  |  |  |  | (See "Current Assignee") |


### Sheet: Cognitive

| Technology Owner | Commercial Product | Range | Proof of Relationship | Direct Link (Where to look) |
| --- | --- | --- | --- | --- |
| Ceva (Adaptil®) | Adaptil® Chew | Vet | Brand Owner: The official product site is hosted on Adaptil.com, which is copyrighted by Ceva Animal Health. | 🔗 Adaptil.com |
|  |  |  |  | (See Copyright Footer) |
| Ingredia (Lactium®) | Vetoquinol Zylkène® | Vet | Ingredient Match: The Vetoquinol site lists the active as "alpha-casozepine" (the generic name for Lactium). | 🔗 Vetoquinol Zylkene |
|  |  |  |  | (See "Ingredients" tab) |
| Taiyo (Suntheanine®) | Virbac Anxitane® | Vet | Tech Profile: Virbac's technical sheet explicitly displays the Suntheanine® logo and attribution to Taiyo Kagaku. | 🔗 Virbac Tech Profile |
|  |  |  |  | (See "Suntheanine" Bullet Point) |
| ElleVet (Proprietary) | ElleVet Calm | DTC | Study Funding: The published Cornell study explicitly states: "Funding: This study was funded by ElleVet Sciences." | 🔗 Frontiers in Vet Science |
|  |  |  |  | (See "Funding" section) |


### Sheet: Immunity

| Technology Owner | Commercial Product | Range | Proof of Relationship | Direct Link (Where to look) |
| --- | --- | --- | --- | --- |
| Nestlé (SF68) | Purina FortiFlora® | Vet | Proprietary Strain: The Purina Institute confirms E. faecium SF68 is their proprietary strain (NCIMB 10415). | 🔗 Purina Institute |
|  |  |  |  | (See "Proprietary Microencapsulation") |
| ADM (DE111®) | Zesty Paws Gut Health | Retail | Label Trademark: The ADM brochure highlights Zesty Paws as a case study for their DE111® strain. | 🔗 ADM Microbiome Brochure |
|  |  |  |  | (Search for "DE111") |
| AnimalBiome | AnimalBiome Restore | DTC | Patent Inventor: The patent for "Therapeutic Administration of Microorganisms" lists founder Holly Ganz. | 🔗 US Patent App 2018 |
|  |  |  |  | (See "Inventor: Holly H. Ganz") |


### Sheet: Green 

| Technology Owner | Commercial Product | Range | Proof of Relationship | Direct Link (Where to look) |
| --- | --- | --- | --- | --- |
| DSM-Firmenich | Arla Bovaer® Pilot | Dairy | Official PR: Arla's corporate site hosts the press release: "Arla and DSM start large scale pilot." | 🔗 Arla Press Release |
|  |  |  |  | (Headline) |
| Bond Pet Foods | Hill's Micro-Protein | Food | Official PR: Hill's official statement: "Hill's partners with Bond Pet Foods to develop alternative proteins." | 🔗 Pet Food Processing |
|  |  |  |  | (Article Title) |
| Central Life (Altosid®) | Purina Wind & Rain® | Farm | Product Name: The product is literally named "Wind & Rain® with Altosid® IGR". | 🔗 Purina Mills Shop |
|  |  |  |  | (See Product Title) |


### Sheet: Specialized 

| Technology Owner | Commercial Product | Range | Proof of Relationship | Direct Link (Where to look) |
| --- | --- | --- | --- | --- |
| Innovet (Redonyl®) | Dechra Redonyl® | Vet | Annual Report: Dechra's 2017 Annual Report lists the acquisition of rights to Redonyl from Innovet. | 🔗 Dechra Annual Report |
| Vetnique (Glandex®) | Vetnique Glandex® | Retail | Patent Assignee: The patent for "Anal gland health" is assigned directly to Vetnique Labs LLC. | 🔗 US Patent 9585925 |
|  |  |  |  | (See "Current Assignee") |


### Sheet: Microbiome 

| Company | Product / Platform | Target | Mechanism of Action (MoA) | Relation to Nutraceuticals (Regulatory Strategy) | The Strategic Claim |
| --- | --- | --- | --- | --- | --- |
| BiomEdit | Biome-Actives | Livestock | Synthetic Biology: Engineered microbial strains that produce specific enzymes/metabolites. | The "Trojan Horse": Functionally a precision drug, but legally classified as a Zootechnical Feed Additive to bypass pharma trials. | "Living Factories": Microbes that act as continuous manufacturing plants inside the gut. |
| Proteon | BAFASAL® | Poultry / Aqua | Bacteriophages: Lytic phages that selectively target and kill Salmonella. | The "Additive" Hack: Successfully lobbied to classify Phages as Feed Additives (not Vaccines), allowing them to be sold without a vet prescription. | "The Sniper": Kills superbugs without harming the beneficial microbiome (unlike antibiotics). |
| Folium Science | Guided Biotics™ | Poultry | CRISPR-Cas: Technology that triggers self-destruction in pathogenic bacteria DNA. | The "Hygiene" Play: Positioned as a "Processing Aid" or Hygiene technology to avoid "GMO" labelling in sensitive markets. | "Genetic Scalpel": Removes pathogens by reading their DNA sequence; zero impact on good bacteria. |
| MicroHarvest | Single Cell Protein | Pet / Aqua | Biomass Fermentation: Bacteria that convert ag-waste into protein. | The "Super-Ingredient": Sold as a premium Feed Material (Protein source), evading the complex "Additive" approval process entirely. | "Speed & Scale": Produces protein 5000x faster than soy with a carbon-negative footprint. |
| Anizome | Discovery Platform | Multi | Therapeutic Discovery: Mapping the gut to find druggable targets. | The "Pharma Bridge": Does not sell a nutraceutical; sells Data to Big Pharma to help them create drugs derived from the microbiome. | "The Map Makers": Providing the "Google Maps" of the animal gut. |


### Sheet: New Business Models 

| Company | Model | Product | Strategic Similarity | Relation to Nutraceuticals (Regulatory Strategy) | The Differentiation |
| --- | --- | --- | --- | --- | --- |
| AnimalBiome | DTC (Direct to Consumer) | FMT & Testing: Poop pills & sequencing kits. | The "Patient Owner": Uses testing to sell supplements. | The "Wild West" Supplement: Operates as a Complementary Feed (Supplement). Relies on owner discretion rather than vet prescription or FDA approval. | "Ecosystem Transplant": The only scalable way to restore a lost microbiome after antibiotics. |
| Biome9 | DTC | AI Gut Test: At-home sequencing. | The "European Twin": Similar to AnimalBiome but UK-based. | The "Data Play": Sells the insight (Nutrigenomics) as the product; the nutraceutical is the upsell. | "Predictive AI": Claims to predict health issues before symptoms appear. |
| Gnubiotics | B2B (Ingredient) | Glycans: Structural mimics of milk oligosaccharides. | The "Intel Inside": Sells to Purina/Mars, not consumers. | The "Premium Nutrient": Classified as a Feed Material (like a vitamin), allowing instant adoption by big brands without safety dossiers. | "Mother’s Milk Mimic": The first non-biological ingredient to replicate maternal immunity structures. |
| CanBiocin | B2B (Ingredient) | K9-17 Strain: Species-specific probiotics. | The "Strain Bank": Sells living tech to manufacturers. | The "Verified" Additive: Sells Approved Strains (EFSA/FDA listed) to validate claims on pet food bags. | "Native Logic": Bacteria isolated from dogs for dogs (higher colonization than human strains). |
| Bond Pet Foods | B2B (Ingredient) | Brewed Protein: Yeast-fermented meat proteins. | The "SynBio Chef": Creating meat without animals. | The "Food" Status: Navigating GRAS (Generally Recognized As Safe) to be sold as standard Pet Food, not a supplement. | "Nature Identical": Chemically identical to chicken protein, but made by yeast. |


### Sheet: Financial Performance  Margin 

| Segment | Market Size (2024) | EBITDA Margin | CAGR (2024–2030) | Risk Profile |  |
| --- | --- | --- | --- | --- | --- |
| Ingredient Suppliers (IP-based) | USD 1.5–2.0B | 25–30% | 8–10% | Medium (IP protection) |  |
| CDMOs & Premixers | USD 2.0–2.5B | 15–20% | 5–7% | Medium-High (customer concentration) |  |
| Pet Brands (Traditional) | USD 3.5–4.5B | 18–22% | 5.5–6.5% | High (low barriers to entry, CAC inflation) |  |
| Pet Brands (DTC) | USD 1.0–1.5B | 20–25% | 12–15% | High (CAC volatility, retention risk) |  |
| Livestock Integrators | USD 5.5–6.5B | 8–12% | 4.0–6.0% | Low (essential, sticky customers) |  |
| Sources: |  |  |  |  |  |
| DSM-Firmenich Q3 2025 Trading Update (Animal Nutrition 22.1% EBITDA) https://www.dsm-firmenich.com/content/dam/dsm-firmenich/investors/documents/results |  |  |  |  |  |
| Dechra Pharmaceuticals Annual Report 2023 (Pet brands 20-25%) https://www.dechra.com/Admin/Public/Download.aspx? |  |  |  |  |  |


### Sheet: Competition

| Layer / Archetype | Company | 2024 Revenue (approx.) | Primary Markets | Core Nutraceutical / Additive Focus | EBITDA Margin | Valuation Positioning | Strategic Positioning |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| PHARMA & ANIMAL HEALTH MAJORS |  |  |  |  |  |  |  |  |
| Pharma & Veterinary Pharma | Zoetis | USD 9.3B | Global (companion, livestock, aqua) | Vaccines, biologics, parasiticides; companion-animal supplements (joint, skin, gut). Divested feed additives. | 20–25%+ | High multiples (15–20x EBITDA) on pharma comps; quality/innovation premium | Market leader; focus on high-margin innovation; divesting commodity feed additives |  |
| Pharma & Veterinary Pharma | Merck Animal Health | USD 5.9B | Global (companion, livestock) | Livestock vaccines & therapeutics; BRAVECTO parasiticide (USD 1.1B); expanding aqua via Elanco acquisition | 18–22% | High multiples on quality assets | Pharma heritage; strong livestock and aqua platforms |  |
| Pharma & Veterinary Pharma | Boehringer Ingelheim Animal Health | EUR 4.7B (~USD 5.0B) | Global (companion, livestock) | NexGard parasiticide portfolio; SENVELGO (feline diabetes); poultry & ruminant solutions; vaccines | 18–20% | Premium multiples on innovation | Innovation-driven; strong R&D pipeline |  |
| Pharma & Veterinary Pharma | Phibro Animal Health | USD 1.4B (pro forma post-acquisition) | North America, international | Feed additives, specialty livestock products; acquired Zoetis MFA portfolio (USD 350M deal, 2024) | 15–18% | Mid-teens multiples | Consolidation play; feed-additive focus |  |
| Pharma & Veterinary Pharma | Elanco Animal Health | USD 4.4B | Global (companion, livestock) | Pet: parasiticides (Credelio Plus, Advantage), therapeutics; Farm: antibiotic alternatives (Experior), methane reduction | 0.205 | Mid-teens multiples | Recovery story; innovation (Zenrelia, Credelio Quattro); divestiture of aqua business |  |
| Pharma & Veterinary Pharma | Ceva Santé Animale | EUR 1.77B (~USD 1.91B) | 47 countries (companion, livestock, aqua) | Nucleotide vaccines, gene therapy, immunology; preventive medicine focus | 15–18% | High valuation (EUR 9.2B recent round) | Pre-IPO; innovation-heavy; gene therapy differentiation |  |
| Pharma & Veterinary Pharma | Vetoquinol | EUR 539M (~USD 580M) | Global (companion, livestock) | Essential products: joint health (Dogmamil, Prof®), oral care, digestive aids (60% of sales, growing 8%+ annually) | 16–18% | Mid-teens multiples | Strategic shift to high-margin preventive nutrition ("Essentials") |  |
| FEED & SPECIALTY NUTRITION MAJORS |  |  |  |  |  |  |  |  |
| Feed & Additives | DSM-Firmenich ANH | EUR 3.32B | Global (livestock, aqua) | Vitamins, minerals, probiotics, enzymes, methane-reduction additives (Bovaer), mycotoxin solutions | 0.103 | Mid-single to mid-teens multiples | Science-driven; sustainability focus (ESG); margin expansion via premium additives |  |
| Feed & Additives | Novonesis (Novozymes + Chr. Hansen) | EUR 2.10B (H1 2025) | Global (livestock, aqua) | Fermentation-based probiotics, enzymes, yeast derivatives, organic acids; Planetary Health segment (37.4% EBITDA margin) | >35% (specialty) | High multiples (15–20x) on biotech comps | Microbial biotech platform; exceptional margins on fermentation IP |  |
| Feed & Additives | Cargill Animal Nutrition | ~USD 10–12B (part of USD 165B+ company) | Global (livestock, aqua, pet) | Premixes (Provimi), yeast products (Diamond V), phytogenics (Delacon), aquafeed (EWOS); methane solutions (SilvAir™) | 10–12% | Integrated conglomerate valuation | Scale & vertical integration; precision nutrition focus |  |
| Feed & Additives | ADM Animal Nutrition | ~USD 2–3B (segment) | Global (livestock, aqua) | Amino acids, protein meals, enzymes, probiotics, mycotoxin solutions; organic acids | 8–10% | Mid-single digit multiples | Recovery mode (2024 improved); leveraging fermentation capabilities |  |
| Feed & Additives | Alltech (merging with ADM) | ~USD 2–2.5B (private) | Global (livestock, aqua) | Yeast products, fermentation science, organic acids, probiotics | 10–14% | Merger consideration TBD | Fermentation biotech specialist; merger expected to create scale |  |
| Feed & Additives | Nutreco (Trouw Nutrition) | EUR 8B+ (parent company) | Global (livestock, aqua) | Premixes, specialty ingredients, methane solutions, gut-health diagnostics | 8–10% | Mid-single digit multiples | Regional consolidation; sustainability messaging |  |
| Feed & Additives | ForFarmers | EUR 2.75B | Europe (livestock) | Compound feeds, premixes, additive blends; low-cost producer model | 0.037 | Single-digit multiples | Commodity-exposed; consolidating regionally |  |
| PET FOOD & SUPPLEMENT BRANDS |  |  |  |  |  |  |  |  |
| Pet Brands | Nestlé Purina PetCare | ~USD 22.4B (U.S. estimate) | Global (primarily North America, Europe, Asia) | 900+ products across premium (PRO PLAN) and mass-market brands; joint, digestive, senior, immune formulations | 20–24% | Premium multiples (15–20x EBITDA) on CPG comps | Market leader; scale & innovation; pet humanization positioning |  |
| Pet Brands | Mars Petcare | ~USD 22B (estimate) | Global (50+ brands) | PEDIGREE, Whiskas, Royal Canin, Iams, Cesar, Greenies; premium nutrition & therapeutic positioning | 20–23% | Premium multiples on brand equity | Market leader; brand strength; vertical integration (vet services) |  |
| Pet Brands | Hill's Pet Nutrition | USD 4.4B | Global (veterinary channel primary) | Therapeutic & prescription diets (joint, kidney, digestive); 300+ SKUs; veterinary-endorsed | 22–25% | High multiples (15–18x EBITDA) on vet-channel positioning | Veterinary professional differentiation; clinical evidence strength |  |
| Pet Brands | General Mills Pet (Blue Buffalo) | USD 2.3B | North America (declining 4% FY2024) | Premium natural pet food; joint health, immune support, digestive wellness; strong DTC/subscription | 18–20% | Mid-teens multiples; declining trajectory | Premium positioning; e-commerce/DTC focus; facing consolidation pressure |  |
| Pet Brands | Swedencare AB | ~EUR 70–75M (~USD 75–80M) | Europe, North America, select global | High-margin joint health (Arthropharm), oral health (Trixie), digestive aids; veterinary-channel & DTC | >20% | High multiples (15–20x EBITDA) on growth | High-growth niche player; Scandinavian premium positioning |  |
| Pet Brands | Freshpet | ~USD 500M+ | North America | Fresh/refrigerated pet food; premium natural positioning; positive net income 2024 | 15–18% | Mid-teens multiples on growth | Positive inflection; fresh/natural category leadership |  |
| Pet Brands | Nutramax Laboratories | Private (~USD 500M+ estimate) | North America (veterinary channel) | Dasuquin (joint, peer-reviewed), Cosaquin; clinical differentiation driving premium pricing | 22–26% | Very high multiples (18–25x EBITDA) on clinical data + brand | Clinical evidence as competitive moat |  |
| Pet Brands | Nulo Pet Food | USD 261.8M | North America (premium retail & online) | Premium natural pet food; grain-free, high-protein positioning; 2.1% growth | 18–22% | Mid-teens multiples | Premium segment; steady growth |  |
| Pet Brands | Wellness Pet | Private (USD 300–400M estimate) | North America | Premium natural pet food & supplements; owned by Clearlake Capital; strong DTC | 20–24% | High multiples on brand value | Premium natural positioning; PE-backed |  |
| RETAIL & DISTRIBUTION |  |  |  |  |  |  |  |  |
| Distribution | Chewy Inc. | ~USD 9B | North America (online dominant) | E-commerce platform; private-label pet food & supplements; veterinary partnerships; subscription model | 12–15% | High-growth multiples (premium) | Data aggregation; veterinary integration; margin expansion via private-label |  |
| Distribution | Veterinary Practice Groups | Fragmented (~USD 100B+ aggregate) | Local/regional | Formulary curation; private-label supplement development; direct client relationships | 15–25% (varies) | Varies by size and consolidation | Trusted advisor positioning; increasing M&A consolidation |  |
| Distribution | Pet Specialty Retail | Consolidated (~USD 15–20B aggregate) | North America, Europe | PetSmart, Petco (Amoeba), Pets at Home, etc.; shelf curation; private-label development | 8–12% | Mid-single digit multiples | Margin pressure from e-commerce; increasing private-label |  |



---

